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Proteins and peptides have become an important class of therapeutics due to their high 
specificity and general biocompatibility. However, using proteins and peptides as drugs has several 
intrinsic challenges. These macromolecules are generally cleared rapidly due to renal filtration and 
enzymatic degradation following administration. Issues of instability during storage due to their 
chemical composition and specific three-dimensional confirmations necessitate that most protein 
and peptide therapeutics be stored in the refrigerator or as a lyophilized powder. Additionally, they 
must be administered through injection and are not responsive to intrinsic biological signals, unlike 
endogenous processes. Thus, it is important to develop methods to improve characteristics of 
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protein and peptide therapeutics to improve their stability, pharmacokinetics, and delivery in 
response to biological stimuli. 
Chapter Two describes the investigation of the insulin stabilization properties of trehalose 
glycopolymer as excipient and conjugate. Addition of a styrenyl backbone trehalose polymer 
excipient stabilized insulin against aggregation induced by exposure of insulin to heat or 
mechanical agitation. Conjugation of the trehalose polymer to insulin was achieved by reductive 
amination and the stability assays were repeated with the conjugate, showing results like the 
excipient. The conjugation site was identified as GlyA1 and LysB29 by indirect characterization 
through acid-cleavage of the polymer. While conjugation prolonged the half-life in mice, addition 
of trehalose polymer excipient did not alter protein pharmacokinetics. The mechanism of insulin 
stabilization was investigated with a methacrylate backbone trehalose polymer excipient, showing 
presence of the polymer inhibits both fibrillation and deamidation. 
Chapter Three continues the development of a new strategy for site-specific conjugation of 
a trehalose polymer to insulin for improved stability and bioactivity. Conditions for AGET ATRP 
under mild, aqueous conditions were optimized. A site-specific insulin macroinitiator was 
prepared targeting modification at LysB29 utilizing its higher nucleophilicity over the other 
possible amine conjugation sites and purifying to isolate the desired species. Trehalose monomer 
was polymerized directly from this site-specific macroinitiator resulting in a conjugate with 
improved heat stability. A lower dosage of the site-specific conjugate compared to the nonspecific 
conjugate was needed to achieve the same change in blood glucose. 
Chapter Four details the synthesis of blood triggered self-immolative linkers designed for 
use as spacers for rapid-acting insulin-trehalose glycopolymer conjugates. Linkers triggered by 
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serum albumin through base-catalyzed β-elimination were first prepared and triggering was 
characterized. During conjugation, the first linker underwent premature triggering from the 
primary amines of insulin and the exposed amine catalyzed further triggering. The second linker 
design underwent base-catalyzed self-immolation over the course of 20 h. Linkers that could be 
triggered by the thiol concentration in the blood were then synthesized and evaluated. Both 
aliphatic and aromatic linkers underwent rapid self-immolation with small molecules across the 
disulfide under relevant glutathione concentrations. Conjugation with trehalose glycopolymer 
slowed the kinetics of the self-immolation, likely because of the increase in steric bulk. 
Chapter Five describes optimization of the background release of insulin from a trehalose 
glycopolymer hydrogel for improved stability and glucose-responsive delivery of the protein. 
Several strategies were used to decrease the background release. Two methods to increase the 
binding affinity of the boronic acid to polyols was used to strengthen the hydrogel network. The 
influence of pore size/crosslink density was also explored. Finally, incorporation of comonomers 
for electrostatic attraction to insulin resulted in the lowest background release of insulin without 
glucose after optimization of gelation procedure. 
Chapter Six introduces glucose-responsive materials for regulation of glucagon delivery. 
Glucose-responsive nanogels are prepared by precipitation polymerization and post-
polymerization modification with phenylboronic acid as glucose-sensing unit. Nanogels were 
thermo- and glucose-responsive through incorporation of thermoresponsive pNIPAM or pPEGMA 
with glucose acting as an additive that alters the hydration of the polymers. Native glucagon was 
found to degrade during the loading of the nanogels, so a more stable soluble analog was used that 
improved to loading.  
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Chapter 1. Introduction: Preparation of Biomolecule-Polymer Conjugates by 
Grafting-From using ATRP, RAFT, or ROMP 
 
 
Reproduced with permission from: Messina, M.S.; Messina, K.M.M.; Bhattacharya, A.; 
Montgomery, H.R.; Maynard, H.D. “Preparation of biomolecule-polymer conjugates by grafting-






Biomolecule-polymer conjugates represent an important class of macromolecular 
architectures that combine the advantageous properties inherent to both the biomolecule and 
synthetic polymer(s) appended to it. The attachment of poly(ethylene glycol) (PEG) to 
biomolecule therapeutics represents the most utilized form of biomolecule-polymer conjugates in 
the pharmaceutical realm, and there currently exist 17 PEGylated peptide and protein therapeutics 
which have garnered approval from the food and drug administration (FDA).1-8 In this instance, 
PEG acts to increase the in vivo biomolecule half-life by protecting the therapeutic from 
recognition by the immune system and/or reducing clearance.2 The development of controlled 
polymerization techniques has equipped the scientific community with the ability to prepare 
specially tailored polymers of controlled molecular weights and well-defined architectures from a 
wide array of monomers.9-11  This has led to the development of diverse polymers able to invoke 
unique characteristics such as pH responsiveness, increased storage and in-vivo stability, thermo-
responsiveness, and in PEG alternatives which exhibit lower immunogenicity.1, 12-16 Commonly 
used controlled polymerization techniques for biomolecule-polymer modification are atom-
transfer radical polymerization (ATRP), reversible addition-fragmentation chain-transfer 
polymerization (RAFT), and ring-opening metathesis polymerization (ROMP), which are the 
focus of this review.11, 16-18 It is important to note that nitroxide-mediated radical polymerization 
(NMP) has also been used to great extent to prepare bioactive polymers and conjugates, and 
interested readers are directed to the many interesting reviews and manuscripts which detail the 




Figure 1-1. Schematic representations depicting different methods of preparing biomolecule-
polymer conjugates along with a list of key advantages or disadvantages. 
Biomolecule-polymer conjugates prepared using controlled polymerization techniques are 
typically accessed through three different routes: grafting-to in which a polymer is first 
synthesized, purified, and subsequently coupled to the biomolecule, grafting-from in which a 
small-molecule reactive handle is attached to the biomolecule and used as an initiation site to grow 
the polymer from the surface of the protein, and grafting-through in which monomers 
functionalized with a specific payload are polymerized (Figure 1-1).15, 23-24 Grafting-through has 
been used to a great extent in the preparation of bioactive polymers synthesized using ROMP and 
we will briefly cover a few examples in that area towards the end of the review. The grafting-to 
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strategy has been employed to a greater extent most likely due to the great advances that have been 
made in coupling chemistry and the introduction of so-called “click” reactions which are highly 
versatile and efficient methods to generate bioconjugates (Figure 1-1A). However, the grafting-
from technique offers many advantages, especially in regard to the purification of the prepared 
biomolecule-polymer conjugate (Figure 1-1B).15, 23 Using an excess amount of a small-molecule 
for bioconjugation is a straight-forward process, as any unreacted material can easily be removed 
either by dialysis or size-exclusion chromatography (SEC) due to the large disparity in molecular 
weights between the protein and small-molecule. In contrast, using an excess amount of polymer 
to couple onto a biomolecule can be problematic due to the time intensive nature of polymer 
synthesis. Purification of polymers from the bioconjugates is also challenging due to similarities 
in molecular weight. Additionally, in grafting-from limitations due to sterics, which are inherent 
to the coupling of polymers to biomolecules, are avoided and characterization of the locations of 
the polymer chains on the conjugate is easier. However, grafting-from techniques require 
polymerization conditions which are suited to the stability of the biomolecule and it remains 
challenging to generate low dispersity conjugates. 
Over the course of this review, we will cover recent progress in the formation of 
biomolecule-polymer conjugates which have been prepared using the grafting-from technique. For 
reading ease, the review is sectioned in terms of the controlled polymerization technique used. The 
initial section will cover select works using ATRP, the second section will cover RAFT 
polymerization, and the third will be devoted to ROMP with a brief discussion on grafting-through 
techniques to develop bioactive polymers (Figure 1-1C).  
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1.2  Conjugation of reactive groups onto biomolecules 
Key to the successful implementation of the grafting-from technique is the installation of 
small molecule reactive handles capable of initiating or mediating polymerization processes from 
the biomolecule surface. Throughout the years this has taken many forms, with lysine (Lys) and 
cysteine (Cys) amino acid residues being the most frequently targeted sites for modification on 
proteins (Figure 1-2).1, 25 For the purposes of grafting-from, Cys amino acid modifications have 
taken the form of pyridyl disulfide (PDS) exchange and Michael addition using maleimide-
modified substrates. The weaknesses of these linkages lie in their inherent instability with disulfide 
bridges being reversible in the presence of external reductants and the thiol-ether bond from the 
maleimide being susceptible to retro-Michael processes in vivo. However, Cys remains a popular 
site for conjugation due to the low relative abundance on proteins, thereby allowing for site 
selectivity.25 Lys is also a popular site for conjugation of reactive groups with several research 
groups taking advantage of conjugation through acid-halides, N-hydroxysuccinimide (NHS)-
esters, nitrophenyl carbonates, and squaric acid containing functionality (Figure 1-2).1, 25-26 
However, Lys residues typically have a high abundance on proteins and conjugation methods are 





Figure 1-2. Commonly used protein modification techniques for grafting-from. 
Other methods of conjugating reactive handles onto protein substrates include non-
covalent modification taking advantage of the streptavidin (SAv)-biotin interaction, genetic 
incorporation of non-native amino acids, sortase A (SrtA)-mediated modifications targeting 
LPGXTG/A sequences on the proteins C-terminus, and oxime formation after treatment by 
pyridoxal-5-phosphate (PLP) which targets the protein N-terminus.1, 23, 30-31 Given the expansion 
of amino acid modification techniques along with the introduction of transition-metal-mediated 
conjugation techniques, there remains a wealth of opportunities to modify proteins with reactive 




Figure 1-3. Commonly used peptide and nucleic acid modification techniques for grafting-from. 
Typical peptide conjugation for grafting-from has been performed via on-resin reactions 
targeting the amine terminus of the peptide by either acid-halide conjugation or N,N-
dicyclohexylcarbodiimide (DCC) coupling of reactive handles.42-43 Deoxyribonucleic acid (DNA) 
modification for grafting-from has typically made use of either PDS exchange on a thiol terminated 
DNA strand, NHS-ester or pentafluorophenyl (PFP)-ester conjugation on amine terminated DNA, 




1.3 Biomolecule-polymer conjugates accessed through ATRP 
 ATRP is a living and controlled radical polymerization technique, first reported 
independently by the Matyjaszewski group and the Sawamoto group in 1995, which falls under 
the category of reversible deactivation radical polymerization (RDRP).18, 46-47 In the traditional 
ATRP mechanism, homolytic cleavage of a C(sp3)-X (where X = Br or Cl) bond on an ATRP 
initiator is imposed by a reduced metal halide catalyst thereby initiating polymerization (Figure 
1-4). The then oxidized metal catalyst can reversibly deactivate the radical propagation of the 
polymer chain transfer of the halide to the end of the propagating polymer chain. This reversible 
deactivation ultimately imposes control over the polymerization process by decreasing the amount 
of active radicals in solution thereby minimizing unproductive termination pathways (Figure 
1-4).9, 18  
 
Figure 1-4. Mechanism of the traditional ATRP process. 
There are many alternatives to typical ATRP procedures which differ in the method of 
initiation used. A few commonly used alternative ATRP strategies for grafting-from processes 
include initiators for continuous activator regeneration (ICAR), activators generated by electron 
transfer (AGET), activators regenerated by electron transfer (ARGET), and photo-induced ATRP 
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among others.18  Though there exist many other ATRP strategies, we will only focus on those used 
for the grafting-from polymerization.9, 18  
1.3.1 Traditional ATRP to access protein-polymer conjugates by grafting-from 
Workers at Biocompatibles Ltd synthesized hydroxysuccinimide ester substituted ATRP 
initiators which were then appended onto Lys residues of the protein lysozyme (Lyz).48 Protein 
functionalization was performed in borate buffer at room temperature and the resulting protein-
macroinitiator was used without purification. A variety of olefin substituted monomers and 
zwitterionic monomers were polymerized from the protein surface under traditional ATRP 
conditions in the presence of a copper bromide catalyst and bipyridyl ligand at room temperature. 
The resulting protein-polymer conjugates could be isolated via capillary electrophoresis.48  
Our group published grafting-from methodology by employing traditional ATRP to 
polymerize N-isopropylacrylamide (NIPAAm) from both SAv and T4 lysozyme (T4-Lyz) (Figure 
1-5A and B).49-50 In our initial disclosure targeting SAv bioconjugates, we developed a biotin 
functionalized ATRP initiator. The strong binding affinity of biotin to SAv (Kd = 10
-15 M) was 
utilized to modify the protein with up to four of the biotin ATRP initiators thereby forming the 
SAv-macroinitiator (Figure 1-5A).49, 51 The room temperature polymerization of NIPAAm using 
the SAv-macroinitiator was carried out in an aqueous solution in the presence of copper (I) 
bromide (CuBr) and the 2,2’-bipyridine ligand.49 In a follow-up article that same year, our group 
modified a Cys amino acid residue (Cys-34) on bovine serum albumin (BSA) as well as a Cys 
residue (Cys-131) on a genetically engineered T4-Lyz protein with an ATRP initiator. The BSA- 
or T4-Lyz-macroinitiators were prepared using either pyridyl disulfide exchange to modify the 
proteins with reversible disulfide linkages or by maleimide conjugation (Figure 1-5B).50 Grafting-
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from polymerization of NIPAAm was carried out similarly to the previous report grafting-from 
SAv (Figure 1-5B).49-50 The polymer-conjugates were purified via preparative SEC and 
characterized using gel permeation chromatography and sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE). Additionally, the T4-Lyz-polymer conjugate retained activity as 
determined by a commercially available fluorescence assay which monitored lysis of the 
Micrococcus lysodeikticus substrate. Though these works provided a foundation for the 
introduction of the grafting-from concept, polymerization from the SAv and T4-Lyz bioconjugates 
required the addition of a 2-bromoisobutyryl-functionalized resin which was introduced in order 
to increase the concentration of initiating sites Figure 1-5A and B).49-50 The addition of a sacrificial 
initiator is not needed when there is an abundance of the protein substrate, as is the case with 
cheaper proteins such as BSA.   
Matyjaszewski, Russell, and co-workers also disclosed an example of grafting-from using 
traditional ATRP from chymotrypsin functionalized at Lys amino acid residues with 2-
bromoisobutyramide initiators (Figure 1-5C).52 The authors expanded the monomer scope to 
include polymerization of monomethoxy poly(ethylene glycol)-methacrylate (MPEGMA), sodium 
4-styrenesulfonate, and 2-(dimethylamino)ethyl methacrylate (DMAEMA) from the chymotrypsin 
macroinitiator, which was carried out in the presence of phosphate buffered saline (PBS) (pH 6.0), 
CuBr, and 2,2’-bipyridine (Figure 1-5C). All of the protein-polymer conjugates retained their 
bioactivity to varying degrees’ dependent on the nature of the polymer, with the poly(MPEGMA) 
conjugated protein retaining the highest at 76%, as determined by a spectrophotometric assay 
monitoring enzymatic hydrolysis of an oligopeptide sequence.52 An important feature represented 
in this manuscript is that uniform protein-polymer conjugates could be accessed when attaching 
one initiator onto the protein.52 Taking further advantage of grafting-from using traditional ATRP 
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techniques, the groups have gone on to publish manuscripts detailing the tuning of enzyme activity 
and stability based on the polymers attached to the enzyme.53 Additionally, redox active polymers 
have been polymerized from the surface of glucose oxidase (GOx) and exhibited an increase in the 
efficiency of current generation when testing the GOx-polymer conjugates on the surface of an 
anode.54  
 
Figure 1-5. Examples of grafting-from polymerization using ATRP. (A) Maynard and co-workers 
use of SAv-biotin interaction in order to develop a SAv-macroinitiator to be employed in the 
controlled polymerization of NIPPAm.49 The Maynard group Cys targeted approaches towards 
polymer-protein conjugate generation via grafting-from.50 (C) The Matyjaszewski and Russell 
groups work in developing a chymotrypsin macroinitiator through Lys conjugation.52 
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The initial reports on grafting-from were followed-up extensively with reports, which 
demonstrated expansions in the conjugation chemistry, monomer scope, variance in polymer 
architectures, and the protein substrates used.  The Haddleton group developed protein 
macroinitiators using maleimide conjugation chemistry to target the Cys-34 on BSA and NHS-
ester conjugation to target Lys residues on Lyz.55 They were able to co-polymerize methacrylate-
functionalized fluorescent monomers based on either rhodamine B or hostasol along with 
PEGMA.55-56 An impressive example of grafting-from is a report by the Velonia group in which 
they combined copper-catalyzed azide-alkyne cycloaddition (CuAAC) and ATRP which resulted 
in the polymerization, from a Cys-34 modified BSA, of alkyne-functionalized methacrylate 
monomers and subsequent attachment of azide-functionalized small-molecules for the in-situ 
production of giant amphiphiles.57 The Klok group has also shown success in using squaric acid 
mediated conjugation techniques to install ATRP initiators on Lys amino acid residues of BSA.26  
Mehl, Matyjaszewski, and co-workers devised an elegant approach to installing ATRP 
initiators within proteins by genetically encoding the ATRP initiator containing unnatural amino 
acid 4-(2’-bromoisobutyroamido)phenylalanine within green fluorescent protein (GFP).58 The 
authors evolved a Methanococcus jannaschii tyrosyl-tRNA synthetase/tRNACUA pair that installed 
the novel amino acid in the presence of an amber codon. Incredibly, up to 420 mg of the ATRP 
initiator modified GFP was purified from one liter of medium. Upon purification of the GFP-
macroinitiator and characterization by ESI-mass spectrometry, which showed an increase in mass 
from the wild type GFP corresponding to addition of the ATRP initiator, polymerization was 
carried out using traditional ATRP techniques in the presence of PBS and methoxy OEG 
methacrylate monomer (MOEGMA) at room temperature.58 
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The scientific community also gained interest in grafting-from larger types of biomolecule 
constructs. Wang and co-workers modified Lys residues on horse spleen apoferritin (apo-HSF) 
with bromoisobutyrate initiators via NHS-ester bioconjugation.59 Matrix assisted laser 
desorption/ionization time-of-flight  (MALDI-ToF) analysis following tryptic digestion of the apo-
HSF macroinitiator revealed modification of Lys-83, Lys-97, Lys-104, and Lys-143, all of which 
are highly exposed on the surface of the biomolecule. Polymerization of PEGMA from the apo-
HSF macroinitiator was carried out in a 4:1 mixture of PBS (pH 8.5) and N,N-dimethylformamide 
(DMF) at 4°C upon treatment with CuBr and bipyridine. Hydrogels could be formed in the 
presence of high monomer loadings (up to 1800 equiv to the macroinitiator) which could be 
subsequently solubilized in dichloromethane (DCM). The biomolecule-polymer conjugates were 
characterized via fast protein liquid chromatography (FPLC) and transmission electron 
microscopy (TEM).59 The Russell and Emrick research groups also used grafting-from to access 
horse spleen ferritin (HSF) and poly(methacryloyloxyethyl phosphorylcholine) poly(MPC) 
conjugates.60 Poly(MPC) is a biocompatible zwitterionic polymer which is resistant to non-specific 
protein adsorption, similarly to PEG, though it is much more hydrophilic. The authors used NHS-
ester chemistry to conjugate up to 45 bromoisobutyryl ATRP initiators onto Lys residues of HSF 
and accessed HSF-poly(PEGMA) conjugates in a similar manner to what was previously 
reported.59 Notably, the HSF-poly(MPC) and HSF-poly(PEGMA) conjugates exhibited distinct 
changes in recognition properties due to the presence of the polymers on the protein surface. This 
was apparent in the decreased ferritin antibody binding as determined by an enzyme-linked 
immunosorbent assay (ELISA)-based assay.60 The Ye group has also utilized NHS-ester 
bioconjugation to develop temperature and pH responsive hybrid biomaterials made by 




Figure 1-6. Grafting-from example from the Finn group in which they modified QB VLP-
macroinitiators to synthesize polymers which could undergo post-polymerization modification 
with an array of bioactive substrates.62 
Finn and co-workers demonstrated an elegant example of grafting-from virus-like 
nanoparticles (VLP’s) using traditional ATRP (Figure 1-6).62 The group developed bacteriophage 
Qβ VLP macroinitiators by reacting azide functionalized NHS-ester linkers to Lys residues on the 
biomolecule and using CuAAC to add on the alkyl bromide ATRP initiator. It was found by protein 
digestion and subsequent mass spectrometry analysis that ~180 Lys residues were modified 
(Figure 1-6). Polymerization of oligoethylene glycol methacrylate (OEGMA) was carried out by 
treating the macroinitiator and monomer solution with 2,2’-bipyridine, CuBr, and CuBr2 in water.  
The purified conjugates were characterized via dynamic light scattering (DLS) and SEC which 
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showed that the VLP-polymer conjugates were much larger in size to the Qβ wild-type. Notably, 
the bromine end-groups present on the polymers of the VLP-poly(OEGMA) conjugates could be 
modified further through treatment with sodium azide to form azide terminated polymers which 
could undergo CuAAC with an alkyne bearing AlexaFluor488 fluorescent dye (Figure 1-6). 
Additionally, the authors developed VLP-poly(OEGMA-N3) conjugates in which each OEGMA 
repeat unit was modified with a pendent azide. This allowed for post-polymerization modification 
using CuAAC with the AlexaFluor488 dye, doxorubicin (Dox), or a gadolinium (Gd) complex 
(Figure 1-6). This is a notable achievement given the importance of Gd-modified nanoparticles in 
magnetic resonance imaging. Through inductively coupled plasma optical emission spectroscopy 
(ICP-OES), the authors found that the VLP-poly(OEGMA-Gd) particles contained 500-650 Gd 
complexes per conjugate. Additionally, the authors conjugated Dox via ‘click’ chemistry on the 
pendent poly(OEGMA-N3) and found about 150 Dox molecules appended onto the particle. The 
drug could be released in the presence of pH 5.5 2-(N-morpholino)ethanesulfonic acid (MES) 
buffer through degradation of the hydrazone linkage present on Dox and were also found to be 
cytotoxic towards HeLa cells at the same concentrations as free Dox. Interestingly, control 
experiments in which Dox was loaded directly on the VLP through triazole linkages and subjected 
to pH 5.5 MES buffer led to complete degradation and subsequent precipitation of the biomolecule 
indicating that the presence of poly(OEGMA) conjugated to the protein surface is required for 
stability.62  
The Chilkoti group has targeted the N-terminus of myoglobin (Mb) to attach an ATRP 
initiator by-way of oxime ligation chemistry.31 This modification resulted in a single reactive site 
on the protein surface. The site-specific conjugation of the ATRP initiator was confirmed by liquid 
chromatography with tandem mass spectrometry (LC-MS/MS) of peptide fragments after trypsin 
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digestion of the Mb-macroinitiator. In-situ ATRP of OEGMA from the singly modified Mb-
macroinitiator in aqueous conditions resulted in the formation of a Mb-poly(OEGMA) 
bioconjugate which retained bioactivity and exhibited an increased in vivo half-life compared to 
native Mb.31 Chilkoti and coworkers have also used SrtA-mediated conjugation to attach an ATRP 
initiator on the C-terminus of GFP.30 GFP harboring a SrtA recognition site was expressed and 
purified then subsequently treated with an amine functionalized ATRP initiator in the presence of 
SrtA. This reaction resulted in a singly modified GFP-macroinitiator which was modified 
exclusively at the C-terminus of the protein. Notably, this methodology proved to be highly 
efficient with the GFP-macroinitiator purified in >85% yield.30 SrtA mediated installation of a 
reactive handle has also been used in the attachment of an ATRP initiator onto the C-terminus of 
interferon-α (IFN-α) by the Gao group.63 Using traditional ATRP techniques they were able to 
polymerize OEGMA thereby developing IFN-α-poly(OEGMA) conjugates which exhibited 
increased in-vivo half-life compared to native IFN-α. Additionally, IFN-α-poly(OEGMA) showed 
increased anti-proliferative activity in mice compared to IFN-α-PEG conjugates used clinically.63 
The Gao group has also made use of SrtA mediated transformations to produce a cyclized GFP 
(cGFP) derivative and subsequently coupled an ATRP initiator using maleimide chemistry to 
target an engineered Cys residue on the protein.64 Polymerization of OEGMA to produce cGFP-
poly(OEGMA) conjugates resulted in a hybrid protein with increased thermal stability and 




1.3.2 Peptide-polymer conjugates 
Traditional ATRP techniques have also been used to access peptide-polymer conjugates 
via grafting-from. Though it is important to note that peptide-polymer conjugates had been 
previously prepared by grafting-from using NMP and additionally, ATRP had been previously 
shown to operate using substrates attached to a Wang resin.65-66  In 2004, the Washburn group used 
ATRP to prepare peptide-polymer conjugates via grafting-from to prepare GRGDS-poly(2-
hydroxyethyl methacrylate) (poly(HEMA)) conjugates.67 GRGDS is an oligopeptide sequence 
within the protein fibronectin, which has been shown to interact with cell surface integrins. The 
GRGDS sequence was prepared through solid-phase peptide synthesis (SPPS) using Wang resin. 
The ATRP initiator, 2-bromopropionyl bromide, was introduced in the final coupling step thereby 
producing an initiator-terminated protected oligopeptide on resin. Polymerization of HEMA was 
carried out by treatment of the GRGDS-resin initiator with the monomer, CuCl, and 2,2’-
bipyridine in the presence of butanone and 1-propanol. Cleavage from the resin and subsequent 
deprotection of the prepared GRGDS-poly(HEMA) was carried out by treatment with a standard 
peptide cleavage cocktail (trifluoroacetic acid (TFA), triisopropylsilane (TIPS), H2O). A cell 
adhesion assay was carried out using mouse NIH-3T3 fibroblasts and the results indicated 
successful adhesion of cells to the GRGDS-poly(HEMA) conjugate and cell spreading while no 
adhesion was detected using the poly(HEMA) control thereby indicating the biocompatibility of 
the peptide-polymer conjugate and retention of the cell adhesive peptide moiety.67 The Börner 
group also disclosed a report detailing their preparation of peptide-polymer conjugates via 
grafting-from soon after.43 Incorporation of an ATRP initiator on the amine terminus of an 
oligopeptide during SPPS using DCC coupling chemistry and subsequent cleavage of the 
oligopeptide from the resin afforded an oligopeptide-macroinitiator. The authors carried out 
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polymerization of n-butyl acrylate (nBA) in the presence of the oligopeptide-macroinitiator and 
performed an extensive study on the polymerization kinetics. Though the CuBr catalyst was found 
to interact with the amine functionality on the oligopeptide, this interaction was found not to have 
an effect on the controlled synthesis of monodisperse polymers.43  
 
Figure 1-7. Development of peptide containing amphiphilic block copolymers which assemble 
to form micelles exhibiting a high degree of anti-microbial activity.[42] 
The Wooley group was also able to utilize ATRP of protected peptides on-resin, in addition 
to NMP.42, 65 They prepared the 13 amino acid residue tritrpticin peptide, an oligopeptide which 
exhibits anti-microbial activity, using SPPS on Wang resin (Figure 1-7). The tritrpticin-resin was 
treated with bromoisobutyryl bromide to install the ATRP initiator on the oligopeptide end. The 
group was able to polymerize block co-polymers made from tert-butyl acrylate (tBA) and styrene 
monomers by treatment of the tritrpticin-resin with CuBr and N,N,N′,N′′,N′′-
pentamethyldiethylenetriamine (PMDETA) in the presence of the monomers. Cleavage and 
deprotection were carried out to afford the tritrpticin-b-poly(acrylic acid-b-styrene) conjugate 
(Figure 1-7). Micelles from the peptide-polymer conjugates were generated and found to have 
improved anti-microbial activity at lower concentration towards Staphylococcus aureus and 
Escherichia coli in comparison to tritrpticin alone (Figure 1-7).  
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1.3.3 DNA-Polymer Conjugates 
 Grafting-from to access DNA-polymer conjugates using traditional ATRP was used by the 
He group for the amplification of signal to specific DNA sequences.68 Hybridization and ligation 
of an ATRP-functionalized single-stranded DNA (ssDNA) onto complementary ssDNA sequences 
modified on a gold surface led to the formation of DNA-macroinitiators. Polymerization of HEMA 
from the DNA-macroinitiators led to the surface formation of DNA-poly(HEMA) conjugates 
which were characterized by atomic force microscopy, ellipsometry, and contact angle 
measurements. Notably, the formed polymer films could be detected visually without the need for 
an optical microscope, and the technique allowed for the detection of single point mutations as 
ATRP modified ssDNA exclusively hybridizes to complementary sequences on the surface.68 An 
interesting observation was found that initial polymerization rates from DNA surfaces were 
considerably accelerated.69 The authors have attributed this initial rate enhancement to an 
interaction of Cu with the highly charged phosphate backbones on DNA.69 Using similar 
methodology to their previous reports, the He group was also able to develop DNA-polymer 
conjugate coated core-shell Au nanoparticles using traditional ATRP under aqueous conditions.70 
Again, only nanoparticles harboring the complementary ssDNA strands to the ssDNA-
macroinitiator were able to undergo polymerization leading to the visual detection of DNA-
polymer conjugate loaded nanoparticles.70  
1.3.4 AGET and ARGET ATRP 
While the effectiveness of traditional ATRP to prepare biomolecule-polymer conjugates 
via grafting-from has been well established, the main challenges with traditional ATRP techniques 
include sensitivity to oxygen which may limit its implementation by novice users and low 
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efficiency in aqueous solutions.71-72 Activator generated by electron transfer (AGET) ATRP relies 
on the introduction of an external reducing agent to reduce the transition metal species in solution 
thereby promoting activation of the initiator or halide terminated polymer chain. AGET ATRP is 
much more tolerant to low oxygen concentrations which allows for better control over 
polymerization in aqueous media at lower temperatures. The higher oxygen tolerance arises from 
the use of oxidatively stable transition metal-based catalysts coupled with the ability for the 
introduced reductant to remove dissolved oxygen and to reduce the transition metal catalyst 
(Figure 1-8).18 This important characteristic makes AGET ATRP a more feasible technique for 
the novice user and a popular approach to access protein-polymer conjugates via ATRP.  
 
Figure 1-8. Mechanism of AGET ATRP. 
In an early example using AGET ATRP to graft-from biomolecules, He and co-workers 
expanded on their previous work (vide supra) but instead used AGET ATRP with water soluble 
ascorbic acid as a reducing agent, thereby employing an oxygen-tolerant and homogenous method 
to make DNA and protein sensors based on a unique amplification-by-polymerization strategy.73 
Polymerization of HEMA from an ssDNA macroinitiator following hybridization and ligation to 
the immobilized complimentary ssDNA strand allowed for detection and determination of DNA 
concentration, which was proportional to the film thickness. The sensitivity of this method was 
comparable to that of sensors using traditional ATRP techniques but the turnaround time was 
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reduced by 2.5 times and a purging step to remove dissolved oxygen was eliminated, making it 
more attractive for portable applications.73 The authors extended this work further by the 
implementation of electrochemical sensors based on polymers harboring pendant ferrocene-based 
monomers. Post-polymerization modification of ssDNA-polymer conjugates made from either 
glycidyl methacrylate (GMA) or HEMA was carried out by coupling aminoferrocene to the 
pendant chains on the polymer thus generating electrochemically active polymers. This method 
allowed for detection of unlabeled DNA or proteins with sensitivity modulated by the length of 
the polymer chains and amount of aminoferrocene added to the polymers.73 
Other groups have also utilized AGET ATRP to graft from oligonucleotides. Das, 
Matyjaszewski, and co-workers incorporated an acid-stable amide initiator during solid-phase 
DNA synthesis using phosphoramidite coupling chemistry.44 A variety of methacrylate monomers 
were polymerized from the DNA macroinitiator which either remained attached on the solid 
support or was polymerized from while in solution after cleavage from the solid support. DNA 
remained stable under the mild polymerization conditions and was able to hybridize with 
complementary strands. The DNA-polymer hybrids were characterized via gel permeation 




Figure 1-9. Development of siRNA-polymer conjugates via grafting-to or grafting-from. Use of 
the grafting-from technique exhibited improved conjugation efficiency and easier purification 
than the grafting-to method.74 
Lin and Maynard prepared polymer conjugates with small interfering ribonucleic acid 
(siRNA) using AGET ATRP (Figure 1-9).74 A macroinitiator was prepared by modifying a 5’-
thiol siRNA with a PDS-functionalized ATRP initiator. Ethylene glycol methacrylate monomers, 
which varied in length, were polymerized in the presence of CuCl2, tris(2-pyridylmethyl amine 
(TPMA), and ascorbic acid (AA) from siRNA in PBS using a sacrificial resin, due to the low 
quantities of the siRNA-macroinitiator available. The authors compared the grafting-to strategy to 
prepare siRNA-polymer conjugates by conjugating pyridyl disulfide terminated polymers to 
siRNA through disulfide exchange reactions. Ultimately, the grafting-from process exhibited 
improved conjugation efficiency and a more facile purification process (Figure 1-9). All siRNA-
polymer conjugates were characterized by PAGE analysis. 
The groups of Wu and Weil used a bottom-up approach to construct nanoscale polymer 
patterns by grafting-from ATRP initiator modified DNA origami.75 Different DNA origami 
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patterns were formed on a surface and underwent hybridization with ATRP-initiator functionalized 
complementary strands. AGET ATRP of MPEGMA in the presence of a sacrificial initiator was 
then performed from the DNA origami initiating sites and polymer growth was followed using 
atomic force microscopy (AFM). The purified polymer products were characterized by agarose 
gel electrophoresis which showed a molecular weight increase from the native DNA origami and 
AFM which showed an increase in the height from the surface. The surface height could be 
controlled depending on the ratio of monomer to initiator employed which led to differences in the 
molecular weight of the polymer. Interestingly, after the preparation of cross-linked polymers 
using similar techniques and the degradation of the DNA origami template under heat stress, the 
polymers retained their shape. Ultimately, this work showcased the great potential of pairing 
grafting-from techniques using AGET ATRP with DNA origami templates to create unique 2D 
and 3D polymer shapes.75  
Enzyme conjugates have also been prepared by the grafting-from method using AGET 
ATRP. Liu and coworkers prepared an enzyme-polymer conjugate by polymerizing acrylamide 
from horseradish peroxidase (HRP) in the presence of air, thus taking advantage of the oxygen 
tolerance inherent to AGET conditions.76 Molecular weight was controlled by the ratio of the HRP 
macroinitiator to monomer and the polymers exhibited low dispersity values. Modification of HRP 
with the small-molecule ATRP initiators decreased the activity of the protein by nearly 50 %, 
likely due to the use of dichloromethane during the initial modification step. However, no change 
in activity after polymerization was detected and the stability of the conjugate to elevated 
temperatures (55 °C) and enzymatic degradation by trypsin was improved. Magnusson, Alexander, 
and co-workers prepared thermo-responsive trypsin conjugates using AGET ATRP.77 The Lys 
residues on trypsin were modified using a heterobifunctional NHS-ester functionalized 
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tetraethylene glycol ATRP initiator and MALDI characterization of the trypsin macroinitiator 
determined there to be an average of 5 initiating sites per protein. Trypsin proteins harboring 
PEGMA-based copolymers or block copolymers which varied in molecular weight were 
synthesized through grafting-from under typical AGET ATRP conditions in aqueous buffer 
solutions at low temperature (4 °C) to form trypsin-polymer conjugates which were characterized 
by SDS-PAGE. The polymers were analyzed by GPC after cleavage from trypsin using tetra-n-
butylammonium fluoride (TBAF) to validate differences in molecular weight. The trypsin-
polymer conjugates exhibited different self-assembly behaviors above the lower critical solution 
temperature (LCST) dependent on the molecular weight of the polymers appended to the protein. 
Conjugate activity could also be regulated through the phase transition of the conjugated 
polymers.77  
Conjugates with therapeutically relevant proteins have also been prepared by grafting-from 
using AGET ATRP conditions. As an alternative to traditional grafting-to PEGylation, Caliceti 
and coworkers utilized AGET ATRP to polymerize PEGMA from recombinant human growth 
factor (rh-GH), a hormone used as a therapeutic for growth deficiency (Figure 1-10A).78 
Conjugation of Lys amino acid residues on rhGH was carried out by treatment of the protein with 
a tetraethylene glycol based heterobifunctional ATRP initiator harboring an NHS ester functional 
group in the presence of pH 7.5 PBS. MALDI-ToF analysis revealed rh-GH functionalized with 
6-8 initiating sites. Polymerization from the rh-GH macroinitiator was performed in phosphate 
buffer at 4 °C using standard AGET ATRP conditions. This conjugate exhibited improved stability 
to heating at 37 °C, mechanical agitation, and enzymatic degradation compared to the native 
protein (Figure 1-10A). The rh-GH-polymer conjugates were characterized via SDS-PAGE which 
indicated a large increase in molecular weight from the native rh-GH. Additionally, acidic 
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hydrolysis to liberate the polymers from the protein allowed for GPC analysis which showed 
relatively monodisperse (Ð = 1.2) polymers. The stability of native rh-GH and the rh-GH-polymer 
conjugate during exposure to heat stress or in the presence of the enzyme pepsin was tested. In 
each case, the rh-GH-polymer conjugates exhibited a higher degree of stability over native rh-GH. 
In vivo studies were carried out wherein rats were injected with either native rh-GH or the rh-GH-
polymer conjugates. It was found that the rh-GH-polymer conjugates retained biological activity 
similarly to the native rh-GH as indicated by weight increase following dosage in rats with a daily 
dosage schedule. Notably, the rh-GH-polymer conjugate retained bioavailability when following 
a twice weekly dosage schedule as indicated by a weight gain in rats, in contrast to rats injected 
with native rh-GH which maintained their weight.78  
 
Figure 1-10. (A) Use of grafting-from to develop rh-GH-PEGMA. (B) Generation of insulin-
poly(trehalose) conjugates. Both conjugates retained bioactivity and exhibited an increased in-vivo 
lifetime in comparison to the native proteins.78-79 
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We have previously used AGET ATRP to prepare a trehalose glycopolymer conjugate of 
insulin (Figure 1-10B). Using the grafting-from approach simplified purification and 
characterization of the insulin-macroinitiator.79 A site-specific insulin macroinitiator was prepared 
by treatment of insulin with a nitrophenyl carbonate modified ATRP initiator in the presence of 
pH 11.0 borate buffer (Figure 1-10B). Basic conditions were used in order to favor modification 
at the Lys residues due to the residues higher nucleophilicity over other N-terminal amines. 
Purification of the insulin-macroinitiator by HPLC and characterization by MALDI and LC-
MS/MS after reduction of the conjugate with DTT revealed a single modification at the LysB29 
residue on insulin. A methacrylate trehalose monomer was polymerized from the insulin-
macroinitiator in pH 7.4 PBS using AGET ATRP conditions in the presence of a sacrificial resin 
and the insulin-polymer conjugate was purified via HPLC after polymerization. The purified 
insulin-polymer conjugate was characterized by SDS-PAGE which appeared as a higher molecular 
weight band to that of native insulin and the polymer was characterized by GPC after digestion of 
insulin with proteinase K and found to be well defined.  Though a 3-fold increase in dosage was 
needed in order to achieve similar decreases of blood glucose to native insulin in mice, the insulin-
polymer conjugate retained bioactivity to a greater extent than nonspecific insulin-polymer 
conjugates prepared by grafting-to.79 
Other groups have prepared nanostructures with covalently incorporated proteins by 
grafting-from ATRP macroinitiators in the presence of cross-linkers to encapsulate the protein 
over the course of polymerization. Matyjaszewski and co-workers prepared GFP nanogels wherein 
GFP was incorporated into a polymer matrix through the course of AGET ATRP in a water-in-oil 
inverse miniemulsion. GFP containing a genetically incorporated ATRP initiator was expressed 
through site-directed mutagenesis. Polymerization from the GFP macroinitiator was carried out in 
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the presence of a PEGMA monomer and a bifunctional methyl methacrylate PEG cross-linker.80 
The GFP-nanogels were characterized by DLS and confocal microscopy. Importantly, it was found 
that grafting-from was essential for keeping the protein covalently entrapped in the nanogel. 
Polymerization using similar conditions to form the nanogel in the presence of wt-GFP, which did 
not contain a genetically incorporated ATRP initiator, resulted in GFP leaching out of the nanogel, 
as determined by the UV-vis absorption spectrum of the purified product. Liu, Zhao, and co-
workers prepared core-corona type nanoparticle with a BSA decorated corona and a cross-linked 
poly(HEMA) core.81 The BSA-macroinitiator was prepared through disulfide exchange with a 
PDS-functionalized ATRP initiator to modify Cys-34 on BSA. Polymerization from the BSA-
macroinitiator was carried out in aqueous solutions using typical AGET ATRP conditions in the 
presence of HEMA and the cross-linker N,N’-methylene diacrylamide. Because the protein 
macroinitiator functioned as a colloidal stabilizer, particle size was controlled by the amount of 
the BSA-macroinitiator employed: loading of a smaller amount of BSA-macroinitiator resulted in 
larger nanoparticles. Interestingly, upon treatment of the nanoparticles with dithiothreitol (DTT) 
in order to reduce disulfide linkages thereby removing BSA from the particle coronas, the 
nanoparticles underwent aggregation as determined by TEM. This indicated that the BSA-
macroinitiator was also important for the stabilization of the nanoparticles in addition to its role in 
initiating polymerization. Additionally, the authors found that covalently immobilized BSA on the 
nanoparticle surface retained up to 76% activity in comparison to native BSA as determined by a 
spectrophotometric assay measuring the hydrolysis of 4-nitrophenyl acetate. The BSA-
nanoparticles were also found to be non-toxic when incubated with HepG2 cells and were 
internalized in the same cell line. These examples illustrate the utility of AGET ATRP grafting 
from in preparing more complex architectures with retention of protein structure and activity.81 
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Matyjaszewski and coworkers systematically screened conditions to polymerize PEGMA 
from BSA using ATRP in aqueous conditions resulting in conjugates with good control over 
molecular weight and dispersity.71 Conditions were first screened with traditional ATRP methods, 
then AGET ATRP was then investigated to prepare BSA conjugates. Interestingly, different 
CuX/ligand conditions were optimal for traditional ATRP compared to AGET ATRP. 
Additionally, controlled polymerization in PBS buffer, which can be challenging from formation 
of insoluble phosphate salts and displacement of ligands by chloride, was achieved with different 
CuX/ligand conditions than was optimal in water. The authors also observed that slow feeding of 
the ascorbic acid reducing agent resulted in the highest molecular weight and narrowest molecular 
weight distribution by minimizing termination with very active ligands like TPMA for 
polymerization of PEGMA under AGET ATRP conditions. 
This observation of improved control with slow feeding of reducing agent, or activators 
regenerated by electron transfer (ARGET) ATRP, was then investigated in depth by the 
Matyjaszewski group to polymerize from proteins.82 This technique allows for low catalyst loading 
and an extra handle of control to start/stop polymerization based on the feed of reducing agent. 
Systematic optimization of polymerization conditions with OEGMA was first accomplished with 
a small molecule initiator; addition of halide salt (30-100 mM), increased equiv of ligand (4/1 
L/Cu), and altering copper concentration (300 to 100 ppm) resulted in the best control with 
acceptable rates of polymerization. Additionally, a block copolymer could be prepared with the 
optimized method and polymerization could be stopped and started with the ascorbic acid feed. 
Polymerization of OEGMA from a BSA macroinitiator was accomplished in PBS buffer with 300 
ppm Cu. Matyjaszewski and coworkers also utilized this technique to polymerize OEGMA from 
GFP with a genetically encoded, base-cleavable initiator.83  
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1.3.5 ICAR ATRP 
During initiators for continuous activator regeneration (ICAR) ATRP, addition of a 
conventional thermal radical initiator (typically an azo-initiator) generates the active Cu(I)/L 
complex in situ, enabling use of low (<100 ppm) levels of copper catalyst.84 Similar to ARGET 
ATRP, oxidatively stable Cu(II) reagents are used and the technique allows for some tolerance to 
oxygen. However, continuous feeding to regenerate the active species is not required due to the 
slow decomposition of the radical initiator. Polymerization conditions are generally mild, although 
with slightly elevated temperatures to activate the thermal initiator, this method may not be 
appropriate for more sensitive biomolecules. The Matyjaszewski group was the first to report the 
use of ICAR ATRP to polymerize from a biomolecule.85 The group initially optimized aqueous 
polymerization conditions for homopolymers of oligo(ethylene glycol) acrylate (OEGA) with a 
small molecule initiator in the presence of TPMA, CuBr2, an excess of tetraethylammonium 
bromide (TEA-Br, 20-300 mM) to maintain the concentration of the deactivator complex, and 2,2'-
azobis[2-(2-imidazolin-2-yl)propane]dihydrochloride (VA-044) as the thermal initiator. Cu 
catalyst concentrations as low as 20 ppm could be employed while maintaining control over 
molecular weight and dispersity. Optimized conditions (100 ppm Cu, 44 °C, 8 h) were then used 
to polymerize OEGA from a BSA macroinitiator, resulting in a conjugate with polymers of 
controlled molecular weight and molecular weight distribution.85 
ICAR ATRP has also been used by the Averick group to polymerize homo- and block- 
copolymers of acrylamide monomers.86 Conjugates of BSA with a block copolymer of acrylamide, 
N,N-dimethylacrylamide (DMA), and N-vinylimidazole (VI) were prepared by ICAR using PBS 
buffer as the halide source as opposed to TEA-Br. BSA conjugates harboring block copolymers of 
VI and OEGA underwent cross-linking in the presence of palladium through the metal interaction 
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with the imidazole containing block, thus forming a biohybrid nanoparticle capable of serving as 
a catalyst for Suzuki-Miyaura cross-coupling reactions.86 Further work used ICAR ATRP to 
explore the effect of conjugation site on Thermomyces languginosa lipase (TL)-poly[N-(3-(N,N-
dimethylamino)propyl) acrylamide] conjugates.87 TL was modified with an ATRP initiator at 
either Lys residues with an NHS-ester or acidic (glutamic and aspartic acid) residues with 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide (EDC) coupling. Enzyme activity was increased by 50 % 
for conjugates grafted from acidic residues compared to from Lys residues, despite 6 initiating 
sites for the former compared to 3 for the latter.87  
1.3.6 SET-LRP 
Single electron-transfer living radical polymerization (SET-LRP) or Cu(0)-mediated LRP 
involves disproportionation of Cu(I) in polar solvents to generate active Cu(0) species and Cu(II) 
species which deactivate the propagating polymer chains; thus aqueous conditions are well suited 
for this polymerization method. Haddleton and coworkers utilized SET-LRP to polymerize water 
soluble monomers from a small library of proteins and peptides.56 BSA, bovine hemoglobin (Hb), 
human Lyz, salmon calcitonin (sCT), and bovine insulin were chosen as model proteins and 
peptides with a variety of molecular weights and properties. Macroinitiators were prepared by 
reacting ATRP initiators with proteins/peptides through NHS-ester coupling at Lys amino acid 
residues. Conditions were screened to polymerize NIPAAm, DMA, and OEGA from the 
protein/peptide-macroinitiators. Synthesis of well-defined BSA conjugates were achieved through 
an excess of CuBr relative to Me6TREN ligand to improve control. Conjugates of Hb were 
obtained, though with broad dispersities (D >1.6) likely due to interactions with Cu(II) with the 
Fe(II) containing heme centers present on the protein. Lyz and sCT macroinitiators were insoluble 
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in aqueous conditions, but the addition of 0.5% SDS denaturant to solubilize the protein-
macroinitiators and sodium bromide (NaBr) to minimize loss of halide anions from SDS resulted 
in well-defined protein-polymer conjugates. The insulin-macroinitiator formed a stable colloid in 
aqueous solution but polymerization could be accomplished in this heterogeneous system with the 
SET-LRP conditions. These conjugates also exhibited interesting self-assembly behavior in 
solution. Demonstration of the range of conjugates prepared by SET-LRP indicates that this is a 
versatile method to prepare polymer conjugates by the grafting from method.56 
In collaboration with the Haddleton group, Joensuu, Milani, Linder and coworkers 
synthesized protein-polymer conjugates by the grafting from method using Cu(0)-mediated LRP 
to make antifouling surfaces.88 A Cys mutant of hydrophobin (NCysHFBI), a protein that self-
assembles on hydrophobic surfaces, was used and conjugation with a maleimide modified initiator 
afforded a site-specific macroinitiator. Growth of poly(PEGA) from the macroinitiator already 
self-assembled on a hydrophobic surface resulted in a surface with decreased nonspecific binding. 
Utilization of this method to graft from NcysHFBI enabled facile synthesis of these surfaces.88 
1.3.7 Photo-mediated ATRP (photo-ATRP) 
Photo-ATRP processes have also gained considerable interest due to the high degree of 
temporal control provided by using light as an external stimulus for the generation of active Cu(I) 
species. The need for external radical initiators or reducing agents is replaced with the requirement 
of additional ligands in the system which also serve as reductants under light irradiation.89 The 
Matyjaszeski group has recently utilized visible-light (Blue LED) mediated ATRP to graft 
oligo(ethylene oxide) methyl ether methacrylate (OEOMA) monomers from the surface of BSA 
and DNA in order to develop BSA- and DNA-polymer conjugates.90 Notably, polymerization was 
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carried out in aqueous conditions and in the presence of low ppm of Cu (50-1000 ppm). The 
deployment of glucose, glucose oxidase, and sodium pyruvate (Glu, GOx, SP) was used to 
deoxygenate the polymerization mixture, thus precluding the need for N2 sparging or freeze-pump-
thaw procedures.90 The complete elimination of metal catalysts in order to synthesize protein-
polymer conjugates would be a welcome development, especially given the recent progress in 
metal-free photo-ATRP methodology.91-94 
1.3.8 Electrochemical ATRP (e-ATRP) 
Electrochemically mediated ATRP was first reported by the Matyjaszewski group in 2011 
and has garnered attention due to its general tolerance of oxygen, low catalyst loading, removal of 
chemical reducing agents, and feasibility of temporal control.95 In the case of eATRP, 
polymerization is performed in an electrochemical cell with regeneration of the reduced metal 
species controlled by an applied cathodic current. Application of an anodic current acts to oxidize 
the metal species thereby terminating the polymerization.95-97 Many groups have taken advantage 
of eATRP for a variety of unique applications.98-100  The Matyjaszewski group recently utilized 
eATRP for grafting-from initiator functionalized DNA substrates under aqueous conditions.101 A 
screen printed electrode (SPE) was used to bypass the large reaction volumes required of 
electrochemical setups, which would render grafting-from using eATRP an unreasonable method 
for expensive biomolecules. SPE’s are inexpensive substrates that can be smaller than 1 cm2 and 
contain a working electrode, counter electrode, and a reference electrode typical of electrochemical 
setups. Interestingly, the authors were able to decrease reaction volumes down to 75 µL using 
SPEs. This large decrease in reaction volume necessitated the use of an enzyme degassing system 
consisting of GOx, glucose, and SP rather than traditional degassing methods. Polymerization of 
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2-(methylsulfinyl)ethyl acrylate (MSEA) and OEGMA was carried out from the DNA-
macroinitiator in the presence of CuBr2 and TPMA under eATRP conditions and an extensive 
study was carried out to elucidate the effects that different catalyst and ligand loadings had on the 
reaction outcome. Notably, DNA-polymer conjugates larger than 25 kDa were able to be 
synthesized in <30 min, despite the low monomer conversion observed.101  
1.4 Biomolecule-polymer conjugates accessed through RAFT polymerization 
RAFT polymerization is a living and controlled radical polymerization technique that 
quickly garnered popularity after its initial discovery reported in 1998.102-104 Control during RAFT 
polymerization is obtained through a degenerative chain transfer process that is mediated by a 
chain transfer agent (CTA; also referred to as a RAFT agent).11, 105-106 The RAFT agent is a small 
molecule organic compound typically composed of a thiocarbonylthiol group, some common 
architectures include xanthates, trithiocarbonates, dithioesters, and dithiocarbamates.107-108 The 
RAFT agent structure is often conceptually split into two parts, the “R” group and the “Z” group 
(Figure 1-11).105-106  The R group initiates radical polymerization while the Z group is involved 
in both modulating the reactivity of the thiocarbonyl bond towards radical addition and also in 
stabilizing the subsequent radical formed on the thiocarbonyl carbon atom (Figure 1-11). A useful 
feature of RAFT polymerization is that both the R and Z groups are incorporated on the polymer 
chain ends upon termination, allowing for further functionality to be engendered at either end.105-




Figure 1-11. RAFT polymerization mechanism. 
The widely accepted mechanism for traditional RAFT polymerization involves initiation 
using a prototypical radical initiator such as the thermally activated initiator 
azobibsisobutyronitrile (AIBN) (Figure 1-11).11, 106, 109 Photochemical initiation is another popular 
form of initiation for RAFT polymerization and will be discussed later in the review. Initiation and 
radical addition to monomers produce propagating oligomeric radicals which can then enter into 
the RAFT equilibrium whereby the propagating radicals add into the thiocarbonyl bond of the 
RAFT agent (I) and produce a stabilized radical on the thiocarbonylthio carbon atom (II) (Figure 
1-11). During this equilibrium process, (II) can fragment back to produce the oligomeric 
propagating radical and the intact RAFT agent, or homolytic cleavage of the R group can occur 
whereby the RAFT agent becomes appended to the end of the oligomer (III) and the R group 
radical can then re-initiate polymerization. After this initial equilibrium process, polymer chains 
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propagate through the addition of monomers and either enter into the RAFT equilibrium process 
again with the thiocarbonylthio capped polymer chains or continue adding monomers. It is this 
rapid equilibrium process that affords control over the polymerization because the concentration 
of stabilized radical intermediates is greater than that of the propagating radicals, thus 
unproductive termination pathways are greatly limited (Figure 1-11). RAFT polymerization is a 
popular method in the bioconjugation realm due to its wide monomer scope, solvent compatibility, 
and general avoidance of transition metals (though there are exceptions such as in photo-induced 
electron transfer-RAFT (PET-RAFT)).110-111 Although there exist many examples of generating 
polymers through RAFT with bioactive functionality either at the end of the polymer or as pendant 
groups, this section of the review will only cover peptide-, protein-, and nucleic acid-polymer 
conjugates by grafting-from using RAFT.112-116  
1.4.1 Protein-polymer conjugates 
 The initial report of grafting-from a protein using RAFT polymerization was by Davis, Bulmus 
and co-workers where they developed a pyridyl disulfide functionalized trithiocarbonate RAFT 
agent which could undergo disulfide exchange with Cys-34 on BSA thereby forming a 
macroRAFT agent where BSA acted as the Z-group. This was planned due to Z-group retention 
on polymer chain ends (Figure 1-12, top).117 Formation of the macroRAFT agent was monitored 
by UV-vis spectroscopy to visualize the formation of the 2-pyridinethione byproduct that occurs 
after PDS exchange and absorbs in the 340-370 nm range. The authors opted to initiate 
polymerization of PEG-acrylate (PEGA) using γ-irradiation which offered the benefit of room 
temperature initiation in aqueous conditions suitable to the stability of BSA. Though γ-irradiation 
can potentially be detrimental to protein structure and function, the authors determined both BSA 
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and glucose oxidase to retain up to 92 % and 88 % activity after 6 h of γ-irradiation, respectively. 
Polymerization of PEGA was carried out in the presence of the macroRAFT agent in a mixture of 
water and DMF under γ-irradiation at room temperature thereby producing BSA-polymer 
conjugates which were characterized by GPC, MALDI, and non-denaturing PAGE. The BSA-
polymer conjugate was treated with tris(2-carboxyethyl)phosphine (TCEP) in order to reduce the 
disulfide linkage thus facilitating disassembly of the polymer from the protein to allow for 
characterization of the polymer itself. However, the disulfide bond remained intact upon treatment 
with TCEP, only demonstrating partial reduction for low molecular weight conjugates which the 
authors attributed to the shielding of the disulfide bond by the polymer. Treatment of the BSA-
poly(PEGA) conjugates in the presence of concentrated TCEP solutions completely denatured the 
protein but allowed for analysis of the polymers. Characterization of the polymers revealed a few 
drawbacks: though the molecular weight of the polymers increased linearly with increasing 
monomer conversion, the polymers exhibited dispersity values of up to 2.0 with increasing 
molecular weight. This observation was attributed to the steric hindrance imparted by BSA in 
addition to the growing polymer chains during the equilibrium process. Additionally, there was an 
observed two-hour inhibition period at the start of polymerization which was attributed to slow 
fragmentation of the macroRAFT agent. Despite these minor drawbacks, this elegant work paved 
the way for the expansion of grafting-from using RAFT to generate biomolecule-polymer 




Figure 1-12. (Top) The Davis and Bulmus groups work developing protein Z-group modified 
macroRAFT agents and polymerization from BSA.117 (Bottom) Sumerlin group work on 
developing R-group modified macroRAFT agents to develop thermoresponsive protein-polymer 
conjugates.118 
 The Davis and Bulmus groups quickly expanded on their initial work by polymerizing NIPAAm 
and hydroxyethyl acrylate (HEA) in the presence of the BSA-macroRAFT agent using a room 
temperature and water soluble radical initiator (VA-044).119 An inhibition period was observed at 
the beginning stages of polymerization as in their earlier work, however the polymerization 
exhibited a linear evolution of Ln[M]0/[M] versus time indicative of a steady concentration of 
radicals in solution over the course of polymerization. TCEP reduction of the protein-polymer 
conjugate was carried out and the polymers analyzed via GPC which again showed a linear 
increase in molecular weight with increasing monomer conversion. Interestingly the 
poly(NIPAAm) samples were relatively monodisperse exhibiting dispersity values up to 1.3 for 
the higher molecular weight polymers. This is in stark contrast to their above described grafting-
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from polymerization of PEGA which exhibited dispersity values up to 2.0. Activity studies were 
also carried out to determine the esterase-like activity of BSA to hydrolyze p-nitrophenyl acetate. 
The BSA-macro RAFT agent, BSA incubated with VA-044, and BSA-poly(NIPAAm) conjugates 
all remained active, while controls in which BSA was heated to 85 °C in buffer for 4 h lost up to 
80 % activity. Additionally, BSA-poly(NIPAAm) conjugates displayed increased LCST values in 
comparison to poly(NIPAAm) alone, which increased as the polymer molecular weight of the 
conjugate decreased.119 In an interesting follow-up work, the Davis group was able to employ 
similar polymerization methodology in the presence of a bifunctional PDS trithiocarbonate RAFT 
agent to access polymers harboring biomolecules at each end through a combination of grafting-
to and grafting-from approaches.120 
 The thermoresponsive properties of BSA-poly(NIPAAm) conjugates were studied further by the 
Sumerlin group (Figure 1-12, bottom).118 A BSA-macroRAFT agent was developed through 
attachment of a maleimide functionalized RAFT agent on Cys-34. Instead of attaching BSA to the 
Z-group portion of the RAFT agent similar to the Bulmus and Davis work mentioned above, 
Sumerlin and co-workers attached BSA on the R-group portion of the RAFT agent (Figure 1-12, 
bottom). This offers several unique advantages; the thiocarbonyl bond is more accessible for chain 
transfer thereby improving on the control over polymerization processes. Additionally, having the 
thiocarbonylthio group at the polymer chain end would allow for post-polymerization modification 
without interfering with the protein on the other end of the polymer. Polymerization of NIPAAm 
in the presence of the BSA-macroRAFT agent was carried out in pH 6.0 phosphate buffer using 
VA-044 as the radical initiator similar to earlier reports. Purification of the BSA-poly(NIPAAm) 
conjugates was carried out via thermal precipitation at 40 ˚C. The purified BSA-poly(NIPAAm) 
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conjugates were treated with TCEP and the corresponding polymers characterized via GPC which 
showed an increase in polymer molecular weight with increasing monomer conversion and high 
molecular weight polymers (234 kDa) exhibited a dispersity of 1.38. The BSA-macroRAFT agent 
and the BSA-poly(NIPAAm) conjugate both retained their secondary structure as determined by 
circular dichroism and also retained esterase-like activity (>90 % activity compared to native 
BSA). The activity of the protein could be modulated due to the thermally responsive nature of 
poly(NIPAAm) (Figure 1-13). Upon exposure to heating above the LCST of the BSA-
poly(NIPAAm) conjugate (40 ˚C), the protein activity was reduced to 75 %. Interestingly, the 
protein activity was regained upon cooling of the conjugate solution below the LCST and this 
process was cycled up to 5 times with no apparent loss in protein activity after each cycle (Figure 
1-13).118  
 
Figure 1-13. “(a) Activity of (1) BSA, (2) BSA-macroCTA, (3) BSA-poly(NIPAAm) (free BSA 
present) with conjugated polymer of 234,000g/mol, (4)BSA-poly(NIPAAm) thermal precipitate, 
(5) BSA-poly(NIPAAm) thermal precipitate at 40 °C assay temperature (with respect to BSA at 
40 °C), (6) BSA+poly(NIPAAm) physical mixture, (7) poly(NIPAAm), (8) BSA after incubation 
at 75 °C for 3 h. All assays were conducted with identical [BSA]. (b) Activity of BSA-
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poly(NIPAAm) thermal precipitate during thermal cycling between 25 and 40 °C.” 118, Copyright 
2008. Reproduced with permission from the American Chemical Society. 
 The Sumerlin group next explored the synthesis of more complex thermoresponsive protein-
polymer conjugates through RAFT polymerization by implementing methodology which allowed 
for the formation of block copolymer architectures through grafting-from.121-122 In their initial 
work, the group attached a RAFT agent to Cys-34 on BSA through a maleimide linkage, again 
appending the protein to the R-group of the RAFT agent.121 The BSA-poly(NIPAAm) conjugate 
was synthesized, purified, and subsequently characterized using SDS-PAGE. Retention of the 
trithiocarbonate end-group could be visualized using UV-vis spectroscopy with the characteristic 
absorption appearing at ~310 nm. The BSA-poly(NIPAAm) conjugate was then employed as the 
macroRAFT agent in the subsequent polymerization of DMA using similar conditions to those 
mentioned above to produce the second block. UV-vis spectroscopy indicated retention of the 
trithiocarbonate end-group even after addition of the DMA block. Additionally, the 
thermoresponsive properties were measured using DLS which showed an increase in the 
hydrodynamic diameter of the protein-polymer conjugate at elevated temperatures.121 Similar 
work targeted the seven Lys amino acid residues on Lyz using a NHS-ester functionalized RAFT 
agent thereby forming a Lyz-macroRAFT agent with the protein on the R-group.122 Lyz-
poly(NIPAAm)-b-poly(DMA) conjugates were synthesized using similar polymerization 
conditions to their previous work and their thermoresponsive solution behavior analyzed.122 
 Konkolewicz, Page, Berberich, and co-workers used RAFT polymerization and a combination 
of grafting-to and grafting-from procedures to perform a thorough study detailing the effects of 
different types of polymers of varying lengths and structures on the stability and activity of Lyz 
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conjugates.123 The activity of Lyz was tested using a standard spectrophotometric technique that 
measures lysis of Micrococcus lysodeikticus in the presence of Lyz. As might be expected, the 
Lyz-polymer conjugate activity was reduced as the molecular weight of the polymer increased. 
Charged polymers attached to Lyz were also studied with negatively charged polymers resulting 
in reduced enzyme activity due to charge repulsion on the negatively charged M. lysodeikticus cell. 
Cationic polymers had the opposite effect. Additionally, the thermal stability of the Lyz-polymer 
conjugates was reduced. However, the chemical stability towards treatment with the protein 
denaturant guanidine HCl was increased with the highest molecular weight conjugates exhibiting 
the greatest stability, most likely due to a shielding effect imposed by polymers on the enzyme 
surface.123  
 The establishment of photochemically initiated grafting-from polymerization using RAFT 
proved to be a significant addition to the practitioners’ toolbox which introduced an additional 
degree of control over the polymerization process. Chen and co-workers used a specially prepared 
Escherichia coli inorganic pyrophosphatase (PPase) protein in which they exchanged the Lys-148 
amino acid residue with Cys through site-directed mutagenesis.124 The Cys amino acid residue was 
used as the conjugation site for the attachment of a maleimide functionalized RAFT agent, thus 
generating the PPase-macroRAFT agent with the protein appended as the R-group. Polymerization 
of NIPAAm was performed in water and at room temperature under visible (420 nm) light 
irradiation in the presence of (2,4,6-trimethylbenzoyl)phenyl phosphonic acid sodium (TPO-Na) 
as the photoinitiator. The polymerization exhibited rapid kinetics with molecular weights reaching 
150 kDa within 30 min. Notably, the authors were able to control polymerization by either turning 
the light source ‘on’ or ‘off’. Polymerization was halted upon removal of the light source but 
42 
 
continued when the light source was turned on. This process was cycled and the molecular weight 
of the PPase-poly(NIPAAm) conjugate was followed by SDS-PAGE. Because the conjugation site 
of the RAFT agent and the conjugated polymer are near the active site of the protein, the PPase 
activity was greatly reduced. However, an interesting observation was made when it was 
determined that PPase-poly(NIPAAm) conjugates harboring higher molecular weight 
poly(NIPAAm) show an increased activity over the wild-type PPase above the LCST of the 
conjugate (45 ˚C).124  
 
Figure 1-14. Proposed mechanism of a prototypical PET-RAFT polymerization using a transition-
metal based chromophore. 
 Boyer and co-workers reported on using PET-RAFT to graft-from BSA in aqueous conditions 
(Figure 1-14).125 PDS exchange was used to append a trithiocarbonate-based chain transfer agent 
on BSA to generate the BSA-macroRAFT agent where BSA was appended as the R-group. 
Grafting-from polymerization of either DMA or OEGA was carried out in aqueous conditions in 
the presence of Ru(bpy)3Cl2, the BSA-macroRAFT agent, and blue LED irradiation and proceeded 
in a controlled manner to produce monodisperse protein-polymer conjugates. Additionally, the 
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prepared BSA-polymer conjugates retained identical activity to native BSA as determined by an 
esterase activity assay.125 In 2017, the Sumerlin group expanded on PET-RAFT methodology by 
employing an organophotocatalyst to polymerize an extended class of monomers under visible-
light irradiation and also demonstrated the construction of block copolymers grafted-from Lyz.126 
 
Figure 1-15. Modification of yeast cells with RAFT agents and polymerization from yeast cell 
surfaces. 
 Beyond protein-polymer conjugation, the ability to engineer whole live cell surfaces with 
polymers of controlled molecular weights and architectures represents an important challenge.127 
Seminal work by Soh, Hawker, and coworkers used grafting-from techniques to assemble 
polymers on live cell surfaces (Figure 1-15).128 Though there were a few previous reports of using 
grafting-to methods to obtain polymer-functionalized cells, the conjugation efficiencies were often 
minimal which necessitated the need for a large excess of synthesized polymer. Additionally, 
uncontrolled polymerization techniques to encapsulate cells resulted in the cells being difficult to 
access. Polymerization of PEG modified acrylamide monomers was carried out in the presence of 
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live wild-type Saccharomyces cerevisiae (Baker’s yeast) cells under PET-RAFT conditions using 
eosin Y as the photocatalyst and triethanolamine as the co-catalyst Figure 1-15). In order to 
maximize cell viability, the PET-RAFT conditions were modified in order to quicken 
polymerization kinetics and monomer conversion was kept low in order to maximize end-group 
retention. Notably, the yeast cells remained intact and were able to undergo cell proliferation after 
being subjected to polymerization conditions. After these promising initial results, the authors 
introduced dibenzocyclooctyl (DBCO) functionality on the yeast cell surfaces through NHS-ester 
conjugation (Figure 1-15). This allowed for the efficient conjugation of azide-modified RAFT 
agents through strain-promoted 1,3-dipolar cycloaddition (SPAAC) thereby producing cell-based 
macro-RAFT agents.  PEG-based acrylamide monomers were then polymerized using the 
modified PET-RAFT conditions employing the cell-based macro-RAFT agents and also a 
sacrificial RAFT agent in order to maintain control over polymerization. Additionally, the authors 
were able to incorporate azide functionality along the polymer chain for post-polymerization 
functionalization with an Alexa Fluor 647 strained alkyne analogue. Using confocal microscopy 
of the fluorescently labelled cell-polymer conjugates indicated that fluorescence was localized 
only on the cell surface. This experiment showcased that cell-surface polymers were able to 
undergo post-polymerization modification using bioorthogonal methods and that polymerization 
only occurred on the cell surface without any observable polymer growth occurring inside the cell. 
Notably, the cell-polymer conjugates derived from grafting-from polymerization exhibited much 
greater grafting densities than those prepared using the traditional grafting-to technique. The 
authors were able to carry this technique forward to a mammalian cell line through the non-
covalent modification of Jurkat cell membranes with a RAFT agent modified lipid. Cell viability 
assays performed after polymerization from the cell surface exhibited up to 90 % viability and also 
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retained their metabolic activity.128 
1.4.2 Peptide-polymer conjugates 
 
Figure 1-16. Development of oligopeptide-macroRAFT agents. 
Some examples of grafting-from oligopeptide sequences using RAFT polymerization were 
reported by the Perrier and Börner groups.129-131 Börner and coworkers’ first manuscript of this 
kind describes the SPPS of an oligopeptide in which the N-terminus was modified with a 
dithiobenzoate-based RAFT agent via DCC coupling while on-resin (Figure 1-16).129 Treatment 
of the resin-bound peptide with a TFA cleavage cocktail and subsequent precipitation resulted in 
the production of the oligopeptide-macroRAFT agent (1) with the oligopeptide positioned as the 
R-group. The authors noted the formation of a thioamide byproduct which is due to nucleophilic 
attack of the peptide amine terminus with the dithioester functionality during the DCC coupling 
step (Figure 1-16). This byproduct was observed via electrospray ionization mass spectrometry 
(ESI-MS) and is probable given the sensitivity of dithiobenzoate-based RAFT agents towards 
aminolysis. Despite this, the authors proceeded with polymerization of nBA using 1 as the 
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thioamide byproduct would not interfere with polymerization conditions. However, the authors 
also developed a second approach to creating oligopeptide-macroRAFT agents by modifying an 
oligopeptide ATRP macroinitiator on resin. This was then reacted with a pyridinium salt of 
dithiobenzoic acid to produce 2 without formation of the previously observed thioamide byproduct 
(Figure 1-16). Polymerization of nBA employing either of the oligopeptide-macroRAFT agents 
generated monodisperse polymers and exhibited linear polymerization kinetics typical of a 
controlled RAFT process. However, it is important to note the significant inhibition observed at 
the start of polymerization which lasted between 4-8 h depending on the oligopeptide-macroRAFT 
agent used.129 In a later report, the authors developed a trithiocarbonate-based GGRGDS 
oligopeptide-macroRAFT agent (3) which was much more stable than the dithiobenzoate 
derivative published earlier.130 Notably, polymerization of nBA using 3 did not exhibit an 
inhibition period at the start of the polymerization, though it is not clear if the inhibition period 
was due to differences in the oligopeptide structure or differences between the dithiobenzoate or 
trithiocarbonate structures. The authors employed 3 in the polymerization of NIPAAm to produce 
oligopeptide-poly(NIPAAm) conjugates, the ω-trithiocarbonate group was then reduced to afford 
a poly(NIPAAm) terminated with a free thiol which could be used for surface functionalization on 
a gold substrate. Cell adhesion of L929 mouse fibroblasts was examined on the GGRGDS-
poly(NIPAAm) functionalized surface and was found to be faster than the corresponding 
poly(NIPAAm) functionalized surfaces.130 The Börner group has also developed ABC-triblock co-




Figure 1-17. Exhibited hydrolysis of nitrile substituted RAFT derivatives after treatment with 
standard peptide cleavage cocktails.133 
An important additional consideration in the construction of oligopeptide-macroRAFT 
agents is hydrolysis of nitrile (CN) groups on the RAFT agent structure during cleavage of resin-
bound peptides (Figure 1-17).133 Because typical peptide cleavage cocktails make use of strongly 
acidic conditions (>95 % TFA), RAFT agents appended to peptide structures during SPPS undergo 
hydrolysis thereby forming carboxamide functional groups in place of the nitrile substituent 
(Figure 1-17).133-135 Despite this, Thang and co-workers were still able to perform controlled 
RAFT polymerization of DMAEMA, OEGMA, and n-butyl methacrylate (nBMA) monomers 
employing trithiocarbonate-based oligopeptide-macroRAFT agents in which the nitrile substituent 
had undergone hydrolysis to the corresponding carboxamide.133 Though the earlier reports by the 
Börner group made use of nitrile modified dithiobenzoate RAFT agents in which no carboxamide 
formation was reported, they used a 2 % TFA in DCM cleavage cocktail which cleaved the 




1.4.3 Nucleic acid-polymer conjugates 
  Grafting-from DNA using RAFT was first employed by the He group for purposes of DNA 
biosensing.136-137 A few of their reports detailing their use of grafting-from for DNA detection 
made use of ATRP conditions (vide supra), however the transition metals employed for 
polymerization formed complexes with DNA molecules which complicated their intended 
application due to unwanted background noise. RAFT seemed to be a promising alternative due to 
the absence of transition metals.136 Complementary oligonucleotide probes were functionalized on 
a gold surface and a separate complementary oligonucleotide sequences were synthesized with a 
trithiocarbonate-based RAFT agent attached to the amine terminus of the sequence via NHS-ester 
chemistry. The strands were allowed to hybridize and ligation was performed using a T4 ligase, 
thereby affixing the RAFT agent to the complementary strand placed on the gold substrate, 
forming surface immobilized DNA-macroRAFT agents. RAFT polymerization of OEGMA was 
performed from the modified surfaces in the presence of water at 30 ˚C using AIBN as the thermal 
initiator. Film characterization was performed using AFM, ellipsometry, and ATR-FTIR. Notably, 
the polymer film generated from the DNA-macroRAFT agents were much thicker than those 
generated by ATRP described in their previous reports and a large reduction in the background 
signal was observed, most likely due to the absence of transition metals during polymerization.136 
A thorough follow-up report was published soon after detailing the effects of variations in 
polymerization conditions (initiator concentration, temperature, reaction time, RAFT agent surface 
density) on film thickness of the DNA-polymer conjugates.137  
  RAFT polymerization from DNA-macro-RAFT agents have also been used for 
electrochemical target DNA (tDNA) biosensing applications.138-139 Recently reported 
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methodology makes use of immobilized peptide nucleic acid (PNA)-DNA duplexes on gold 
electrode substrates that have been modified with dithiobenzoate-based RAFT agents using Zr4+ 
mediated coupling chemistry targeting the phosphate groups on the PNA-DNA duplexes. 
Polymerization of ferrocenylmethyl methacrylate (FcMMA) using VA-044 in the presence of the 
DNA-macroRAFT agent-modified surface was carried out and the electrochemical response of the 
prepared polymer modified surfaces was tested. Only gold electrodes which contained the tDNA-
polymer conjugates exhibited an oxidation peak on the square-wave voltammogram, with a peak 
potential of 0.3 V. Electrochemical analysis of gold substrates which served as controls (PNA 
probe, tDNA, Zr4+, RAFT agent, VA-044, or FcMMA) did not exhibit any visible oxidation peaks 
on the square-wave voltammogram. Notably, oxidation peak currents of the tDNA-polymer 
substrates increased linearly as the surface concentration of tDNA increased and allowed for the 
detection of the tDNA at concentrations as low as 3.2 aM.138-139  
  Recently, photo-RAFT processes have also been used to develop DNA-polymer conjugates 
via grafting-from.45 Barner-Kowollik, Ng, Weil, and co-workers developed two ssDNA-
macroRAFT agents based on either 4-cyano-4-(phenylcarbonothioylthio)pentanoic acid (CPADB) 
or 2-(butylthiocarbonothioyl)propionic acid (BTPA) with the ssDNA appended as the R-group of 
the RAFT agent. CPADB and BTPA were functionalized with either a PFP or NHS-ester group 
and coupled to the amine terminus of the purified ssDNA (NH2-ssDNA). RAFT polymerization 
employing the BTPA- or CPADB-DNA macroRAFT agents was performed using acrylamide, 
acrylate, or methacrylate based monomers in the presence of eosin Y and ascorbic acid under blue 
LED irradiation. DNA-polymer conjugates could be purified by membrane filtration and were 
characterized by GPC and native PAGE. While polymerization from the ssDNA-macroRAFT 
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agent was operative, the polymers were not monodisperse owing to potential side reactions with 
the ssDNA which produced low molecular weight tailing in the GPC traces of the DNA-polymer 
conjugates. Additionally, high molecular weight shoulders were observed in the GPC spectra of 
ssDNA-poly(OEGMA) conjugates most likely due to transesterification or side reactions to the 
growing polymer backbone.45, 140 Impressively, the purified ssDNA-polymer conjugates were able 
to undergo hybridization with a complementary ssDNA sequence which had been modified with 
a Rhodamine dye on the DNA terminus thereby showcasing that the prepared ssDNA-polymer 
conjugates maintain functionality.45 
1.5 Biomolecule-polymer conjugates accessed through ROMP 
Ring-opening metathesis polymerization (ROMP) has early roots stemming from the initial 
discovery of olefin metathesis in the 1950s, unlike the more recently developed ATRP and RAFT 
methodologies which were reported in the mid-1990s.17, 46-47, 141-142 The introduction of well-
defined single-component carbene complexes based on molybdenum or ruthenium, spearheaded 
by the Schrock and Grubbs groups, has paved way for significant advances in ROMP thereby 
enhancing the synthesis of well-defined and monodisperse polymers through the living 
polymerization of strained cyclic olefin monomers.10, 17, 143-144 In particular, the augmented 
functional group tolerance and increased stability in aqueous media of the ruthenium-based 
carbenes introduced by Grubbs and co-workers expanded the scope of chemical transformations 
and facilitated expansion of ROMP into the realm of biomolecule-polymer conjugation.145-148 As 
such, ROMP bolsters the chemical toolbox available to chemical biologists and materials chemists 
alike through the expansion of available polymers with unique function, structures, and material 




Figure 1-18. General mechanism of ROMP polymerization. 
The ROMP mechanism involves coordination of a transition-metal based carbene to a 
strained cyclic olefin and subsequent [2+2] cycloaddition to form a metallacyclobutane 
intermediate.17, 150 The metallacyclobutane then undergoes [2+2] cycloreversion to yield a new 
olefin and transition-metal carbene which exists on the end of the propagating polymer chain 
(Figure 1-18). The transition-metal carbene catalyst will continue to react with other cyclic olefin 
monomers with the typical driving force being the release of ring strain from the strained cyclic 
olefin or an increase an entropy when polymerizing non-strained cyclic olefins. Ruthenium-based 
transition-metal carbene complexes are the most widely utilized in the context of biomolecule 
modification due to their stability and functional group tolerance.17, 39  
1.5.1 Grafting-from proteins using ROMP 
Isarov and Pokorski reported the only example of developing protein-polymer conjugates 
through grafting-from using ROMP (Figure 1-19).151 Because the polymerization needed to be 
carried out in buffered aqueous solutions compatible with the protein, the authors synthesized a 
water-soluble Grubbs 3rd generation carbene analogue. Taking inspiration from the Emrick group 
w0 prepared PEG-functionalized ruthenium carbene derivatives, Isarov and Pokorski synthesized 
a PEGylated Grubbs 3rd generation derivative (4) through a ligand exchange reaction of to displace 
52 
 
the original bromopyridyl groups with PEGylated pyridyl ligands to generate 4 (Figure 1-19).151-
152 The catalyst was found to be stable in water for over 10 h as confirmed by 1H NMR monitoring 
of the alkylidene resonance in D2O which remained unchanged over the course of the study. Test 
polymerizations to evaluate catalyst activity were carried out with PEGylated norbornene 
monomers in both DCM and PBS in order to compare reactivity in both organic and aqueous 
conditions. Ultimately, polymerization kinetics were found to be slower in aqueous solutions most 
likely due to a decreased rate of ligand dissociation.151 
 
Figure 1-19. ROMP from Lyz to develop Lyz-polymer conjugates using a water-soluble Ru-based 
carbine. 151, Copyright 2015. Adopted with permission from the American Chemical Society. 
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Norbornenyl groups were added to reactive Lys residues on the protein surface of Lyz. 
Treatment of the protein with exo-norbornene dicarboxylic anhydride resulted in the modification 
of up to 5-6 Lys residues per protein. Excess amounts of 4 were then reacted with the norbornenyl 
modified Lyz to yield the protein macroinitiator which was used for the in-situ growth of 
PEGylated norbornene monomers from the protein surface. Large monomer loadings (>200 equiv 
per protein) were ultimately needed to initiate polymerization due to the poor accessibility of the 
catalytic site on the protein. As a result, only high molecular weights were able to be targeted, 
since at low monomer concentrations no polymerization could be initiated.151 
In a follow-up work from the Pokorski group, this challenge was resolved by using a 
grafting-to approach to instead attach the synthesized polymer to the protein.153 This allowed for 
greater control during polymerization and enabled the synthesis of monodisperse polymers of 
varying molecular weights to be fully characterized and subsequently conjugated to the protein 
through the Lys residues. The grafting-to strategy is utilized to a greater extent for the conjugation 
of polymers prepared through ROMP.12, 154-155 Though grafting-from is under-utilized in the 
context of ROMP, the initial disclosure from Isarov and Pokorski provides an important foundation 
with which to develop improved systems through careful tuning of catalyst systems.151, 153 
1.5.2 Grafting-through approaches with ROMP 
The bulk of examples for ROMP in the context of biomolecule modification use the 
grafting-through strategy. In grafting-through, a biomolecule or bioactive material is attached 
directly to a monomer (such as norbornene) thus generating a “macromonomer”. The prepared 
macromonomer can then be polymerized, resulting in a polymer chain with the pendant bioactive 
cargo attached. Several elegant examples make use of grafting-through using ROMP to prepare 
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polymer materials with potential therapeutic utility.156-159 The employment of grafting-through 
using ROMP in the context of biomolecule modification has been developed extensively for 
materials bearing nucleic acids or DNA and oligopeptides.  
1.5.2.1  Oligopeptides 
There exist many examples of grafting-through using ROMP to generate polymer architectures 
harboring pendant amino acids and oligopeptides. Grubbs and co-workers disclosed many of the 
initial reports detailing the modification of amino acids and peptides using ruthenium-based 
carbene complexes. Early manuscripts in the 1990’s detailing the extensive use of ring-closing 
metathesis (RCM) for the generation of cyclic peptides established a foundation for the use of 
ruthenium-based carbenes to invoke chemical transformations on densely functionalized 
substrates; interested readers are directed to these literature reports.160-162 In an early example from 
Maynard and Grubbs transitioning into ROMP, template directed RCM was used to create cyclic 
crown ether monomers with a pendent phenylalanine (Phe) amino acid residue.163 These cyclic 
monomers were subsequently polymerized through ROMP to yield polyethers with novel olefinic 
backbone structures and bioactive side chains. Olefin containing polyethers are of interest 
primarily due to their structural similarity with PEG; however the presence of olefins along the 
backbone of the polymer introduces a greater degree of synthetic utility making possible the 
introduction of complex functionality through post-polymerization modification techniques. 
Polymerization attempts using unprotected phenylalanine substrates were ultimately stymied due 
to solubility challenges which led to the employment of protected amino acids in earlier 
approaches.164-166 Follow-up work focused on developing co-polymers with more complex 
functionality. Polymers composed of a norbornenyl backbone with pendant oligonucleotide 
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sequences Gly-Arg-Gly-Asp (GRGD) and Pro-His-Ser-Arg-Asn (PHSRN) were synthesized and 
their biological activity tested.167-168 RGD is a peptide sequence on cell surface integrins which 
mediates the binding of extracellular proteins thereby influencing cell processes. The SRN 
sequence, physically near the near the RGD sequence in the extracellular matrix protein 
fibronectin, enhances binding. Norbornene monomers harboring the RGD or SRN oligopeptides 
were homo- or copolymerized using Grubbs 2nd generation catalyst. Using ROMP allowed for the 
fine-tuning of the final polymer to incorporate a controlled amount of RGD. The oligopeptide 
functionalized monomers remained protected over the course of polymerization in order to 
maintain solubility which necessitated a post-polymerization deprotection strategy resulting in 
water-soluble polymers to be used in biological assays. Cell adhesion inhibition studies were 
performed where fibronectin coated surfaces were incubated with human foreskin fibroblast (HFF) 
cells in the presence of either oligopeptide homo- and co-polymers, the oligopeptides alone, or 
buffer. Interestingly, the co-polymers consisting of pendant GRGDS and PHSRN sequences 
inhibited HFF adhesion to fibronectin to a greater degree than homopolymers with pendant 
GRGDS and the GRGDS or PHSRN peptides alone, highlighting the synergistic effect of the two 
oligopeptide sequences and underscoring the utility of ROMP to prepare bioactive materials.  
Several groups sought to expand or improve upon the use of ROMP to access pendant 
oligopeptide polymer architectures in order to better understand structure/function relationships of 
oligopeptide grafted polymers. The Muthukumar and Emrick groups used ROMP to generate 
polyelectrolytes through the polymerization of OEG or pentalysine oligopeptide functionalized 
cyclooctene monomers thereby accessing homo- or co-polymers which differed in charge 
density.169 Solution behavior could be modulated based on the length of the OEG or Lys blocks 
and on the graft density of Lys blocks. Additionally, it was found that poly(cyclooctene)-graft-
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pentalysine polymers underwent complexation with DNA under acidic conditions but was 
disrupted under basic conditions. This characteristic can potentially be utilized in plasmid DNA 
transfection applications.169 Conrad and Grubbs also utilized ROMP to develop polymers bearing 
the pendant VPGVG elastin oligopeptide attached to a norbornene monomer.170 An OEG 
functionalized norbornene comonomer was also included to varying degrees along the polymer 
chain. The LCSTs of each polymer were then studied as a function of the polymer concentration 
in solution, degree of polymerization, or OEG comonomer feed. Ultimately it was found that the 
LCST depended greatly on the ratio of oligopeptide versus OEG monomers along the copolymer 
chain and on the concentration of the copolymer in solution, but to a lesser degree on the molecular 
weight of the copolymer.170 
 
Figure 1-20. Development of copolymers containing pendent oligopeptides via ROMP for the 
generation of peptide-containing nanoparticles. [171], Copyright 2013. Reproduced with 
permission from The Royal Society of Chemistry. 
The Gianneschi group has greatly expanded on the development of oligopeptide containing 
homo- or block- (co)polymers prepared via grafting-through using ROMP. In their earliest 
examples, copolymerization of either hydrophilic or hydrophobic norbornene-based monomers 
functionalized with oligopeptides was achieved via ROMP which resulted in the formation of 
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bioactive nanoparticles (Figure 1-20).171 The Gianneschi group has also been successful in 
developing protecting-group free strategies towards accessing polymers harboring pendant 
oligopeptides using ROMP.172 These initial works served as a foundation to understand proteolytic 
stability of peptide-based nanoparticles and established a set of synthetic principles to better 
develop polymers harboring pendant oligopeptide functionality.  Expansion of this platform led to 
the development of polymer brushes harboring pendant cell-penetrating peptides (CPPs) which 
were resistant to proteolysis and also maintained their cell penetration activity.173-174 The elegant 
use of ROMP has also allowed for facile tuning of polymer architectures and grafting densities 
which has made possible unique nanoparticle materials for drug delivery, fluorescence imaging, 
and for either the evasion or uptake of macrophages.175-176  The ring-opening metathesis 
polymerization-induced self-assembly (ROMPISA) ushered in by the Gianneschi group has also 
proven to be an extremely useful method for the generation of well-defined nanostructures.177-178   
1.5.2.2  Nucleic acids 
ROMP has been used to great extent in the polymerization of nucleic acid containing 
polymers. Initial reports by Williams and co-workers have utilized ROMP to develop polymers 
with pendant nucleic acid functionality via grafting-through of norbornene monomers substituted 
with either thymine, adenine, cytosine, guanine, or uracil.179-180 The monomers were poorly 
soluble, however, and polymerization of the monomers was only able to produce short oligomers 
due to precipitation over the course of the reaction. Bazzi and Sleiman were able to successfully 
synthesize homopolymers and copolymers containing adenine side chains via ROMP using a 
succinimide additive to solubilize the resulting polymer through hydrogen bonding interactions.181 
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Work by Weck and co-workers has also developed template-directed strategies to carry out ROMP 
of nucleic acid based monomers.182-183  
Expanding further on this, Herrmann and co-workers recently reported a strategy to 
solubilize DNA in the organic phase by exchanging counter-ions on the backbone with quaternary 
ammonium surfactants.184 These DNA-side chains are then modified with norbornene and 
polymerized via ROMP to yield DNA homopolymers of varying architectures. This strategy 
allowed for higher yields for DNA-based conjugates and overcame challenges of nucleic acid 
modification in organic solvents.184  
Gianneschi and co-workers have shown recent progress in preparing nucleic acid brush 
polymers and co-polymers from PNA functionalized norbornene monomers.185 Homopolymers 
made from the oligonucleotide substituted monomers or amphiphilic brush copolymers made up 
of a pendant oligonucleotide block and a benzyl-substituted poly(norbornene) block were 
synthesized through ROMP. The authors were able to develop spherical nanoparticles from the 
synthesized brush copolymers which harbored the oligonucleotide block exposed as the outer shell 
of the sphere. Notably the oligonucleotides present on the nanoparticle surface were able to 
undergo hybridization with complementary DNA oligonucleotide sequences thereby showcasing 
post-polymerization functionality.185  
1.6 Summary and outlook 
Utilizing controlled polymerization methods to graft-from biomolecules has enabled rapid 
access to biomolecule-polymer conjugates which combine the unique traits of both the 
biomolecule and the synthetic polymer attached to it. Over the course of the review, we have 
examined recent developments in the generation of biomolecule-polymer conjugates synthesized 
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using grafting-from techniques tracing back from the initial discoveries employing ATRP, RAFT, 
or ROMP. There are many advantages to utilizing grafting-from techniques with purification and 
small molecule coupling efficiencies being the two most critical. Additionally, each controlled 
polymerization process holds inherent advantages and disadvantages in the context of grafting-
from biomolecules. While an advantage of ATRP is the high degree of flexibility offered by the 
availability of many different variations based on the polymerization process, this also presents a 
challenge as the correct choice of ATRP method to use may not always be straightforward to the 
novice user. The deployment of transition-metal based reagents and the need for oxygen-free 
conditions also presents a challenge in the context of grafting-from. RAFT polymerization is an 
incredibly versatile method which allows for the polymerization of a wide range of monomers in 
a variety of solvent conditions, and the absence of transition-metal based reagents is also a 
significant advantage of the technique. However, RAFT in the context of grafting-from suffers 
from relatively slow reaction kinetics or long inhibition periods which may be dependent on the 
structure of the biomolecule-macroCTA, the amount of oxygen in the reaction mixture, or on the 
reagent concentrations. On the other hand, ROMP typically exhibits fast polymerization kinetics 
and allows access to polymers made from monomers which may not be readily polymerized using 
controlled radical techniques. However, the need to employ transition-metal based reagents, 
especially from the biomolecule surface represents a significant challenge. Fortunately, all together 
these methods provide scientists with a plethora of opportunities to prepare protein-polymer 
conjugates of choice.   
We anticipate continued interest in grafting-from processes, given the recent resurgence 
and creativity by many groups to investigate new bioconjugation techniques which have expanded 
the scope of targetable amino acid residues and increased the conjugation yields.6, 36-38, 41, 186-190 
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The relatively recent highly-efficient methods to label methionine and histidine residues on 
proteins provide additional, less abundant, amino acid residues with which to polymerize from, if 
reagents bearing ATRP initiators can be accessed.36-37, 191-193 Additionally, the rapid progress of 
metal-free and photo-induced controlled polymerization techniques paves way for the synthesis of 
polymers from more therapeutically relevant biomolecules that exhibit greater sensitivity to 
reaction conditions.91-93, 126, 194-195 It would be an exciting and much needed addition to identify 
water-soluble organic photo-reductants capable of promoting ATRP processes in purely aqueous 
solutions in the absence of transition metals.196-197 Oxygen tolerant polymerization techniques that 
can operate at low volumes also represent a significant breakthrough that may play a role in further 
development of grafting-from techniques.198-200 Combined altogether, newly developed 
polymerization and conjugation techniques may soon allow for rapid access and high-throughput 
screening of constructs to develop new biomolecule-polymer conjugates with vastly unique 
properties that would give additional insights into structure-property relationships of complex 
bioconjugates.  
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Chapter 2. Solution Stability of Insulin is Improved by Addition or 
Conjugation of Trehalose Glycopolymer 
 
 
This chapter contains portions of an edited version of the following published paper reprinted with 
permission from: Liu, Y.;† Lee, J.;† Mansfield, K.M.; Ko, J.H.; Sallam, S.; Wesdemiotis, C.; 
Maynard, H.D. “Trehalose Glycopolymer Enhances Both Solution Stability and Pharmacokinetics 
of a Therapeutic Protein.” Bioconjugate Chem. 2017, 28, 836-845. (†Equal contribution). 





Diabetes mellitus affects 29.1 million people in the United States alone and estimates for the 
incidence of diabetes continue to rise.1-2 The disease leads to a higher risk of secondary conditions 
including kidney disease, heart disease, stroke, blindness, and the need for amputations.2 Diabetes 
is a high management disease and type I diabetes requires the use of insulin replacement therapy 
with 3-4 injections per day of the therapeutic protein. However, insulin must be refrigerated while 
stored and it has been shown to degrade under conditions observed during storage and 
transportation such as heat and mechanical agitation.3-4 Patients with diabetes must make special 
considerations for activities and routines to take the required insulin injections while avoiding 
conditions that would cause the protein to degrade. 
However, if insulin degrades from exposure to deleterious environmental conditions, it 
must be discarded. Decreasing the frequency of insulin disposal due to protein degradation could 
save an estimated $1 billion dollars in the US.5 More importantly, degradation can lead to patients 
taking less than their required dose or immune responses to degradation products, which poses a 
risk to patient safety and may even lead to life threatening situations. Improved stability could 
prevent these incidents. In addition to improving safety, enhanced stability would decrease 
dependence on the cold chain and associated costs required during transportation and storage of 
protein therapeutics such as inulin.  
Patient compliance could potentially be improved by more convenient storage 
requirements. Strategies to stabilize insulin have been reported in the literature using alteration of 
the amino acid sequence,6 addition of small molecule excipients,7-9 and delivery in liposomes or 
polymer nanoparticles.10-13 Additionally, several insulin analogs are available clinically with 
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alterations in the time of onset for tighter control of blood glucose.14-15 However, diabetes 
prevalence continues to grow and the disease remains challenging to manage.1-2, 16 Thus, further 
investigation into improving the ease of storage and use of insulin to maintain glucose homeostasis 
is imperative. 
In this chapter, we demonstrate that the trehalose polymer can stabilize a protein 
therapeutic at elevated temperature and under mechanical stress and pharmacokinetics can be 
altered based on whether or not the trehalose glycopolymer is conjugated to the protein. Insulin 
was chosen as a model protein because of its importance in clinical usage and established structure 
and bioactivity assays.17  
 
Figure 2-1. Insulin-trehalose glycopolymer conjugate where the polymer improves both the 
storage stability and in vivo plasma half-life (protein structure from the Protein Data Bank 4INS). 
Figure reprinted with permission from the previously published report.18 
2.2 Results 
Insulin loses its potency when stored at room temperature, thus storage at 2-8 °C is 
reccomended.19-21 The protein is also prone to aggregation during mechanical agitation associated 
with transportation.22 Aggregation of insulin exposed to these stressors decreases the activity and 
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poses a risk of diabetic ketoacidosis and other complications for patients.20 Thus, we examined 
whether or not the trehalose glycopolymer with a polystyrene backbone and acetal-linked trehalose 
(TreSA) could stabilize insulin to thermal and mechanical stress.  In our initial tests we added the 
polymer as an excipient (Figure 2-1).  An accelerated thermal stability study of insulin was carried 
out by comparing insulin heated with and without the TreSA for 30 min. High performance liquid 
chromatography (HPLC) was employed to evaluate the percent of intact insulin because this 
technique is established as a way to quantify and distinguish intact insulin from its degradation 
products caused by aggregation.19 HPLC analysis of the stressed insulin showed that while insulin 
significantly degraded after heating or agitation, adding 2 mol equiv of the TreSA stabilized the 
protein to a much greater extent (Figure 2-2 a). Though the addition of 2 mol equiv of PEG during 
heating extended the initial time to denaturation of insulin, the insulin in the presence of PEG 
eventually degraded to the same extent as the insulin alone at 30 min. Dynamic light scattering 
(DLS) was employed to study whether or not the trehalose glycopolymer prevented aggregation 
of insulin.  The analysis showed that before stress, the diameter of insulin alone was 4 ± 1 nm and 
with TreSA was 7 ± 1 nm. After heating, the diameter increased to 1291 ± 189 nm for the insulin 
sample, while it remained at 6 ± 2 nm when the trehalose glycopolymer was present (Figure 2-2 
b). The mechanical stress stability study was carried out by agitation at 250 rpm and 37 °C for 3 
h.  Both the HPLC and DLS analyses showed that TreSA as an excipient (2 mol equiv) completely 
prevented aggregation of the protein (Figure 2-2 c and d). Interestingly, the addition of PEG 
resulted in destabilization of insulin during agitation (Figure 2-2 c). This may be due to the 
hydrophobic interactions of PEG with exposed hydrophobic residues of insulin, which has been 
previously reported for PEG with other proteins.23-24  These results demonstrated that the trehalose 
glycopolymer effectively prevents insulin aggregation induced by both heat and mechanical stress, 
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which are major mechanisms of insulin degradation.9, 25 The data further suggested that the 
polymer was a good candidate for conjugation to insulin.   
 
Figure 2-2. In vitro stabilization of insulin (0.5 mg/mL) by trehalose glycopolymer. (a) HPLC 
AUC (area under the curve) of insulin peak during heating (90 °C), n = 3. (b) Insulin aggregation 
upon heating (90 °C, 30 min) measured by DLS (n = 3, representative image shown). (c) HPLC 
AUC of insulin peak during agitation (250 rpm, 37 °C), n = 3. (d) Insulin aggregation upon 
agitation (250 rpm, 37 °C, 3 h) measured by DLS (n = 3, representative image shown). 
Insulin stability with a methacrylate backbone trehalose polymer (TreMA) excipient was 
also explored. Closer examination of the analytical HPLC traces after the heating assay revealed 
more information about the mechanism of insulin stabilization by the trehalose polymer. After 
heating to 90 °C for 30 min, the area under the curve of the intact insulin peak decreased 
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dramatically (Figure 2-3 a). Two additional peaks also appeared in the HPLC trace, corresponding 
to aspartyl derivatives that are products of deamidation consistent with the literature.26 In the 
presence of trehalose polymer as excipient, a significantly greater amount of intact insulin remains. 
Additionally, the aspartyl derivative peaks are less intense than for no additive. These results 
indicate that the polymer inhibits insulin degradation by deamidation and aggregation. 
 
Figure 2-3. In vitro characterization of insulin stabilization by trehalose polymer. (a) Analytical 
HPLC traces comparing insulin before and after heating (90 °C, 30 min) with or without 2 mol 
equiv trehalose polymer and (b) Native (lane 1: fresh insulin, lane 2: fresh insulin + 2 mol. equiv 
trehalose polymer, lane 3: insulin heated 90 °C, 30 min, lane 4: insulin + 2 mol equiv trehalose 
polymer heated 90 °C, 30 min) and SDS PAGE (lane 1: ladder, lane 2, fresh insulin, lane 3: fresh 
insulin + 2 mol. equiv trehalose polymer, lane 4: insulin heated 90 °C, 30 min, lane 5: insulin + 2 
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mol equiv trehalose polymer heated 90 °C, 30 min) with Coomassie staining, and (c) ThT assay 
comparing insulin before and after heating (90 °C, 30 min) with or without 2 mol. equiv trehalose 
polymer (** p < 0.01). 
The insulin stabilization mechanism was further explored by biochemical assays. Native 
and SDS PAGE agree with the analytical HPLC results (Figure 2-3 b). The presence of the 
trehalose polymer as an excipient preserved the intensity of the intact insulin band and decreased 
the intensity of bands corresponding to insulin degradation products (aspartyl derivatives and 
aggregates). Thioflavin T (ThT) assay was used to assess the effect of trehalose polymer on insulin 
fibrillation. Without additive, a large fold change in fluorescence was observed from the binding 
of ThT dye to insulin fibrils (Figure 2-3 c). No significant change in fluorescence intensity was 
observed for insulin heated in the presence of trehalose polymer, indicating that trehalose polymer 
inhibits fibrillation of insulin during heating. 
A trehalose polymer for conjugation to insulin was prepared through reversible addition-
fragmentation chain transfer (RAFT) polymerization using an aldehyde-functionalized chain 
transfer agent (Mn = 9.9 kDa and Đ = 1.10) and subsequently conjugated to the amines of insulin 
by reductive amination (Figure 2-4).27-28 The trithiocarbonate of the RAFT polymer was not 
reduced under these reductive amination conditions as demonstrated by UV-vis spectroscopy 
(Appendix A: Figure 2-9). If required, the trithiocarbonate could be removed using standard 
protocols.29  Conjugation was confirmed by native gel and Western blot (Figure 2-5 c and d) and 




Figure 2-4. Synthesis of insulin-trehalose glycopolymer conjugate. (a) RAFT polymerization 
and (b) subsequent conjugation of trehalose glycopolymer to insulin (PDB: 4INS) by reductive 
amination. Revised figure from previously published report.18 
The conjugates were also characterized by mass spectrometry. We have observed that the 
trehalose glycopolymer inhibits evaluation by mass spectrometry and prevents protein ionization 
even when added to samples; thus, a two-step treatment of the sample was necessary for its 
analysis. First, the trehalose glycopolymer-insulin was treated with formic acid to cleave the 
polymer chain at the ester leaving a 106 Da linker (corresponding to the 4-hydroxybenzaldehyde 
moiety) attached to the conjugation site. Second, dithiothreitol (DTT) or tris(2-
carboxyethyl)phosphine (TCEP) was used to reduce the disulfide bridges of insulin to release chain 
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A (2382 Da) and chain B (3427 Da) plus the mass of the attached linker. The matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) mass spectrum of the conjugate (Appendix A: 
Figure 2-10) shows two species with 106 and 212 Da greater mass than insulin, suggesting the 
presence of mono- and disubstituted conjugates. Note that trace amount of insulin in the conjugate, 
although not detectable by Coomassie stain and Western blot, was visible in the spectrum due to 
very high ionization efficiency of insulin and nonquantitative nature of polymer cleavage from 
insulin. Nevertheless, the formic acid treatment was sufficient for characterization of the 
conjugate. Electrospray ionization mass spectrometry (ESI-MS) of the conjugate confirmed the 
MALDI results (Figure 2-5 a and b). Both chain A and chain B exhibited a peak that corresponded 
to modification with a single polymer. These results suggest that the trehalose glycopolymer was 
conjugated to the N-terminal glycine of chain A (GlyA1) and to N-terminal phenylalanine or lysine 
of chain B (PheB1 or LysB29). Since the previously reported reactivity of these amines followed 
the order GlyA1 > LysB29 >> PheB1,30 we expected LysB29 to be the modification site on the 
chain B. To confirm this, tandem mass spectrometry experiments were performed on the chain B 
ion of both native and conjugated insulin (Appendix A: Figure 2-11). The spectrum of the 
conjugate exhibited y3 + 106 Da (m/z 451.20) ion, which confirmed that the linker was attached 
to LysB29 adjacent to the C-terminus. This analysis indicates that the trehalose glycopolymer was 
conjugated to GlyA1 and LysB29, consistent with the literature report that these two amine 
functionalities are shown to be much more reactive toward conjugation than PheB1.30 The 




Figure 2-5. Characterization of insulin-trehalose glycopolymer conjugate. ESI-MS spectra of (a) 
chain A and (b) chain B after acid treatment and disulfide reduction each show modification with 
a single polymer. Native-PAGE after (c) Coomassie staining and (d) western blot show 
conjugation of aldehyde-functionalized trehalose glycopolymer to insulin (lane 1: insulin, lane 2: 
trehalose glycopolymer, lane 3: unpurified insulin-trehalose glycopolymer conjugation mixture, 
lane 4: purified insulin-trehalose glycopolymer, PDB: 4INS). 
Once conjugation was confirmed, the thermal and mechanical stability of the insulin-trehalose 
glycopolymer was evaluated as described above for the added polymer. In both cases, the 
conjugated polymer stabilized the protein in its monomeric form as shown by both HPLC and 
DLS.  Further, the results of the conjugate closely resembled that of the excipient data for HPLC, 
demonstrating that conjugated polymer stabilized insulin as well as excess polymer excipient 
(Figure 2-2 a and c). DLS analysis showed that before stress the diameter of the insulin-trehalose 
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glycopolymer conjugate was 6.4 ± 1.2 nm (Figure 2-2 b and d). The diameter did not increase 
after stress like insulin itself (≥1000 nm) and remained low at 4.7 ± 0.7 nm after heating and 6.5 ± 
1.3 nm after agitation. Bioactivity was also retained significantly more for excipient and conjugate 
than no additive after the heating assay, found using insulin tolerance test in mice.18 Therefore, 
covalently conjugating two trehalose glycopolymer chains stabilized the monomeric form of 
insulin as well as adding 2 mol equiv (10 weight equiv) of the polymer as an excipient.   
 
 
Figure 2-6. Pharmacokinetics of insulin (120 µg/kg dosage) with or without TreMA (2 mol equiv 
to insulin) as excipient (n = 4, p > 0.05 at all timepoints). 
Conjugation of the TreSA to insulin enhanced the plasma lifetime of insulin in mice.18 
Influence of TreMA as excipient on pharmacokinetics was tested to determine if presence of the 
polymer without conjugation could affect the half-life of insulin. CD-1 mice were injected 
intravenously with 120 µg /kg insulin or insulin with 2 molar equiv TreMA and the amount of 
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insulin in the blood was measured by ELISA. No significant difference was detected between 
groups at all timepoints. Additionally, insulin dosage required to detect native insulin in the blood 
was the same with and without polymer, while previously  7.5x dosage was needed compared to 
insulin conjugates to detect native insulin in the blood.18 This data shows that addition of trehalose 
polymer as excipient does not alter pharmacokinetics. 
2.3 Discussion 
Our results demonstrate that trehalose glycopolymer is promising for stabilization of the 
therapeutic protein insulin to prevent aggregation and deamidation. Additionally, conjugation of 
the trehalose polymer also stabilizes the protein in addition to extending the half-life in vivo. 
Extending the circulation time is desirable for basal insulin to control blood glucose throughout 
the day. However, some applications require fast action, like for rapid-acting insulins, so alteration 
of pharmacokinetics is not desirable. Addition of trehalose polymer excipient improved stability 
without alteration of protein pharmacokinetics. Prevention of degradation upon exposure to heat 
and mechanical agitation is also helpful to maintain stability during storage and transportation. 
Thus, this data demonstrates the utility of trehalose polymer as a means to improve storage stability 
of therapeutic proteins with or without enhancement of pharmacokinetics. Research of stabilizing 
formulations for protein therapeutics is important to move away from dependence on the cold 
chain. 
We chose insulin as the model therapeutic protein since insulin instability is clinically relevant 
and has been reported to cause dangerous emergencies with protein degradation.20 Work 
stabilizing insulin using insulin analogs,6 small-molecule excipients,7-9 liposomes,10 and polymeric 
vehicles11-13 has been reported, but the high demand and growing prevalence of diabetes 
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worldwide warrants exploration of new strategies. Our research shows that adding trehalose 
glycopolymer as an excipient can prevent heat and mechanically induced aggregation and heat 
induced deamidation. These data suggest trehalose polymer as an excipient for stabilization of 
proteins should be investigated further. 
2.4 Conclusion 
This chapter describes research on a trehalose polymer that can enhance the solution stability of 
insulin upon exposure to heat and mechanical agitation. Addition of trehalose polymer as an 
excipient or conjugated to the protein decreased the aggregation of insulin. Investigation of the 
mechanism of the polymer’s stabilization of insulin revealed that it inhibits both aggregation and 
deamidation during heating. Finally, conjugation of the trehalose glycopolymer is needed to alter 
pharmacokinetics. Addition of trehalose polymer excipient did not alter insulin half-life in vivo, 
enabling a stabilized rapid-acting insulin. Together, this research demonstrates that the trehalose 
polymer should be explored for formulation of protein therapeutics because of its ability to 
enhance aqueous stability. 
2.5 Appendix A 
Materials 
Materials were purchased from Sigma Aldrich or Fisher Scientific without purification 
unless otherwise noted. Azobis(isobutyronitrile) (AIBN) was recrystallized from acetone. 
Trehalose was purchased from The Healthy Essential Management Corporation (Houston, TX), 
azeotropically dried with ethanol, and stored under vacuum before use. Recombinant human 
insulin was purchased from Sigma Aldrich. Human insulin ELISA kit for quantification of insulin 
was purchased from Mercodia (Uppsala, Sweden). 2-(Ethyltrithiocarbonate)propionic acid was 
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synthesized by Jeong Hoon Ko by a previously reported procedure.31 PEG without end group (20 
kDa) was purchased from Sigma-Aldrich. Styrenyl acetal trehalose monomer and trehalose 
glycopolymer (styrenyl acetal trehalose polymer without end-group synthesized by free radical 
polymerization, Mn = 29.5 kDa, Ð = 2.11 by GPC) were prepared by Juneyoung Lee using 
previously reported procedure.32 Methacrylate trehalose monomer was prepared using a previously 




Nuclear Magnetic Resonance (NMR) spectra were recorded on a Bruker AV 400 MHz 
spectrometer. Trehalose monomer was purified by preparatory reverse phase HPLC on a Shimadzu 
HPLC system equipped with a UV detector using a Luna 5 µm C18 100A column (preparatory: 5 
µm, 250 x 21.2 mm) with monitoring at λ = 215 nm and 254 nm. Isocratic solvent system 
(water:methanol = 50:50) was used as the mobile phase at a flow rate of 20 mL/min. Analytical 
HPLC for detection of insulin was conducted on an Agilent 1200 HPLC system equipped with an 
Agilent Quadrupole 6130 ESI-MS detector, using a gradient solvent system (water:acetonitrile = 
70:30 to 60:40 + 0.1 % trifluoroacetic acid over 15 min at 1 mL/min). Gel permeation 
chromatography (GPC) was conducted on a Shimadzu HPLC system equipped with a refractive 
index detector RID-10A and two Polymer Laboratories PLgel 5 µm mixed D columns (with guard 
column). Lithium bromide (0.1 M) in N,N-dimethylformamide (DMF) at 40 °C was used as the 
eluent (flow rate: 0.6 mL/min). Near-monodisperse poly(methyl methacrylate) standards (Polymer 
Laboratories) were employed for calibration.  UV-vis absorbance was measured using a microplate 
reader ELx800 (BioTek Instruments, Winooski, VT). Matrix-assisted laser desorption/ionization 
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(MALDI)-MS analysis of insulin was performed on a Voyager DE-STR (Applied Biosystems, 
Forster City, CA) in linear positive ion mode. For the insulin-trehalose glycopolymer conjugate, a 
Bruker Ultraflex III MALDI-TOF mass spectrometer was used in reflectron mode. The conjugate 
was dissolved in water:acetonitrile 1:1 (v/v) to prepare a 10 mg/ml solution, to which 10 % formic 
acid was added; this solution was then mixed with a solution of either dithiothreitol (DTT) or 
tris(2-carboxyethyl)phosphine (TCEP) for disulfide bond cleavages. 2,5-Dihydroxyacetophenone 
(DHAP) served as a matrix. For ESI-MS analysis, the insulin-trehalose glycopolymer conjugate 
was diluted with water:acetonitrile 1:1 (v/v) at a final concentration of 0.025 mg/ml, and the 
solution was injected into Waters Synapt HDMS quadrupole/time-of-flight (Q/ToF) mass 
spectrometer (Waters, Milford, MA) after treating it with formic acid and 10 mM DTT. Instrument 
parameters were adjusted as follows: ESI capillary voltage, 3.5 kV; sample cone voltage, 30 V; 
extraction cone voltage, 3.2 V; desolvation gas flow, 550 L h-1 (N2); trap collision energy (CE), 
6.0 eV; transfer CE, 4.0 eV; trap gas flow, 1.5 mL min-1 (Ar); sample flow rate, 10 µL min-1; 
source temperature, 80 °C; desolvation temperature, 150 °C; for tandem mass spectrometry 
analysis, the trap CE was adjusted to 20 eV to cause fragmentation by collisionally activated 
dissociation. 
 




A stock solution of azobisisobutyronitrile (AIBN) was created in DMSO. A portion of the 
stock (for 0.15 mg AIBN, 0.9 µmol) was added to the benzaldehyde CTA (2.88 mg, 9 µmol). This 
stock solution was used to dissolve styrenyl acetal trehalose monomer (113.12 mg, 0.247 mmol), 
and the mixture was transferred to a Schlenk flask. The vial was washed with additional DMSO 
for total volume of 0.49 mL and then transferred to the Schlenk flask. The mixture was freeze-
pump-thawed four times, and then stirred under argon at 80 °C for 3.4 hours. After stopping the 
polymerization with liquid nitrogen at 80% conversion, the crude was purified by dialysis 
(MWCO: 3.5 kDa) against water for 2 days and recovered by lyophilization yielding 73 mg 
product. 1H NMR (400 MHz in D6DMSO) δ: 9.92, 7.59, 7.15, 6.52, 5.44, 5.17, 4.92, 4.79, 4.37, 
4.08, 3.95, 3.75, 3.67, 3.55, 3.46, 3.14, 1.49. Mn = 8.2 kDa (by GPC), Ð = 1.14. 
 
Free radical polymerization of methacrylate trehalose monomer 
 
A stock solution of AIBN was created in anhydrous DMSO. A portion of this stock (0.1 
mL for 3.4 mg, 0.02 mmol AIBN) was used to dissolve methacrylate trehalose monomer (214.6 
mg, 0.52 mmol) and this was added to an dry Schlenk flask. More anhydrous DMSO (total volume 
1.9 mL) was added into the Schlenk flask. The mixture was freeze-pump-thawed 3 times before 
initiation at 70 °C. After 5 hours, the polymerization was stopped at 96% conversion by 1H-NMR. 
The polymer was purified by purified by dialyzing against H2O (MWCO 3.5 kDa).
 1H NMR (500 
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MHz in D6DMSO) δ: 5.91, 5.10, 5.06, 4.24, 4.03, 3.94, 3.75, 3.53, 3.35, 1.83, 1.51, 1.61, 0.96, 
0.80. Mn = 19.2 kDa (by GPC), Ð = 4.02. 
 
Preparation of insulin-trehalose glycopolymer conjugate 
Insulin (4 mg, 0.259µmol), sodium cyanoborohydride (4 mg, 63.8 µmol), and 
benzaldehyde end-functionalized styrenyl acetal backbone trehalose polymer (31 mg, 3.1 µmol, 
12 molar eq to insulin) were dissolved in 1 mL of 200 mM phosphate buffer, pH 8.0. The mixture 
was incubated at 4 ºC water bath for 24 h, and the buffer was exchanged to D-PBS pH 7.4, by 
centriprep ultrafiltration (MWCO 3 kDa) several times before purification by FPLC using anion 
exchange chromatography. The amount of insulin was determined using ELISA. To determine if 
the trithiocarbonate could be reduced under these conditions, benzaldehyde end-functionalized 
trehalose polymer (15.5 mg, 1.5 µmol) was dissolved in 0.5 mL 200 mM phosphate buffer, pH 8.0 
with and without sodium cyanoborohydride (2 mg, 31.9 µmol) and incubated at 37 °C 12 h before 
absorption spectra were obtained. 
 
Styrenyl acetal backbone trehalose polymer stability study 
 Free insulin, insulin with the styrenyl acetal backbone trehalose glycopolymer or PEG (20 
kDa without end-group, 2 mol equiv to insulin), and insulin-trehalose glycopolymer conjugate 
were incubated at 90 C in PBS at a concentration of 0.5 mg/mL and total volume of 100 µL. At 
predetermined time interval, each sample was collected and subjected to further analysis. Free 
insulin, insulin with the trehalose glycopolymer or PEG (20 kDa without end-group, 2 mol equiv 
to insulin), and insulin-trehalose glycopolymer conjugate were agitated in PBS at 250 rpm and 37 
°C at a concentration of 0.5 mg/mL and total volume of 100 µL in glass vials secured horizontally. 
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At predetermined time intervals, each sample was collected and subjected to further analysis. For 
RP-HPLC analysis, each sample was filtered and the concentration of insulin that remained in the 
sample was determined. Mobile phase consisted of aqueous phase (Solvent A) and organic phase 
(Solvent B). Solvent A was 0.1% v/v trifluoroacetic acid (TFA) in deionized distilled water and 
solvent B was acetonitrile. The solvent gradient used was 30% Solvent A to 40% Solvent A in 15 
min. The insulin was detected with a UV detector at a wavelength of 215 nm. The measurements 
of the average size of the aqueous suspensions of insulin formulation were carried out on a Malvern 
Zetasizer Nano-ZS dynamic light-scattering (DLS) analyzer (Malvern Instruments Ltd., Malvern, 
Worcestershire, UK).   
 
Pharmacokinetics study 
CD-1 mice (5-6 weeks, male, Charles River Laboratories) were used for the 
pharmacokinetics studies (n = 4). A single dose of insulin (120 µg/kg) with or without methacrylate 
trehalose polymer (2 mol. eq. to insulin) was administered by injection through the tail vein. Blood 
samples were taken from the saphenous vein (30-50 µL) at 10, 20, and 40 minutes and by cardiac 
puncture after euthanasia by inhalation of CO2 at 60 minutes following administration. Blood was 
collected using a pipette with ETDA-coated tips into LoBind tubes coated with EDTA. Blood was 
stored on ice until separation of the plasma by centrifugation (2000 x g, 15 minutes). The amount 
of insulin in plasma samples was determined by ELISA (Mercodia) according to the 
manufacturer’s protocol. 
 
Methacrylate backbone trehalose polymer stability study 
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Insulin was dissolved at 2 mg/mL in DPBS pH 7.4. Trehalose polymer (28.1 kDa) was 
dissolved at 19 mg/mL (2 mol equiv to insulin). Solutions were added 1:1 to a total volume of 100 
µL in a LoBind tube for insulin and insulin with trehalose polymer (n = 3). Samples were stored 
at 4 °C or heated to 90 °C for 30 min. Aliquots of each insulin sample were used directly for SDS 
and native PAGE. Samples were filtered (0.22 µm) to remove insulin aggregates and analyzed by 
RP-HPLC. Thioflavin T (ThT) was prepared at 50 µM (0.0159 mg/mL) in 20 mM DPBS pH 7.4. 
Into a black 96-well plate, 50 µL each insulin sample was pipetted. To these was added 250 µL 
ThT solution and the plate was incubated at room temperature (21 °C) for 20 min. Fluorescence 
intensity was measured on a Tecan M1000 plate reader (λex = 450 nm, λem = 482 nm). 
 
Statistical analysis 
For assessment of the statistical significance of differences, Student’s t-test assuming 
unequal sample variance was employed. Results were considered significantly different if p < 0.05. 
 





Figure 2-7. 1H NMR spectrum of benzaldehyde end-functionalized styrenyl acetal backbone 




Figure 2-8. 1H-NMR spectrum of methacrylate backbone trehalose polymer from free radical 
polymerization (DMSO- D6). 
 
Figure 2-9. UV-vis absorption spectrum of trehalose glycopolymer before (black) and after (red) 




Figure 2-10. MALDI-TOF mass spectrum of insulin-trehalose glycopolymer conjugate after 





Figure 2-11. Tandem mass spectrum of insulin-trehalose glycopolymer conjugate (top) and 
native insulin (bottom). Tandem mass spectrometry fragmentation of chain B charge state +5 from 
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Chapter 3. Site-Specific Insulin-Trehalose Glycopolymer Conjugate by 
Grafting from Strategy Improves Bioactivity 
 
 
Reprinted with permission from: Mansfield, K.M.; Maynard, H.D. “Site-Specific Insulin-
Trehalose Glycopolymer conjugate by Grafting from Strategy Improves Bioactivity.” ACS Macro 





Diabetes is a growing worldwide problem, affecting over 30 million people1 in the United 
States alone, with its prevalence continuing to rise.1-2 Insulin is an important therapeutic protein 
for the treatment of diabetes; type I diabetes requires several injections or infusions of insulin 
daily.3 However, exposure to environmental stressors such as heat and mechanical agitation 
encountered during storage and transportation can lead to protein degradation and aggregation.4-6 
Inadequate dosing resulting from degradation increases risk to the patient. For example, diabetic 
ketoacidosis can result from degradation of insulin from exposure to heat and extended 
hyperglycemia can increase risk for complications such as retinal damage and kidney disease.4 
Our group has synthesized polymers with trehalose side chains that stabilize a variety of 
proteins to stressors such as lyophilization, heat, and mechanical agitation.7-11 We have shown that 
conjugating insulin with a trehalose glycopolymer stabilized the protein to heat and mechanical 
agitation and also improved its pharmacokinetics.9 However, the bioactivity was significantly 
lower than the native protein, requiring 5-fold dosage to achieve the same decrease in blood 
glucose as the native protein. The conjugate was synthesized by reductive amination at pH 8.0 
using a benzaldehyde-functionalized trehalose polymer resulting in modification at both GlyA1 
and LysB29; it has been shown that under similar pH conditions, the relative reactivity of the three 
amines in insulin is GlyA1>LysB29>>PheB1.12 We hypothesized that this non-specific “grafting 
to” conjugation strategy resulting in modification at both GlyA1 and LysB29 contributed to the 
observed decrease in activity. Modification of GlyA1 decreases insulin affinity for its receptor and 
even conjugation of a 2000 Da poly(ethylene glycol) (PEG) can decrease bioactivity.12 
Modification at either PheB1 or LysB29 does not impact bioactivity to the same extent.12-13 
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Furthermore, PheB1 has been shown to react more slowly than the other two amines of insulin and 
modification at lysine can be favored by increasing the pH of the reaction above pH 9.5, taking 
advantage of its higher nucleophilicity than the N-terminal amines.12 Therefore, we decided to 
target modification with the trehalose glycopolymer at LysB29 by conducting an initiator 
conjugation at higher pH and purifying the macroinitiator to contain only the LysB29 modification. 
Polymerizing directly from a protein, or “grafting from” a protein, is a strategy that 
facilitates characterization of conjugation site and purification of the conjugate. Our group was the 
first to report this strategy by modifying biotin with an initiator, forming a biotin/streptavidin 
macroinitiator, and polymerizing N-isopropylacrylamide (NIPAAm) from the protein.14 
Subsequently, our group grafted NIPAAm directly from bovine serum albumin (BSA) and 
lysozyme macroinitiators, with the latter remaining active.15 In addition, Matyjaszewski and 
Russell prepared polymers by first modifying amines and polymerizing poly(ethylene glycol) 
methacrylate (PEGMA).16 Many examples of grafting from proteins have followed. 
Matyjaszewski and co-workers used activators generated by electron transfer atom transfer radical 
polymerization (AGET ATRP) to polymerize oligo(ethylene glycol) methacrylate (OEGMA) from 
BSA in phosphate buffer.17 Bulmus and Davis were the first to demonstrate reversible addition–
fragmentation chain transfer (RAFT) polymerization from a protein by conjugating the Z-group of 
a thiol-reactive chain transfer agent (CTA) to BSA and polymerizing acrylate and acrylamide 
monomers from the protein.18-19 Sumerlin and co-workers subsequently employed RAFT to 
polymerize NIPAAm from BSA by conjugating the R-group of the CTA to the protein.20 
Additionally, Haddleton and coworkers polymerized acrylate and acrylamide monomers from a 
variety of proteins under mild, aqueous conditions.21 
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We devised a strategy to synthesize the insulin-trehalose glycopolymer conjugate 
involving targeted modification of LysB29 with an initiator. We envisioned that modification with 
a small molecule would also facilitate characterization of the conjugation site because the trehalose 
glycopolymer is not directly amenable to mass spectral analysis and purification of the LysB29 
only species. It was expected that polymerizing from this insulin macroinitiator with trehalose 
monomer in mild, aqueous conditions would result in a conjugate with improved bioactivity 
compared to our previous approach, while retaining stabilization properties (Figure 3-1).  The 
results are described herein.   
 
Figure 3-1. Scheme of experimental design. 
3.2 Results and discussion 
 The designed approach required polymerization of a trehalose monomer under mild, 
aqueous conditions. AGET ATRP is a technique that has been performed in aqueous buffer at 
room temperature,17 and our group used this technique to polymerize OEGMA monomers from 
siRNA.22 A methacrylate trehalose monomer (Figure 3-2A) was selected to facilitate controlled 
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polymerization at room temperature in place of the styrenyl acetal trehalose monomer used in 
previous work.8-9 First, the polymerization was explored under the conditions that would be 
suitable for the protein. Polymerization in DPBS with the small molecule initiator 2-hydroxyethyl-
2-bromoisobutyrate (HEBIB), tris(2-pyridylmethyl)amine (TPMA) as the ligand, and ascorbic 
acid as the reducing agent was accomplished at 23 °C. Complete conversion was observed within 
4 h and dispersity was low (Figure 3-2B). This polymer exhibited excipient stabilization of insulin 
to heating with 93 ± 3% intact insulin (Figure S8) compared to 68 ± 2% intact insulin remaining 
with the styrenyl trehalose glycopolymer used in our previous work,9 demonstrating that the 
polymethacrylate backbone polymer also prevented heat-induced aggregation of insulin.  
 
Figure 3-2. Aqueous polymerization of methacrylate trehalose. (A) Reaction scheme to 
polymerize trehalose monomer by AGET ATRP ([HEBIB]/[M]/[CuBr2]/[TPMA]/[AA] = 
1/23/1/1/0.6) in DPBS pH 7.4 at 23 °C 3.5 h and (B) SEC trace of trehalose glycopolymer. 
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 With the success of the trehalose monomer polymerization and resulting polymer 
stabilization of insulin, the protein was then modified with an initiator. Specifically, the insulin 
macroinitiator was synthesized with a nitrophenyl carbonate-activated initiator (NPC initiator) in 
borate buffer at pH 11 (Figure 3-3A). Even at this high pH, modification of multiple amines in 
addition to the desired product and unmodified insulin was observed after 1 h (Figure S9 and 
S10). No increase in the 40% conversion to the desired product was observed for longer reaction 
times and this yield is consistent with other site-selective modifications for insulin.23-24 The singly 
modified product was separated from unmodified insulin and multiply modified products and 
recovered after semipreparative HPLC. The purified macroinitiator exhibited a single peak by 
analytical HPLC and matrix-assisted laser desorption ionization mass spectrometry (MALDI MS; 
Figure 4A and B). Further, the macroinitiator was reduced with dithiothreitol (DTT) for analysis 
by MALDI MS and modification was observed only on the B chain (Figure S11). To confirm the 
modification site, electrospray ionization (ESI) tandem MS was performed on the insulin 
macroinitiator, which showed fragments consistent with modification on LysB29 and not PheB1 
(Table S1). Although only one species was observed for the insulin macroinitiator by HPLC, 
MALDI MS, and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE), two 
bands were observed for the macroinitiator after purification by native PAGE (Figure 4D and 
S13). To determine if insulin was degrading during synthesis or purification of the macroinitiator, 
the insulin macroinitiator was run on a highly cross-linked Tris-Tricine gel under reducing and 
nonreducing conditions (Figure S13). Insulin and the insulin macroinitiator both exhibited one 
band near 6 kDa under nonreducing conditions and shifted bands near 3 kDa, indicating reduction 
of the interchain disulfide bonds. These results indicate that insulin does not degrade by disulfide 
reduction once modified. Insulin readily forms dimers near neutral pH at which the native gel was 
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run. LysB29 is involved in facilitating dimerization and monomeric rapid-acting insulin analogues 
have been prepared by mutating the amino acid at this position.25-26 These two bands may be due 
to dissociation of insulin dimers into monomers with modification at LysB29 in the macroinitiator 
interfering with this interaction.  
 
Figure 3-3. Synthesis of insulin-trehalose glycopolymer conjugate. (A) Preparation of the insulin 
macroinitiator and (B) grafting from the macroinitiator with AGET ATRP 
([Resin]/[M]/[CuBr2]/[TPMA]/[AA] = 1/30/1/10/0.6). 
Attempts to polymerize from the macroinitiator were initially unsuccessful under a range of AGET 
ATRP conditions, likely due to the low concentration of initiating sites from the small amount of 
insulin macroinitiator. To facilitate polymerization from the insulin macroinitiator, a sacrificial 
resin was prepared as described previously.22 This resin was modified with an initiator and 
increased the concentration of initiating sites. With the addition of the resin, the trehalose monomer 
was then successfully polymerized using AGET ATRP in DPBS pH 7.4 at 23 °C (Figure 3-3B) 
although it took 14 h to polymerize indicating that the reaction was slower for the macroinitiator 
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than the small molecule initiator. Also, a large molecular weight peak was observed in addition to 
the main peak by the right-angle light scattering detector equipped on the SEC that was not 
observed during polymerization with the small molecule initiator. This peak had also been detected 
during preparation of the monomer if the temperature was high or pressure too low when removing 
water and observed when insulin was added at 1 mg/mL to the polymerization mixture for the 
small molecule initiator HEBIB (Figure S14). We expected that this peak resulted from 
uncontrolled polymerization of the monomer.  Increasing the amount of TPMA from 1 to 10 mol 
equiv with respect to copper eliminated this peak (Figure S15). We hypothesize that adding excess 
ligand displaces copper from interactions with insulin that result in uncontrolled polymerization. 
The polymerization product exhibited a shift by native and SDS PAGE and this band 
contained insulin by Western blot analysis (Figure 3-4C, D, and S12). To determine if this band 
formed without the macroinitiator, several control polymerizations were performed. Unmodified 
insulin was substituted for the insulin macroinitiator, initiator was excluded with unmodified 
insulin included, or no insulin or initiator was included under the standard AGET ATRP 
conditions. No new bands were observed when the polymerization mixtures were analyzed by 
native PAGE (Figure S16). Polymer formed (D >1.6) for conditions without insulin or initiator, 
which was likely due to autopolymerization. It is interesting to note that the trehalose 
glycopolymer did not stain by Coomassie except when these large molecular weight species were 




Figure 3-4. Characterization of insulin macroinitiator and insulin-trehalose glycopolymer 
conjugate. (A) Analytical HPLC and (B) MALDI MS after purification of the insulin 
macroinitiator, (C) Coomassie stained SDS PAGE (Lane 1: Ladder, Lane 2: Insulin, Lane 3: 
Purified insulin macroinitiator, Lane 4: Trehalose glycopolymer, Lane 5: Crude insulin-trehalose 
glycopolymer conjugate, Lane 6: Purified insulin-trehalose glycopolymer conjugate), (D) native 
PAGE with Western blot analysis (Lane 1: Insulin, Lane 2: Purified insulin macroinitiator, Lane 
3: Trehalose glycopolymer, Lane 4: Crude insulin-trehalose glycopolymer conjugate, Lane 5: 
Purified insulin-trehalose glycopolymer conjugate Lane 6: Insulin-trehalose glycopolymer 
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conjugate after digestion with Proteinase K), and (E) SEC trace of trehalose glycopolymer after 
digestion of insulin with Proteinase K. 
When the crude conjugate mixture was analyzed by analytical HPLC, peaks corresponding 
to free polymer likely hydrolyzed from the resin, insulin-trehalose glycopolymer conjugate, and 
residual insulin macroinitiator were observed (Figure S17). The insulin-trehalose glycopolymer 
conjugate could be separated using the same HPLC method as was used to purify the 
macroinitiator, yielding the final purified product. To characterize the polymer formed when 
grafting from the insulin macroinitiator, insulin was digested using Proteinase K as described in 
literature.27 Polymer alone in the presence of Proteinase K did not change dispersity or molecular 
weight (Figure S18) showing that Proteinase K does not degrade the polymer or overlap with the 
polymer signal. By SEC analysis, the polymer was 8.7 kDa and exhibited similar dispersity (D 
=1.21) as with the small molecule initiator (Figure 3-4B). The analogous insulin-PEG conjugate 
was also prepared with a 10 kDa methoxyPEG nitrophenyl carbonate in borate buffer pH 11. The 
singly modified species was separated by semipreparative HPLC. The insulin-PEG conjugate 
exhibited single a band at approximately 16 kDa by SDS PAGE, which is consistent with one site 
modification (Figure S19). Additionally, analytical HPLC of the purified insulin-PEG conjugate 
also exhibited a single peak (Figures S21). This was corroborated by MALDI MS (Figure S20A) 
and modification was confirmed on the B chain following reduction of the disulfides with DTT 
(Figure S20B). The modification is most likely at LysB29 because of the similarity of conditions 





Figure 3-5. ITT in mice with insulin (16 µg/kg), insulin-PEG conjugate (48 µg/kg), and insulin-
trehalose glycopolymer conjugate (48 µg/kg) (n=4, p > 0.05 at all points between insulin and 
conjugates). 
To evaluate the bioactivity of the conjugates, insulin tolerance test (ITT) was performed in 
mice (Figure 3-5). Animals were injected with insulin, insulin-trehalose glycopolymer conjugate, 
and the analogous insulin-PEG conjugate. Insulin remained active after exposure to HPLC 
purification conditions, exhibiting a decrease in blood glucose 30 min after injection. Both the 
insulin-trehalose glycopolymer conjugate and insulin-PEG conjugate required only a 3-fold 
dosage relative to insulin alone (48 vs 16 µg/kg) to achieve the same change in blood glucose, 
which is a significant improvement over the 5-fold dosage (48 vs 80 µg/kg) required previously 
with a non-selective conjugate prepared by reductive amination at pH 8.0. Insulin conjugated to 
20 kDa PEG through LysB29 had significantly lower binding affinity to the receptor than insulin 
alone.28 Additionally, 2000 Da PEG-insulin conjugates showed decreased in vivo bioactivity, 
while 600 Da PEG-insulin conjugates retained bioactivity.12 Thus, tuning the length of the polymer 
may further improve the retention of bioactivity.10 A balance between stabilization properties and 
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bioactivity may be necessary, yet the site-specific conjugation strategy described herein clearly 
significantly improved retention of bioactivity. 
Next, the stability of the insulin-trehalose glycopolymer was evaluated using an accelerated 
heating assay. Insulin and the insulin-trehalose glycopolymer conjugate were heated for 90 °C for 
30 min and the amount of intact insulin was determined by measuring the area under the curve 
(AUC) of the insulin peak. The amount of intact insulin remaining for the conjugate after heating 
was found to be significantly greater than for insulin without the trehalose glycopolymer (Figure 
3-6). This demonstrates that one polymer chain may be conjugated in a site-specific manner and 
yet still stabilize the protein to heat-induced aggregation.    
 
Figure 3-6. Biochemical stability assay of insulin and insulin-trehalose glycopolymer conjugate 
after heating to 90 °C for 30 min by HPLC AUC (n=3, * p = 0.0056). 
3.3 Conclusion 
In conclusion, we synthesized a site-specific trehalose glycopolymer conjugate with 
improved bioactivity retention compared to nonspecific conjugation. An insulin macroinitiator 
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was prepared at high pH to favor modification at LysB29. Following separation by HPLC, 
modification at the desired position was confirmed with tandem MS. Trehalose glycopolymer was 
polymerized directly from this macroinitiator with AGET ATRP under mild, aqueous conditions. 
The insulin-trehalose glycopolymer conjugate had greater retention of bioactivity than the 
nonspecific conjugate, requiring just over half the dosage used to achieve the same decrease in 
blood glucose. Moreover, the insulin-trehalose glycopolymer conjugate retained its stabilization 
properties by HPLC monitoring of intact insulin after heating. 
3.4 Appendix B 
Materials and methods 
All chemicals were purchased from Sigma-Aldrich and Fisher Scientific and were used 
without purification unless otherwise noted. Methoxy poly(ethylene glycol) nitrophenyl carbonate 
(10.5 kDa by MALDI, D = 1.02) was purchased from JenKem Technology (Plano, TX). Trehalose 
was purchased from The Healthy Essential Management Corporation (Houston, TX) and was 
azeotropically dried with ethanol and kept under vacuum until use. Recombinant human insulin 
was purchased from Sigma-Aldrich (Lot no. 17A061-D). Methacrylate trehalose monomer 
synthesis is described below. The sacrificial resin was synthesized as previously described with 
93% modification by 1H-NMR (Figure S4).22 Cuprisorb was purchased from Amazon.com. 
Glucometer and glucose test strips (TrueTrack) were purchased from RiteAid. 
 
 Analytical techniques 
Nuclear Magnetic Resonance (NMR) spectra were recorded on a Bruker AV 400 MHz 
spectrometer. Size exclusion chromatography (SEC) was conducted on a Malvern Viscotek 
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GPCmax equipped with a TDA 305-040 Quadruple Detector Array (RI + Viscosity + LALS/RALS 
+ UV) and 0.05 M sodium sulfate in water + 10 % methanol as eluent at a flow rate of 1.0 mL/min. 
Molecular weight was calculated using conventional PEG standards. Trehalose monomer was 
purified by preparatory reverse phase HPLC on a Shimadzu HPLC system equipped with a UV 
detector using a Luna 5 µm C18 100A column (preparatory: 5 µm, 250 x 21.2 mm) with monitoring 
at λ = 215 nm and 254 nm. Gradient solvent system (water:methanol = 90:10 to 40:60 over 20 
min) was used as the mobile phase at a flow rate of 20 mL/min. Semi-preparative HPLC to purify 
the insulin macroinitiator was conducted on an Agilent 1260 Infinity II LC System equipped with 
a UV detector and Zorbax 300SB C-18 column with a gradient solvent system (water:acetonitrile 
= 70:30 to 0:100 + 0.1 % trifluoroacetic acid over 20 min at 3 mL/min unless otherwise noted). 
Analytical HPLC for detection of insulin was conducted on an Agilent 1260 Infinity II LC System 
equipped with a UV detector using Zorbax SB300 C-3 column and a gradient solvent system 
(water:acetonitrile = 90:10 to 0:100 + 0.1 % trifluoroacetic acid over 17 min at 0.6 mL/min). 
Matrix-assisted laser desorption/ionization (MALDI)-MS analysis of the insulin macroinitiator 
was performed on a Voyager DE-STR (Applied Biosystems, Forster City, CA) in linear positive 
ion mode. The insulin macroinitiator was desalted by centriprep ultrafiltration (MWCO 3 kDa) 
and mixed 1:1 with sinapinic acid dissolved in 50 % acetonitrile with 0.1 % trifluoroacetic acid on 
the MALDI target plate. Tandem MS was performed with static positive ion electrospray 
ionization mass spectrometry on LTQ-FT Ultra and data was analyzed with Prosight PC 4.0. 
Insulin-trehalose glycopolymer was reduced with 100 mM DTT and cleaned up by stop-and-go 
extraction (StaGE) tip SPE before mass spectral analysis. 
 




2-(2-Aminoethoxy)ethanol (0.57 mL, 5.73 mmol) was dissolved in anhydrous DCM (12 
mL) in an oven-dried round bottom flask under argon. Anhydrous TEA (0.60 mL, 4.30 mmol) was 
added and this was stirred at 0 °C for 10 min. α-Bromoisobutyryl bromide (0.3 mL, 2.69 mmol) 
was added dropwise. The reaction mixture was allowed to rise to 23 °C and stirred for a total of 
14 h. The mixture was purified by silica gel flash chromatography with a gradient of 0-10% 
methanol in diethyl ether (product Rf ~0.65) to afford 618 mg product (90% yield) as a pale yellow 
oil. 1H NMR (400 MHz in CDCl3) δ: 7.07 (s, 1H), 3.78-3.74 (m, 2H), 3.62-3.59 (m, 4 H), 3.51-
3.47 (dt, J = 5.41, 5.73 Hz, 2 H), 1.96 (s, 6H). 13C NMR (400 MHz in CDCl3) δ: 172.4, 72.4, 69.6, 
63.0, 61.9, 40.3, 32.7. IR: ν = 3336, 2932, 2869, 1652, 1525, 1455, 1370, 1291, 1193, 1111, 1060, 
931, 926, 891, 797 cm-1. HRMS (ESI) calculated for C8H16BrNO3Na ([M + Na]
+) 276.0211, found 
276.0216.  
 
 Synthesis of nitrophenyl carbonate initiator (NPC initiator) 
 
In a flame-dried round bottom flask, 2-bromo-N-(2-(2-hydroxyethoxy)ethyl)-2-
methylpropanamide (200 mg, 0.79 mmol) was dissolved in anhydrous DCM (0.79 mL) under 
argon. Anhydrous TEA (0.16 mL, 1.18 mmol) was added and stirred at 0 °C for 10 min. 
Nitrophenyl chloroformate (316 mg, 1.57 mmol) was added and stirred at 0 °C. The reaction 
mixture was allowed to rise to 23 °C and stirred for additional 14 h. The mixture was purified by 
silica gel flash chromatography with a gradient of 20-100% diethyl ether with hexanes (product Rf 
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~0.48 in 3:1 diethyl ether:hexanes) and 281 mg (85% yield) of product was recovered as a pale 
yellow oil. 1H NMR (400 MHz in CDCl3) δ: 8.29 (d, J = 8.19 Hz, 2H), 7.40 (d, J = 9.91 Hz, 2H), 
7.07 (s, 1H), 4.47-4.44 (m, 2H), 3.81-3.79 (m, 2H), 3.64 (t, J = 4.89 Hz, 2H), 3.52-3.48 (dt, J = 
5.41, 4.69 Hz, 2H), 1.96 (s, 6H). 13C NMR (400 MHz in CDCl3) δ: 172.1, 155.4, 152.7, 
145.5,125.6, 121.9, 69.6, 68.5, 68.1, 63.0, 40.2, 32.7. IR: ν = 3413, 3120, 3079, 2973, 2929, 2869, 
1764, 1663, 1617, 1594, 1522, 1454, 1348, 1258, 1207, 1110, 1061, 1011, 901, 859, 774, 723, 663 
cm-1. HRMS (ESI) calculated for C15H19BrN2O7Na ([M + Na]
+) 443.0255, found 443.0265.  
 
 Synthesis of 2-hydroxyethyl 2-bromoisobutyrate (HEBIB) 
 
HEBIB was synthesized slightly modified from literature procedure.29 α-Bromoisobutyryl 
bromide (0.5 mL, 4.05 mmol) was added dropwise to a cold solution of ethylene glycol (1.33 mL, 
23.8 mmol, anhydrous) and anhydrous triethylamine (0.66 mL, 4.74 mmol) at 0 °C for 2 h. The 
reaction was continued at 23 °C for another 12 hrs. The reaction mixture was added to 10 mL of 
water and extracted with chloroform three times. The chloroform layer was washed successively 
with dilute HCl, saturated NaHCO3, and water. The organic layer was dried over anhydrous 
magnesium sulfate and evaporated for the product. The product was further purified silica gel flash 
chromatography with a gradient of 16-100% diethyl ether with hexanes and 407 mg (47.6% yield) 
was recovered as a clear oil. 1H NMR (400 MHz in CDCl3) δ: 4.32 (t, J = 4.65 Hz, 2H), 3.88 (t, J 
= 4.68 Hz, 2H), 1.96 (s, 6H), 1.58 (s, 1H). 1H-NMR agreed with that reported for this compound.29 
 




Trehalose (4.6 g, 13.44 mmol) was dissolved in 60 mL anhydrous DMSO in a flame-dried 
round bottom flask under argon.  Anhydrous TEA (5.6 mL, 40.18 mmol) and methacrylic 
anhydride (400 µL, 2.69 mmol) were added. This was stirred for 15 h at room temperature (23 °C). 
The solution was precipitated into cold (0 °C ice water bath) 1400 mL 8:2 Hex/DCM. The organic 
layer was decanted and the viscous liquid was dissolved in water for a total volume of 70 mL. 
After removing organics by rotary evaporation, the crude product was purified by HPLC with 10-
60% MeOH/H2O over 20 min. To this was added 150 ppm MEHQ as an inhibitor to prevent 
autopolymerization. Methanol and water were removed by rotary evaporation using a 2-neck flask 
equipped with a septa and long needle directly into the water to prevent autopolymerization by 
providing a source of oxygen. The product (340 mg, 31% yield) was recovered after lyophilization. 
1H NMR (400 MHz in D2O) δ: 6.03 (s, 1H), 5.63, (s, 1H), 5.07 (d, J = 3.99, 1H), 5.03 (d, J = 3.87 
Hz, 1H), 4.39-4.36 (dd, J = 12.43, 2.19 Hz, 1H), 4.26-4.23 (dd, J = 12.61, 5.27 Hz, 1H), 3.98-3.94 
(qd, J = 15.51, 4.98, 2.02, 1H), 3.76-3.68 (m, 4H), 3.65-3.60 (m, 1H), 3.57-3.54 (dd, J = 9.80, 3.90 
Hz, 1H), 3.52-3.49 (dd, J = 9.89, 3.88 Hz, 1H), 3.42 (t, J = 9.67 Hz, 1H), 3.32 (t, J = 9.52 Hz, 1H), 
1.82 (s, 3H). 1H-NMR agreed with that previously reported.30 
 




200 mM Dulbecco’s phosphate-buffered saline (DPBS) pH 7.4 was degassed by sparging 
with argon for 40 min. Methacrylate trehalose monomer (100 mg, 0.24 mmol) was placed in a 
Schlenk flask, which was evacuated and refilled with argon 4 times. CuBr2 (2.36 mg, 10.6 µmol) 
and tris(2-pyridylmethyl)amine (TPMA) (3.08 mg, 10.6 µmol) were dissolved in degassed DPBS 
pH 7.4. This was used to dissolve HEBIB (2.24 mg, 10.6 µmol) and transferred to the flask. The 
vial was washed with additional degassed DPBS for a total volume of 0.54 mL (monomer 
concentration of 0.45 M). Ascorbic acid (AA) was dissolved in degassed DPBS and a portion of 
this stock solution (for 1.12 mg, 6.4 µmol AA in 40 µL) was added to the flask to initiate 
polymerization. The polymerization proceeded at 23 °C for 3.5 h under argon. The polymerization 
was quenched by exposure to air (>99% conversion by 1H NMR) and the polymer was purified by 
dialysis against water (MWCO 3.5 kDa, with 100 mL Cuprisorb for 1 day to eliminate copper31) 
for 2 days. The polymer was recovered after lyophilization as a fluffy white solid. 1H NMR (400 
MHz in D2O) δ: 5.10, 5.06, 4.24, 4.03, 3.94, 3.75, 3.53, 3.35, 1.83, 1.51, 1.61, 0.96, 0.80. Number-
average molecular weight (Mn) = 5.3 kDa (by size exclusion chromatography (SEC) with PEG 
standards), molecular weight dispersity (D) = 1.21. 
 
 Preparation of insulin macroinitiator 
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Insulin (15 mg, 2.5 µmol) was weighed into a vial equipped with a stir bar and dissolved 
in 15 mL borate buffer pH 11 in a 0 °C ice bath. Nitrophenyl carbonate activated initiator (NPC 
initiator) (3.25 mg, 7.8 µmol) dissolved in 150 µL DMSO was added and the solution gradually 
turned yellow. The solution was stirred for 1 h in a 0 °C ice bath. The solution was buffer 
exchanged by centriprep ultracentrifugation (MWCO 3 kDa) into DPBS pH 7.4 several times until 
no yellow color remained. The singly modified macroinitiator was purified using semi-preparative 
(Zorbax 300SB C-18 column) with a gradient of 30-90% acetonitrile/water + 0.1% TFA over 20 
min (eluting at 9.5 min). Fractions were pooled and buffer exchanged into DPBS pH 7.4 using 
centriprep ultracentrifugation (MWCO 3 kDa). Concentration was determined by analytical HPLC 
AUC compared to a standard curve. MS (MALDI) expected 6073 Da, found 6070 Da. 
 
 Grafting trehalose glycopolymer from insulin macroinitiator 
DPBS pH 7.4 was degassed by sparging with argon for 30 min. Methacrylate trehalose 
monomer (50.0 mg, 122 mmol) and the sacrificial resin (16.9 mg, 4.1 µmol) were placed in a 
Schlenk tube, and this was evacuated and refilled with argon 3 times. Stock solutions of CuBr2 
(0.91 mg, 4.1 µmol) with TPMA (11.8 mg, 41 µmol) in 100 µL degassed DPBS and added to the 
flask. Ascorbic acid (0.43 mg, 2.4 µmol) in 170 µL degassed DPBS was prepared and used to 
dissolve the insulin macroinitiator (1.2 mg lyophilized from 300 µL DPBS) and transferred to the 
Schlenk flask. The polymerization proceeded at 23 °C for 14 h before being quenched by exposure 
to air. The mixture was stirred with pre-rinsed Cuprisorb for 1 h before purification by centriprep 
ultracentrifugation (MWCO 3 kDa) buffer exchanging into DPBS. The conjugate was further 
purified from residual macroinitiator using semi-preparative HPLC (Zorbax 300SB C-18 column) 
with a gradient of 30-90% acetonitrile/water + 0.1% TFA over 20 min (eluting at 8.8 min). 
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Fractions were pooled and buffer exchanged into DPBS pH 7.4 using centriprep ultracentrifugation 
(MWCO 3 kDa). The polymer was characterized by size exclusion chromatography (SEC) after 
digestion of insulin by Proteinase K.27 Briefly, insulin-trehalose glycopolymer conjugate was 
buffer exchanged by centriprep ultracentrifugation (MWCO 3 kDa) to digestion buffer (10 mM 
Tris HCl, 2 mM CaCl2 pH 7.4) and to 100 µL of this was added 100 µL Proteinase K at 2 mg/mL 
in digestion buffer. The solution was incubated in a 50 °C water bath for 24 h. Peptide fragments 
were removed by centriprep ultracentrifugation (MWCO 3 kDa) before analysis by size exclusion 
chromatography (SEC). Number-average molecular weight (Mn) = 8.7 kDa (with PEG standards), 
molecular weight dispersity (D) = 1.21. 
 
 Preparation of insulin-PEG conjugate 
Insulin (1.5 mg, 0.26 µmol) and methoxyPEG nitrophenyl carbonate (10 kDa, 25.8 mg, 2.6 
µmol) were dissolved in 1.5 mL 100 mM borate buffer pH 11. This solution was incubated for 1 
hour at 4 °C on a rocker. The solution was filtered before purification using semi-preparative 
HPLC (Zorbax 300SB C-18 column) with a gradient of 30-80% acetonitrile/water + 0.1% TFA 
over 30 min (eluting at 10.5 min). Fractions were pooled and buffer exchanged into DPBS pH 7.4 
using centriprep ultracentrifugation (MWCO 3 kDa). 
 
 Determination of concentration by BCA assay 
Insulin conjugate concentrations were determined using Pierce BCA assay kit 
(ThermoFisher Scientific) according to manufacturer specifications. Briefly, 10 µL each sample 
and insulin standard were pipetted into a 96-well plate. To this was added 200 µL working reagent 
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(50 parts A + 1 part B). The plate was incubated at 37 °C for 30 min then cooled to room 
temperature before measuring absorbance at 562 nm. 
 
 Bioactivity Study 
Bioactivity was determined by insulin tolerance test (ITT) using standard protocols.9, 32 
Specifically, CD1 mice (6−8 wks, female, n = 4, Charles River Laboratories) were fasted for 4−6 
h to reduce variability in baseline blood glucose. Mice were injected through the tail vein with 
insulin that had been exposed to the HPLC purification conditions used for the macroinitiator (16 
µg/kg), insulin-trehalose glycopolymer conjugate (48 µg/kg of insulin), or insulin-PEG conjugate 
(48 µg/kg of insulin). Blood glucose was measured at prescribed timepoints by pricking the tail 
vein of conscious mice with a needle and sampling the approximately 2 µL droplet formed with a 
commercial glucometer. 
 
 Stability Study 
Insulin and insulin-trehalose glycopolymer conjugate were prepared at 0.1 mg/mL. These 
solutions were aliquoted 100 µL into 1.5 mL LoBind tubes and heated in a dry heat block at 90 °C 
for 30 min. Samples were cooled in a 4 °C freezer before filtering with 0.22 µm PTFE filters. 
Heated and unheated samples were analyzed by HPLC using a Zorbax 300 SB-C3 column with a 
gradient of 0-100% MeCN/water + 0.1% TFA over 17 min. The area under the curve was used to 





For assessment of the statistical significance of differences, two-tailed Student’s t-test 
assuming unequal sample variance was employed. Results were considered significantly different 
if p < 0.05. 

















Figure 3-9. 1H NMR spectrum of 2-hydroxyethyl 2-bromoisobutyrate (CDCl3). 
 










Figure 3-12. FTIR spectrum of 2-bromo-N-(2-(2-hydroxyethoxy)ethyl)-2-methylpropanamide. 
 






Figure 3-14. Amount of intact insulin by area under the curve (AUC) after heating insulin to 90 




Figure 3-15. HPLC trace of insulin macroinitiator during purification with percent yield 




Figure 3-16. LC-MS of crude insulin macroinitiator. (A) TIC trace with mass spectra showing (B) 
no modification (C) one modification (D) two modifications (E) three modifications (F) four 




Figure 3-17. MALDI MS of purified insulin macroinitiator reduced with DTT. 
 
 
Figure 3-18. Native PAGE of insulin-trehalose glycopolymer conjugate, Coomassie stained (Lane 
1: Insulin, Lane 2: Insulin macroinitiator, Lane 3: Insulin-trehalose glycopolymer polymerization 
mixture, Lane 4: Trehalose glycopolymer with large MW species, Lane 5: Purified insulin-





Figure 3-19. SDS PAGE with 16.5% Tris-Tricine Gel under non-reducing and reducing conditions 
(Nonreducing: Lane 1: Ladder, Lane 2: Insulin, Lane 3: Insulin macroinitiator, Reducing, Lane 8: 
Insulin macroinitiator, Lane 9: Insulin, Lane 10: Ladder). 
 
 
Figure 3-20. SEC trace of polymerization by AGET ATRP with trehalose monomer, 1 mg/mL 





Figure 3-21. SEC trace of polymerization by AGET ATRP with trehalose monomer, 1 mg/mL 
insulin, and 10 equiv TPMA : 1 equiv CuBr2. 
 
Figure 3-22. Native PAGE with control polymerizations (Lane 1: Insulin, Lane 2: Insulin-
trehalose glycopolymer polymerization mixture, Lane 3: AGET ATRP conditions without initiator 
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and with insulin, Lane 4: AGET ATRP conditions without initiator or insulin, Lane 5: Insulin, 
Lane 6: AGET ATRP conditions with resin and insulin). 
 




Figure 3-24. SEC traces of trehalose glycopolymer itself before and after incubation with 
Proteinase K. 
 
Figure 3-25. SDS PAGE of insulin-PEG conjugate (Lane 1: Ladder, Lane 2: Insulin, Lane 3: PEG, 




Figure 3-26. MALDI MS of insulin-PEG conjugate (A) intact and (B) reduced with 100 mM DTT. 
 
Figure 3-27. Analytical HPLC trace of insulin-PEG conjugate. 
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B18 2023.0146 2.9358e+002 2023.0349 -0.0203 -10.0354 
B21 2312.1042 2.7218e+002 2312.1082 -0.0040 -1.7136 
B23 2525.1977 3.2198e+002 2525.2307 -0.0330 -13.0717 
B24 2672.3277 4.7271e+003 2672.2991 0.0285 10.6788 
B26 2982.4270 1.3868e+004 2982.4309 -0.0039 -1.3110 
B27 3082.4512 1.1113e+004 3083.4786 -0.0273 -8.8656 
Y3 623.2110 5.2549e+002 623.2177 -0.0067 -10.6785 
Y4 724.2676 7.8433+002 724.2653 0.0023 3.1715 
Y5 887.3322 6.0729e+002 887.3287 0.0035 3.9557 
Y6 1034.4029 7.9903+002 1034.3971 0.0058 5.6535 
PheB1 
N/A N/A N/A N/A N/A N/A 
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Chapter 4. Preparation of Self-Immolative Linkers for Blood Releasable 





Insulin is an important protein therapeutic for the management of type I diabetes mellitus. To 
improve glycemic control, several insulin analogs with altered pharmacokinetics are available for 
clinical use.1-3 Long-acting (or basal) insulin analogs alter the protein’s solubility to precipitate 
upon subcutaneous injection, creating a depot for extended half-life, or include serum albumin 
binding domains to increase the circulation time. Long-acting insulin analogs are used to control 
baseline glucose throughout a full day, thus are more easily stored in conditions amenable to 
insulin stability. Rapid-acting insulin analogs decrease the protein’s propensity to self-associate, 
enabling action onset within 15 min,2 and are used to control blood glucose spikes near mealtimes. 
Issues of safety and efficacy stem from instability of insulin when the protein is exposed to elevated 
temperatures or mechanical agitation.4-5 Because regular and rapid-acting insulins are administered 
on-the-go near mealtimes to lower blood glucose, often without the ability to refrigerate the 
protein, there is an interest in stabilized formulations without alteration of pharmacokinetics. 
We previously reported the preparation of trehalose-glycopolymer conjugates in chapters 2 
and 3 as a potentially extended action insulin that has improved stability to heat and mechanical 
agitation. In the first design, a trehalose glycopolymer was conjugated nonspecifically to 1-2 
amines of insulin through reductive amination.6 To improve the bioactivity of the conjugate, the 
synthesis strategy was redesigned to achieve a site-specific conjugate by a grafting from method.7 
While both conjugates exhibited stability to environmental stressors, covalent conjugation of a 
polymer increases the circulation time, resulting in an extended action insulin to control baseline 
blood glucose. To achieve the same stability as these conjugates without alteration of the protein’s 
pharmacokinetics, we envisioned a strategy where conjugation of trehalose glycopolymer to 
153 
 
insulin would result in stable insulin, preventing aggregation during storage, while the polymer 
could be quickly released once administered. 
Self-immolative linkers have been used to better control kinetics in prodrugs, sensors, and 
other materials.8-10 These linkers consist of a protecting group (PG) that is removed by a trigger to 
activate elimination through an electronic cascade or cyclization of the spacer, releasing the 
molecule of interest (Figure 4-1). Linker kinetics can be tuned based on their mechanism.8 For 
elimination, addition of electron density on the aromatic ring speeds up the kinetics of self-
immolation because it stabilizes the quinone methide intermediate and facilitates dearomatization. 
For cyclization, increasing steric bulk of strategically placed substituents on the spacer speeds the 
cyclization due to the Thorpe-Ingold effect. In general, elimination is faster than cyclization 
because it does not involve a conformational change. The most common use for self-immolative 
linkers in biomolecule conjugates is to make antibody-drug conjugates that couple anticancer 
drugs to targeting antibodies.11 Additionally, self-immolative linkers have been used in protein-
polymer conjugates to prepare conjugates that release native protein in response to a variety of 
triggers.12 However, these linkers are primarily designed for slow, controlled release of protein 
over time. To our knowledge, protein-polymer conjugates with fast-releasing self-immolative 




Scheme 4-1. Overview of self-immolative spacers and mechanisms used for linker designs. 
Protecting group (PG) is removed during activation to release molecule of interest (MI). 
Herein, self-immolative spacers between insulin and a trehalose glycopolymer were designed 
and synthesized for use as linkers capable of being triggered for release by common components 
of blood. Specifically, linkers were designed to be triggered by albumin or reducing conditions in 
the blood using either elimination or cyclization mechanism. The kinetics of self-immolation and 
release were tested for each linker design. 
4.2 Results and Discussion 
Albumin is a major component of blood and is known to catalyze several proton-transfer 
reactions including Kemp elimination and β-elimination.13-16 Shabat and coworkers have used 4-
hydroxy-2-butanone as a trigger responsive to bovine and human serum albumins in self-
immolative polymers for signal amplification.17-18 With this inspiration, we designed the self-
immolative linker 1 that would be triggered by base-catalyzed β-elimination by serum albumin. 
Synthesis of a polymer conjugate with this linker would be accomplished by grafting from an 




Figure 4-1. Designs of blood-triggerable linkers screened. 
The 1,4-elimination linker 1 was synthesized with an amine-reactive nitrophenyl carbonate 
for conjugation to insulin in order to assess preliminarily release kinetics. However, an unexpected 
molecular weight species were detected by LC-MS during initial conjugation attempts (Figure 4-2 
A). After 30 min reaction time, insulin modified with 150 Da small molecules were detected that 
did not correspond to the expected 264 Da modifications. With an additional 2.5 h of reaction time, 
another 70 Da modification could be observed in the mass spectra. Upon closer examination, we 
hypothesized that the free amines on insulin catalyze the β-elimination to expose more primary 
amines, which also catalyze the self-immolation (Figure 4-2 B). The alkene byproduct may then 
modify the protein through Michael addition, resulting in insulin modified with 70 and 150 Da 
small molecules. To further probe this hypothesis, small molecule model studies were undertaken. 
Exposure of the linker to borate buffer pH 9.0 used during conjugation only showed a small amount 
of hydrolysis of the carbonate (Appendix C: Figure 4-28). In the presence of phenylalanine (Phe) 
as a source of free amine, a rapid decrease in the starting material peak was observed, with minimal 




Figure 4-2. Unexpected product of conjugation with albumin-triggered linker 1. (A) 
Characterization by LC-MS and (B) scheme of byproduct formation. 
To mitigate the premature triggering of the linker during conjugation, the albumin-
triggered linker 2 was designed to release a less basic thiol, which was expected not to further 
catalyze the β-elimination. To test this hypothesis, linker 1 was first incubated in the presence of 
2-mercaptoethanol as a model free thiol to determine if the elimination could be catalyzed by any 
premature release of thiol. No significant change in the starting material peak was observed, 
indicating that a thiol does not catalyze the β-elimination (Appendix C: Figure 4-30). The kinetics 
of self-immolation of linker 2 before conjugation was first tested with Phe as a small molecule 
trigger. The starting material was slowly converted to the desired product, only reaching 22% 
conversion over 50 min and 66% conversion over 20 h (Figure 4-3). This is too slow for use with 
insulin.  Yet, the slower kinetics of self-immolation than linker 1 may be because linker 2 lacked 
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the driving force of CO2 formation. However, this linker may have utility for applications requiring 
a longer persisting conjugate. 
 
Figure 4-3. HPLC trace of albumin triggered linker 2 during reaction with Phe.  
Free thiols including glutathione, cysteine, and albumin have a concentration of 
approximately 0.6 mM in the blood and glutathione has a concentration of 7 mM in the liver.19-20 
Additionally, some antibody-drug conjugates using disulfides as linkers have had issues with 
premature release of cargo from reduction during circulation.21-22 Thus, we hypothesized thiols in 
the blood and liver could be used as a trigger to release insulin from a conjugate. 
Thus, the thiol-triggered linker 3, utilizing a cyclization mechanism, was prepared with 
pyridyl disulfide (PDS) as a model small molecule and conjugated to insulin through an amine-
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reactive nitrophenyl activated carbonate. The kinetics were first tested with the small molecule 
conjugate under physiologically relevant thiol concentrations of 0.6 mM (blood) or 7 mM (liver) 
glutathione, monitoring the reaction by UV-vis and analytical HPLC (Figure 4-4 and Appendix 
C: Figure 4-31). Absorbance at 343 nm rapidly increased from the formation of 2-pyridylthione 
following reduction of the disulfide. By HPLC, the fraction of insulin modified with multiple 
linkers rapidly decreased while the amount of free insulin peaked within 40 min for 0.6 mM 
glutathione and 20 min for 7 mM glutathione. These results were within the desired time range for 
insulin release, so linker 3 was studied further. 
 
Figure 4-4. Kinetics of (A) insulin release conjugate of linker 3 with glutathione concentrations 
from (B) blood (0.6 mM) and (C) liver (7 mM). 
An insulin-trehalose glycopolymer conjugate was then prepared to compare kinetics with 
the polymer (Scheme 4-2). An insulin macroinitiator was first prepared by reacting insulin with 
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an initiator derivative of linker 3. The conjugate was then prepared by polymerizing from the 
insulin macroinitiator using conditions reported previously.7 The conjugate was purified by semi-
preparative HPLC and characterized by native PAGE and analytical HPLC (Appendix C: Figure 
4-34 and Figure 4-35). However, upon reduction with 7 mM glutathione (liver), no appreciable 
amount of insulin was released from the conjugate over 85 min, though a new peak possibly 
corresponding to reduction of one or more linkers on the conjugate appeared (Appendix C: Figure 
4-36). This is most likely due to the increased steric bulk of the polymer slowing kinetics of 
disulfide exchange by hindering the attacking thiol.23 
 
Scheme 4-2. Synthesis of insulin-linker 3 conjugate. (A) Synthesis of insulin-linker 3 
macroinitiator and (B) polymerization from insulin-linker 3 macroinitiator. 
To minimize the impact of polymer bulk on the triggering step of disulfide exchange, linker 
4 was designed with the goal of polymer conjugation across the benzyl linker core to maintain a 
small molecule across the disulfide. Linker 4 was synthesized with nitrophenyl carbonate as 
conjugation handle for insulin and PDS across the disulfide as a model compound. The model 
linker 4 was exposed to reducing conditions (0.6 mM glutathione, blood) and kinetics were 
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monitored over time by analytical HPLC (Figure 4-5). A rapid decrease in the height of the starting 
material peak was observed within the first 5 minutes. Similar kinetics were observed following 
conjugation to insulin, though aqueous solubility and stability of the protein was lowered by 
modification with the hydrophobic small molecule (Appendix C: Figure 4-38). 
 
Figure 4-5. HPLC trace of benzyl disulfide linker 4 during reduction with 0.6 mM glutathione and 
(inset) kinetics of benzyl disulfide linker reduction. 
 Efforts to synthesize linker 4 with an initiator site substituted on the benzyl ring were 
ultimately unsuccessful. The presence of the thiol on the benzyl core complicated synthesis by 
poisoning catalysts and altering expected reactivity on the benzyl ring, resulting in no reaction or 
undesired side products. Additionally, it was decided that polymer added to the insulin as an 
excipient (not conjugated) would be a viable route to stabilize rapid-acting insulin because 
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trehalose added a 2 molar equivalent stabilized as well as conjugated at 1-2 sites.24 Thus, this work 
was not pursued.  Yet what was learned with regard to various linker designs having different 
kinetics of release triggered by relevant conditions in the blood that may be useful for other 
applications. 
4.3 Conclusion 
Herein, we have reported the synthesis of several blood-triggered self-immolative linkers 
for conjugation to insulin. Linkers were either triggered by serum albumin-catalyzed β-elimination 
or disulfide exchange with thiols in the blood or liver. Linker 1 was shown to self-catalyze the 
electronic cascade during conjugation to insulin. Linker 2 was designed to eliminate this self-
triggering, but kinetics was slower because the linker did not possess the production of CO2 as a 
driving force. Kinetics of release for linker 3 was rapid for small molecules but was too slow with 
the addition of the steric bulk of trehalose polymer across the disulfide. Linker 4 also exhibited 
fast kinetics as small molecule and conjugated to insulin. However, synthetic challenges limited 
access to addition of an initiator across the benzyl ring. Though these linkers are not suited for 
preparing rapid-acting stabilized insulin conjugates, they may be useful for other applications 
requiring trigger upon injection. 
4.4 Appendix C 
Analytical techniques 
Nuclear Magnetic Resonance (NMR) spectra were recorded on a Bruker AV 400 MHz 
spectrometer. Trehalose monomer was purified by preparatory reverse phase HPLC on a Shimadzu 
HPLC system equipped with a UV detector using a Luna 5 µm C18 100A column (preparatory: 5 
µm, 250 x 21.2 mm) with monitoring at λ = 215 nm and 254 nm. Gradient solvent system 
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(water:methanol = 90:10 to 40:60 over 20 min) was used as the mobile phase at a flow rate of 20 
mL/min. Analytical HPLC for detection of insulin was conducted on an Agilent 1260 Infinity II 
LC System equipped with a UV detector using Zorbax SB300 C-3 column and a gradient solvent 
system (water:acetonitrile = 90:10 to 0:100 + 0.1 % trifluoroacetic acid over 17 min at 0.6 
mL/min). Analytical HPLC to monitor reaction kinetics was conducted on an Agilent 1260 Infinity 
II LC System equipped with a UV detector using a Poroshell C18 column and a gradient solvent 
system (water:acetonitrile = 90:10 to 5:95 + 0.1 % trifluoroacetic acid over 17 min at 1.2 mL/min). 
Semi-preparative HPLC to purify the insulin macroinitiator was conducted on an Agilent 1260 
Infinity II LC System equipped with a UV detector and Zorbax 300SB C18 column with a gradient 
solvent system (water:acetonitrile = 70:30 to 0:100 + 0.1 % trifluoroacetic acid over 20 min at 3 
mL/min unless otherwise noted). LCMS was conducted on an Agilent 6530 Q-TOF LC/MS with 
1260 Infinity LC equipped with Zorbax SB300 C-3 column and solvent gradient system 
(water:acetonitrile = 90:10 to 5:95 + 0.1 % formic acid over 17 min at 1.2 mL/min). 
 
Methods and Materials 
All materials were purchased from Sigma Aldrich or Fisher Scientific unless otherwise 
noted. Recombinant human insulin was purchased from Sigma-Aldrich (Lot no. 17A061-D). 4-
Mercaptobenzyl alcohol was purchased from Combi-Blocks. Methacrylate trehalose monomer 
was synthesized as previously reported.7 PDS alcohol was synthesized as previously reported.25 
Trehalose was purchased from The Healthy Essential Management Corporation (Houston, TX) 
and was azeotropically dried with ethanol and kept under vacuum until use.  
 




Synthesis was based on previously published literature protocol.17 4-Aminobenzyl 
alcohol (500 mg, 4.1 mmol, 1 eq.) was suspended in a 15 mL mixture of THF: sat. NaHCO3: water 
(ratio 2:2:1). Phenyl chloroformate (638 µL, 4.5 mmol, 1.1 eq.) was added drop wise over 5 
minutes. The solution was stirred at room temperature (21 °C) for 2 h. The solution was extracted 
with EtOAc and the organic phase washed twice with sat. NH4Cl solution, dried with MgSO4, and 
filtered. The solvent was removed under reduced pressure and the crude product purified by 
column chromatography on silica gel (8-100% acetone/hexanes) to give the product (987.5 mg, 
quant. yield) as a white solid. 1H NMR (400 MHz, acetone-d6) δ 9.11 (s, 1H), 7.60 – 7.50 (m, 2H), 
7.42 – 7.34 (m, 2H), 7.34 – 7.26 (m, 2H), 7.25 – 7.15 (m, 3H), 4.56 (d, J = 5.9 Hz, 2H), 4.10 (t, J 
= 5.8 Hz, 1H). IR: ν 3399, 3367, 3064, 3044, 2932, 2880, 1727, 1590, 1593, 1523, 1484, 1456, 
1411, 1316, 1195, 1112, 1107, 1003, 937, 913, 890, 812, 787, 723, 726, 691, 630, 612 cm-1.  
 
Synthesis of 3-oxobutyl (4-(hydroxymethyl)phenyl)carbamate 
 
Synthesis was based on a similar procedure in the literature.17 Phenyl (4-
(hydroxymethyl)phenyl) carbamate (70 mg, 0.28 mmol, 1 eq.) was dissolved in dry DMF (2 mL), 
pre-heated to 90 °C. Dibutyltin dilaurate (DBTDL, 4 µL, 6.9 µmol, 0.024 eq,) and 4-hydroxy-2-
butanone (248 µL, 2.8 mmol, 10 eq.) were immediately added. The reaction was monitored to 
completion by TLC (4:1 EtOAc:Hex) for 3 h. The solvent was removed under reduced pressure 
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and the crude product purified by column chromatography on silica gel (EtOAc:Hex 20-100%). 
The product was recovered as a yellow solid (58.1 mg, 88% yield). 1H NMR (400 MHz, 
chloroform-d) δ 7.38 – 7.27 (m, 4H), 6.67 (d, J = 16.8 Hz, 1H), 4.64 (s, 1H), 4.43 (t, J = 6.1 Hz, 
2H), 4.12 (q, J = 7.2 Hz, 2H), 2.82 (t, J = 6.1 Hz, 2H), 2.04 (s, 3H). 13C NMR (400 MHz, 
Chloroform-d) δ 206.05, 137.29, 136.25, 129.56, 128.08, 65.02, 60.08, 42.77, 30.35. IR: ν 3320, 
3262, 2977, 2923, 2872, 1728, 1704, 1615, 1595, 1542, 1471, 1416, 1391, 1361, 1323, 1247, 1224, 
1166, 1100, 1071, 1012, 823, 794,771, 740 cm-1. 
 
Synthesis of linker 1 
 
In a flame-dried round bottom flask under argon, 3-oxobutyl (4-
(hydroxymethyl)phenyl)carbamate (100 mg, 0.42 mmol, 1 eq.) was dissolved in 0.5 mL anhydrous 
DCM with anhydrous TEA (88 µL, 0.63 mmol, 1.5 eq.) in a 0 °C ice bath. To this was added 
nitrophenyl chloroformate (170 mg, 0.84 mmol, 2 eq.). The reaction was left to rise to room 
temperature 23 °C and stirred 4 h. The reaction mixture was diluted with DCM and washed with 
0.1 M HCl, water, and brine, dried with MgSO4, and purified with silica gel chromatography (8-
66% EtOAc/Hexanes). The product was isolated as a yellow solid (40.0 mg, 24% yield). 1H NMR 
(400 MHz, chloroform-d) δ 8.27 (d, J = 9.2 Hz, 2H), 7.42 – 7.33 (m, 4H), 6.64 (s, 1H), 5.24 (s, 
2H), 4.45 (t, J = 6.1 Hz, 2H), 2.83 (t, J = 6.1 Hz, 2H), 2.21 (s, 3H). 13C NMR (400 MHz, 
acetonitrile-d3) δ 206.14, 155.72, 153.50, 152.49, 139.46, 129.62, 129.23, 125.29, 122.27, 118.46, 
70.47, 59.97, 42.08, 29.34. IR: ν 3353, 3123, 3084, 2966, 2920, 1755, 1729, 1704,1602, 1598, 
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1522, 1491, 1416, 1348, 1285, 1235, 1207, 1163, 1096, 1066, 1036, 923, 863, 836, 805, 768, 751, 
714, 664 cm-1. 
 
Conjugation of linker 1 to insulin 
 
Insulin (0.2 mg, 3.4 x 10-5 mmol, 1 eq.) was dissolved in 40 µL borate buffer pH 9.0 and 
60 µL EtOH. Linker 1 (0.69 mg, 1.7 µmol, 50 eq.) was dissolved in 100 µL EtOH and to this was 
added the insulin solution. The solution was stirred and monitored by LC-MS over 3 hours. MS 
(LC-MS) Expected 5808 (insulin), 6072 (insulin + 1 linker), 6336 (insulin + 2 linkers), 6600 
(insulin + 3 linkers), Found 5809 (insulin), 5959 (insulin + 1 byproduct), 6107 (insulin + 2 
byproducts) (Figure 4-2). 
 
Synthesis of 4-tosyloxy-2-butanone 
 
The procedure was based on a previously published protocol.26 To a solution of 4-
toluenesulfonyl chloride (1660 mg, 8.7 mmol, 1.5 eq.) and 4-hydroxy-2-butanone (0.5 mL, 5.8 
mmol, 1 eq.) in dry DCM (11.6 ml) at 0 °C was added pyridine (1.4 mL, 17.4 mmol, 3 eq.). The 
mixture was stirred overnight (21 °C) while warming up to room temperature naturally. The 
solution was washed with water, and the organic layer was dried over magnesium sulfate. The 
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organic phase was concentrated under reduced pressure, and the residue was purified by silica gel 
column (2-20% EtOAc/Hexanes, Rf ~0.37 in 1:9 EtOAc/Hexanes) to afford the product as a clear 
oil at room temperature? or white solid in freezer (765.5 mg) in 55% yield. 1H NMR (400 MHz, 
chloroform-d) δ 7.79 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 7.9 Hz, 2H), 4.25 (t, J = 6.4 Hz, 2H), 2.83 (t, 
J = 6.4 Hz, 2H), 2.45 (s, 3H), 2.15 (s, 3H). 
 
Synthesis of 4-((4-(hydroxymethyl)phenyl)thio)butan-2-one 
 
To a solution of 4-mercaptobenzyl alcohol (100 mg, 0.71 mmol, 1 eq.) and 4-tosyloxy-2-
butanone (190 mg, 0.79 mmol, 1.1 eq.) in 4 mL anhydrous acetone was added TEA (200 µL, 1.4 
mmol, 2 eq.). The reaction mixture was stirred for 2 h at room temperature (21 °C). Solvent was 
removed by rotary evaporation and the crude was purified by column chromatography (10-65% 
EtOAc/Hexanes). Solvent was removed to yield the product as a yellow oil (119.3 mg, 80% yield). 
1H NMR (400 MHz, Chloroform-d) δ 7.37 – 7.16 (m, 2H), 4.66 (s, 1H), 3.12 (dd, J = 7.6, 6.9 Hz, 
1H), 2.75 (t, J = 7.3 Hz, 1H), 2.14 (s, 1H). 13C NMR (400 MHz, Chloroform-d) δ 206.64, 139.17, 
134.97, 129.82, 127.73, 64.87, 43.08, 30.12, 27.60. IR ν 3398, 2927, 2864, 1709, 1600, 1493, 
1405, 1361, 1279, 1206, 1160, 1090, 1011, 892, 819, 798, 741 cm-1. HRMS (ESI) calculated for 
C11H14O2S ([M]
+) 210.0892, found 210.0314. 
 




4-((4-(hydroxymethyl)phenyl)thio)butan-2-one (100 mg, 0.48 mmol, 1 eq.) was dissolved 
in DCM (1 mL) and pyridine (58 µL, 0.71 mmol, 1.5 eq.) and cooled with an ice bath to 0 °C. To 
this was added 4-nitrophenyl chloroformate (115 mg, 0.57 mmol, 1.2 eq) in DCM (1 mL) dropwise 
over 15 min. The reaction was stirred another 15 h, monitoring by TLC (3:1 DCM/EtOAc). The 
mixture was washed with sat. NH4Cl, water, and brine, dried with MgSO4, and filtered before 
solvent was removed by rotary evaporation. The crude was further purified by silica gel 
chromatography (0-40% EtOAc/DCM gradient) to afford the product as a yellow solid (77.1 mg, 
44% yield). 1H NMR (400 MHz, Chloroform-d) δ 8.27 (d, J = 9.2 Hz, 2H), 7.42 – 7.27 (m, 4H), 
6.64 (s, 1H), 5.25 (s, 2H), 3.16 (t, J = 7.3 Hz, 2H), 2.78 (t, J = 7.2 Hz, 2H), 2.16 (s, 3H). 13C NMR 
(400 MHz, Chloroform-d) δ 206.37, 155.50, 152.44, 145.46, 137.47, 131.96, 129.44, 129.27, 
129.03, 125.33, 121.77, 70.52, 42.90, 30.12, 26.98. IR ν 3118, 3082, 2929, 2854, 1769, 1715, 
16151596, 1520, 1493, 1408, 1348, 1256, 1216, 1160, 1090, 1032, 1012, 954, 933, 862, 801, 797, 
727, 730, 686, 669 cm-1. 
 
Kinetics of self-immolation of linker 2 
To 1 mg/mL linker 2 in EtOH was added an equal volume of 15 mg/mL phenylalanine in 
EtOH/DPBS pH 7.4. The mixture was monitored over time by HPLC (Poroshell column, 10-95% 
MeCN/water +0.1% TFA over 15 min) (Figure 4-3). 
 




Synthesis was based on previous reports in the literature.27-28 PDS alcohol (300 mg, 1.60 
mmol, 1 eq.) and triethylamine (0.25 mL, 1.76 mmol, 1.1 eq.) was dissolved in 9 mL ACN and 
cooled to 0 °C. Nitrophenyl chloroformate (355 mg, 1.76 mmol, 1 eq.) was added. The solution 
was left to rise to 23 °C and stirred for 5 hours. Solvent was removed en vacuo and the product 
was purified by column chromatography (10-60% EtOAc/Hexanes gradient) to afford a yellow oil 
(372.2 mg). The product was further purified by column chromatography (DCM) to remove 
nitrophenol impurity to yield the product as a clear oil (246.6 mg, 44% yield). 1H NMR (400 MHz, 
Chloroform-d) δ 8.47 (ddd, J = 4.8, 1.8, 1.0 Hz, 2H), 7.68 – 7.56 (m, 2H), 7.52 (d, J = 8.3 Hz, 2H), 
7.31 (d, J = 8.5 Hz, 2H), 7.09 (ddd, J = 6.7, 4.8, 1.7 Hz, 1H), 4.66 (d, J = 4.5 Hz, 2H), 1.67 (t, J = 
5.5 Hz, 1H). 
 
 Synthesis of insulin-linker 3 conjugate 
 
Insulin (1mg, 0.17 µmol, 1 eq.) was dissolved in 500 µL borate buffer pH 9 and 100 µL 
EtOH. Linker 3 (0.6 mg, 1.7 µmol, 10 eq.) was dissolved in 200 µL EtOH and to this was added 
the insulin solution. The solution was stirred for 0.5 hour, then another aliquot of linker 3 initiator 
(0.6 mg, 1.7 µmol, 10 eq.) dissolved in 200 µL EtOH was added. The solution was stirred for an 
additional 1 hour before desalting with PD-10 desalting column (centrifuge protocol with DPBS 
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pH 7.4) then concentration and buffer exchange with centriprep (MWCO 3 kDa) and DPBS pH 
7.4 buffer. Macroinitiator was lyophilized after analytical HPLC characterization (Recovered: ~1 
mg). MS (LC-MS) Expected 5808 (insulin), 6022 (insulin + 1 linker), 6236 (insulin + 2 linkers), 
6450 Da (insulin + 3 linkers), Found 5809 (insulin), 6023 (insulin + 1 linker), 6237 (insulin + 2 
linkers), 6450 Da (insulin + 3 linkers). 
 
Kinetics of self-immolation of insulin-linker 3 conjugate 
Stock solutions of glutathione were prepared in DPBS pH 7.4 at 1.2 mM or 14 mM 
glutathione. 100 µL Insulin-linker 3 conjugate (0.6 mg/mL) or DPBS pH 7.4 buffer was pipetted 
into a 96-well plate. Additional 100 µL DPBS buffer with or without glutathione was added to 
each well and the absorbance at 343 nm was monitored at 37 °C over time. Absorbance was 
background corrected using buffer or buffer + glutathione. Similarly, 50 µL insulin-linker 3 
conjugate (0.6 mg/mL) was pipetted into an HPLC vial. Additional 50 µL DPBS buffer with 
glutathione was added and the AUC of insulin peaks were monitored over time (Figure 4-4). 
 
Synthesis of cystamine bis initiator 
 
In a flame-dried round bottom flask, cystamine dihydrochloride (800 mg, 3.55 mmol, 1 
eq.) was dissolved in anhydrous DCM (5.5 mL) and anhydrous TEA (1.24 mL, 8.88 mmol, 2.5 
eq.) and stirred for 10 minutes in a 10 °C ice bath. Bromoisobutyryl bromide (1.11 mL, 10.66 
mmol, 3 eq.) was added dropwise to the stirring solution. This solution was stirred at room 
temperature 23 °C for 16 h. The solution was filtered and washed successively with 1 M HCl, sat. 
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sodium bicarbonate and sat. ammonium chloride solutions. The DCM layer was dried with 
MgSO4, filtered, and the solvent was removed by rotary evaporation. The product was further 
purified by column chromatography (8-100% diethyl ether / hexanes gradient).  The product (final 
peak) was recovered as a white solid (770.0 mg, 48% yield). 1H NMR (400 MHz, chloroform-d) 
δ 7.14 (s, 2H), 3.61 (q, J = 6.2 Hz, 4H), 2.87 (t, J = 6.4 Hz, 4H), 1.96 (s, 12H). 13C NMR (400 
MHz, chloroform-d) δ 172.33, 62.59, 39.20, 37.41, 32.50. IR ν 3340, 2972, 2919, 1650, 1529, 
1435, 1433, 1366, 1293, 1194, 1108, 1031, 928, 831, 730 cm-1. 
 
Synthesis of 2-bromo-N-(2-((2-hydroxyethyl)disulfaneyl)ethyl)-2-methylpropanamide 
 
Cystamine bis initiator (300 mg, 0.67 mmol, 1 eq.) was dissolved in DCM (1.9 mL) and 
TEA was added (187 µL, 1.34 mmol, 2 eq.). To this was added 2-mercaptoethanol (61 µL, 0.87 
mmol, 1.3 eq.) and the mixture was stirred for 16 h. The organic solution was washed with water 
2x and brine, dried with MgSO4, and filtered. The product was further purified by column 
chromatography (8-66% EtOAc/Hexanes gradient, last peak). The product was recovered as a 
clear oil (112.5 mg, 56% yield). 1H NMR (400 MHz, Chloroform-d) δ 7.10 (s, 1H), 3.89 (t, J = 5.7 
Hz, 2H), 3.62 (td, J = 6.5, 5.9 Hz, 2H), 2.89 (t, J = 5.8 Hz, 2H), 2.85 (t, J = 6.5 Hz, 2H), 1.95 (s, 
6H). 13C NMR (400 MHz, Chloroform-d) δ 172.40, 62.77, 60.25, 41.72, 39.25, 37.19, 32.54. IR ν 
3340, 2980, 2927, 2871, 1651, 1523, 1437, 1369, 1280, 1194, 1112, 1044, 1000, 913, 851, 748, 
730 cm-1. 
 




In a dry round bottom flask, 2-bromo-N-(2-((2-hydroxyethyl)disulfaneyl)ethyl)-2-
methylpropanamide (170 mg, 0.56 mmol) was dissolved in 3.4 mL anhydrous DCM with 87 µL 
anhydrous TEA (0.62 mmol) and stirred at 0 °C for 10 minutes. To this was added nitrophenyl 
chloroformate (170 mg, 0.85 mmol). The solution was left to rise to 23 °C and then stirred for 15 
h. The solution was washed with sat. ammonium chloride and brine. The aqueous washes were 
extracted with DCM, the organic phases were collected, dried with MgSO4, and filtered. The 
solvent was removed by rotary evaporation and the product was further purified by column 
chromatography (16-100% DCM/hexanes). Solvent was removed en vacuo and the product was 
recovered as a yellow oil (105.4 mg, 40.4% yield). 1H NMR (400 MHz, Chloroform-d) δ 8.29 (d, 
J = 9.2 Hz, 2H), 7.40 (d, J = 9.2 Hz, 2H), 7.07 (s, 1H), 4.56 (t, J = 6.5 Hz, 2H), 3.63 (q, J = 6.2 Hz, 
2H), 3.05 (t, J = 6.6 Hz, 2H), 2.90 (t, J = 6.3 Hz, 2H), 1.95 (s, 6H). 13C NMR (400 MHz, 
chloroform-d) δ 172.31, 155.39, 152.35, 145.53, 125.37, 121.81, 66.81, 62.74, 39.17, 37.58, 36.58, 
32.52. IR ν 3301, 3127, 3060, 2933, 2859, 1763, 1643, 1594, 1520, 1512, 1449, 1381, 1345, 1262, 
1221, 1193, 1163, 1102, 1062, 1040, 1036, 934, 856, 772, 748, 666 cm-1. 
 
Synthesis of insulin-linker 3 macroinitiator 
 
Insulin (10 mg, 1.7 mmol, 1 eq.) was dissolved in 10 mL borate buffer pH 9.0. Linker 3 
initiator (8.0 mg, 25 mmol, 10 eq.) was dissolved in 100 µL EtOH and to this was added the insulin 
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solution. 3 mL EtOH was added to further solubilize the initiator. The solution was stirred for 1 
hour, then another aliquot of linker 3 initiator (8.0 mg, 17 mmol, 10 eq.) dissolved in 100 µL EtOH 
was added. The solution was stirred for an additional 1 hour before centriprep (MWCO 3 kDa) 
buffer exchange into DPBS pH 7.4 with ~50% EtOH then into DPBS pH 7.4. Insulin-linker 3 
macroinitiator was lyophilized after analytical HPLC characterization for grafting from 
(Recovered: 6.82 mg). MS (LC-MS) expected 5808, 6136, 6464, 6792 Da, found 5808, 6139, 
6467, 6796 Da. 
 
Synthesis of insulin-linker 3 trehalose polymer conjugate 
 
DPBS pH 7.4 was degassed by sparging with argon for 30 minutes. Methacrylate trehalose 
monomer (80.0 mg, 195 mmol, 30 eq.) and the sacrificial resin (23.4 mg, 6.5 µmol, 1 eq.) were 
placed in a Schlenk tube and this was evacuated and refilled with argon 3 times. A stock solution 
of CuBr2 (1.45 mg, 6.5 µmol, 1 eq.) and TPMA (18.9 mg, 65 µmol, 10 eq.) was prepared in 100 
µL degassed buffer and added to the flask. Ascorbic acid (0.69 mg, 3.9 µmol, 0.6 eq.) in 330 µL 
degassed DPBS was prepared and used to dissolve the insulin-linker 3 macroinitiator (~3.1 mg) 
and transfer it to the Schlenk flask. This initiated polymerization which was run at 23 °C for 16 h. 
The mixture was purified by centriprep (MWCO 3 kDa) into DPBS pH 7.4 (Stir with rinsed 
Cuprisorb with resin for 1 h before centriprep). Conjugate was isolated with semi-preparative 
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HPLC using Zorbax SB300-C18 column (3.0 mL/min, ACN/water + 0.1% TFA gradient: 30% for 
1 min, 30-100% for 17 min, 30% 7 min). Fractions were desalted using spin columns then buffer 
exchanged to DPBS pH 7.4. Concentration was determined by BCA assay. 
 
Kinetics of self-immolation of insulin-linker 3-trehalose polymer conjugate 
 
To 75 µL of the insulin-linker 3 trehalose polymer conjugate (0.27 mg/mL in DPBS) was 
added an equal volume glutathione (34.4 mg/mL in DPBS) for a final concentration of 7 mM. 
Release of insulin was monitored over time with HPLC (ACN/water + 0.1% TFA gradient: 1 min 
at 10%, 15 min 10-80%) (Figure 4-36). 
 
Synthesis of PDS benzyl alcohol 
 
Synthesis was based on previous reports in the literature.27 4-Mercaptobenzyl alcohol (200 
mg, 1.4 mmol, 1 eq.) was dissolved in DCM (1 mL) and mixed with a solution of 2,2′-
dithiodipyridine (629 mg, 2.8 mmol, 2 eq.) in DCM (1 mL). After stirring for 3 h, the excess 
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solvent was removed by rotary evaporation, and the crude was purified by silica gel 
chromatography (ethyl acetate/hexane gradient 20-100%, for 1/1 (v/v) Rf = 0.35). After drying 
under vacuum, 4-(2-pyridyldithio)benzyl alcohol was obtained as a yellow oil (279.5 mg, 80% 
yield). 1H NMR (400 MHz, chloroform-d) δ 8.47 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 7.68 – 7.56 (m, 
2H), 7.56 – 7.48 (m, 2H), 7.35 – 7.27 (m, 2H), 7.09 (ddd, J = 6.7, 4.8, 1.7 Hz, 1H), 4.66 (d, J = 
4.5 Hz, 2H), 1.67 (d, J = 5.9 Hz, 1H). IR ν 3300, 3044, 2918, 2863, 1732, 1573, 1489, 1446, 1417, 
1277, 1241, 1148, 1104, 1116, 1058, 1043, 1012, 987, 797, 757, 717 cm-1. 
 
Synthesis of linker 4 
 
4-(2-Pyridyldithio)benzyl alcohol (150 mg, 0.6 mmol, 1 eq.) and catalytic DMAP (7 mg, 
0.06 mmol, 0.1 eq.) was dissolved in anhydrous DCM (5 mL) and pyridine (97 µL, 1.2 mmol) and 
cooled with an ice bath. To this was added a solution containing 4-nitrophenyl chloroformate (242 
mg, 1.2 mmol, 2 eq.) in anhydrous DCM (5 mL). After overnight stirring (14 h), the reaction 
mixture was washed with 2 N HCl (aq.), brine, and dried over MgSO4. After removal of excess 
solvent by evaporation, the product was purified by silica gel chromatography (ethyl acetate/ 
hexane = 1/4 (v/v), Rf = 0.23, then another time with DCM) to obtain 4-nitrophenyl 4-(2-
pyridyldithio)benzyl carbonate as a pale yellow oil (yield: 205.9 mg, 83%). 1H NMR (400 MHz, 
Chloroform-d) δ 8.51 – 8.45 (m, 1H), 8.27 (d, J = 9.3 Hz, 2H), 7.65 – 7.59 (m, 1H), 7.56 (d, J = 
8.3 Hz, 2H), 7.38 (d, J = 6.2 Hz, 2H), 7.36 (d, J = 7.0 Hz, 2H), 7.12 (td, J = 4.9, 3.5 Hz, 1H), 5.25 
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(s, 2H). IR ν 3083, 2959, 1762, 1616, 1592, 1521, 1491, 1446,1418, 1376, 1335, 1270, 1253, 1202, 
1110, 1044, 1013, 986, 917, 862, 802, 753, 669 cm-1. 
 
Kinetics of self-immolation of linker 4 
To 1 mg/mL linker 4 in EtOH was added and equal volume 1.2 mM glutathione in DPBS 
pH 7.4. The mixture was monitored over time by HPLC (Poroshell column, 10-95% MeCN/water 
+0.1% TFA over 15 min) (Figure 4-5). 
 
Conjugation of linker 4 to insulin 
 
Insulin (0.5 mg, 8.5 x 10-5 mmol, 1 eq.) was dissolved in 250 µL borate buffer pH 9 and 50 
µL EtOH. Linker 4 (0.4 mg, 8.5 x 10-4 mmol, 10 eq.) was dissolved in 100 µL EtOH and to this 
was added the insulin solution. The solution was mixed at 4 °C for 1 hour, then another aliquot of 
linker 4 (0.4 mg, 8.5 x 10-4 mmol, 10 eq.) dissolved in 100 µL EtOH was added. The solution 
was mixed for an additional 2 hours before buffer exchange with centriprep (MWCO 3 kDa) with 
borate buffer pH 9.5/EtOH then DPBS pH 7.4. MS (LC-MS) expected 5808, 6084, 6360, 6636 
Da, found 5805, 6084, 6360, 6636 Da. 
 
Kinetics of self-immolation of insulin-linker 4 conjugate 
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To insulin-linker 4 conjugate in DPBS pH 7.4 was added an equal volume 1.2 mM 
glutathione in DPBS pH 7.4. The mixture was monitored over time by HPLC (Zorbax SB300 C3 





























Figure 4-11. 1H- and 13C- NMR of linker 2 in CDCl3 
 










Figure 4-14. 1H- and 13C- NMR of 2-bromo-N-(2-((2-hydroxyethyl)disulfaneyl)ethyl)-2-









Figure 4-16. 1H-NMR of PDS benzyl alcohol in CDCl3 
 




Figure 4-18. FT-IR of phenyl (4-(hydroxymethyl)phenyl)carbamate 
 
 




Figure 4-20. FT-IR of linker 1  
 




Figure 4-22. FT-IR of linker 2 
 




Figure 4-24. FT-IR of 2-bromo-N-(2-((2-hydroxyethyl)disulfaneyl)ethyl)-2-methylpropanamide 
 




Figure 4-26. FT-IR of PDS alcohol 
 





Figure 4-28. HPLC trace of linker 1 over time in borate buffer pH 9.0 only shows some hydrolysis. 
 




Figure 4-30. HPLC trace of linker 1 over time with β-mercaptoethanol shows β-elimination is not 
catalyzed by thiol. 
 
Figure 4-31. Absorbance from release of 2-pyridylthione during reduction of linker 3 with 












Figure 4-34. Native PAGE characterization of insulin-linker 3-trehalose polymer conjugate. 
 













Figure 4-38. HPLC trace over time of insulin-linker 4 conjugate with 0.6 mM glutathione. 
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Chapter 5. Glucose-Responsive Trehalose Hydrogel for Insulin Stabilization 




This chapter contains portions of an edited version of the following published paper reprinted with 
permission from: Lee, J., Ko, J. H., Mansfield, K.M., Nauka, P. C., Bat, E., Maynard, H. D., 
“Glucose-Responsive Trehalose Hydrogels for Insulin Stabilization and Delivery,” Macromol. 







Diabetes is a growing problem in the United States, affecting an estimated 29 million or 
9.3% of the population.1 One of the main problems with insulin therapy is the instability of the 
protein to environmental conditions like elevated temperatures. Under these conditions, insulin 
forms degradation products such as aggregates that are not metabolically active, leading to possible 
patient harm from less effective doses and possible immunogenicity or waste and increased cost 
from disposal.2-3 In addition, patients must self-administer insulin through multiple injections or 
infusions through an insulin pump per day after mealtimes to manage blood glucose.4 Developing 
a delivery device responsive to the concentration of glucose in the blood could decrease the number 
of injections needed per day and simultaneously stabilize the protein would vastly improve patient 
quality of life and treatment compliance. 
Nontoxic phenylboronic acids have been incorporated into materials for glucose sensing 
and delivery of insulin in response to glucose concentration.5-6_ENREF_7 Boronic acids are useful 
for glucose-responsive materials because they form dynamic covalent bonds with 1,2- and 1,3- 
diols such as in saccharides.7 Two main mechanisms of insulin release have been employed: 
swelling and competitive displacement.5-6 Swelling results from the change in charge of the 
boronic acid following binding of glucose, caused by the shift in equilibrium from the neutral 
trigonal to negative tetrahedral geometry, leading to an increase in osmotic pressure.8 
Alternatively, polymers containing boronic acids can crosslink with polymers bearing 1,2- or 1,3- 
diols to encapsulate insulin in situ.9-11_ENREF_12_ENREF_20 Subsequent displacement of the 
crosslinks by glucose leads to the release of insulin from the hydrogel. 
Our group has synthesized polymers with trehalose side chains that have been shown to 
stabilize proteins to heat in solution and lyophilization as both excipients and conjugates.12-15 Our 
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group reported the preparation of hydrogels by cross-linking trehalose polymers with boronic acid-
functionalized  8-arm poly(ethylene glycol) (PEG).12 Upon the addition of glucose, the network 
was disrupted due to boronic acid’s preferential binding to glucose over trehalose, resulting in an 
accelerated dissolution of the hydrogel and release of insulin (Scheme 5-1). Because of the 
presence of the trehalose polymer in the hydrogel, insulin was stabilized to an accelerated heating 
assay. To our knowledge, a hydrogel that is both glucose-responsive and insulin stabilizing had 
not yet been reported until our group’s account. These results demonstrated that the trehalose-
boronic acid hydrogel can deliver insulin upon increase in glucose level, while also stabilizing the 
protein upon thermal stress. However, a significant amount of insulin was released when the 
hydrogel was incubated in solution without glucose. In this chapter, efforts to decrease the release 
of insulin in the absence of glucose (background release) through hydrogel structure alteration and 





Scheme 5-1. Design for insulin delivery using trehalose-boronic acid hydrogel (insulin PDB ID: 
4INS). 
5.2 Results and Discussion 
In previous work, a trehalose-based hydrogel was formed by cross-linking trehalose 
polymer with 8-arm PEG functionalized with  4-phenylboronic acid (Scheme 5-1).12 The gelation 
occurred rapidly after mixing the solutions of the two components. It is viscous within a minute 
and forms the gel within 5 minutes. Insulin was also shown to be stabilized inside the hydrogel to 
heat (90 °C for 30 min) as measured by ELISA.12 It is interesting to note that the hydrogel lost its 
water content under these conditions but could be rehydrated following exposure to heat (Figure 
5-1), indicating that the network remained intact or readily reformed. We have observed that 
trehalose polymers stabilize proteins to both heat and removal of water (lyophilization).14 We 
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hypothesize that the presence of the trehalose network stabilizes insulin in a similar manner even 
if the hydrogel is dehydrated during the heating process. Trehalose is known to bind strongly with 
water16 and we have observed a large loss of water from trehalose polymers during the initial heat 
ramps in differential scanning calorimetry (DSC) (Figure 5-13). One of the proposed mechanisms 
of trehalose protein stabilization is preferential exclusion due to stronger water-trehalose 
interactions,16 which may contribute to the stabilization capabilities observed for the hydrogel. 
Additionally, the trehalose polymer exhibited a glass transition temperature (Tg) of 118 °C, which 
is close to the reported Tg of 116 °C for trehalose.16 Another proposed mechanism of trehalose 
protein stabilization is vitrification, where trehalose forms a glassy matrix around the protein upon 
drying.17 This may also contribute to insulin stabilization in this case because trehalose and the 
trehalose polymer have similar Tg. Insulin was released in a glucose-responsive manner from the 
previously reported hydrogel, however significant background release of insulin was observed 
when no glucose was added.12 Unintended release of insulin from the hydrogel without an 
increased glucose concentration is undesirable and could cause potentially dangerous 
hypoglycemia.  
 
Figure 5-1. Photograph of gel before heating and rehydrated after heating. 
We developed several strategies to address the issue of the high background insulin release 
from the trehalose-based polymeric hydrogel (Figure 5-2). We varied the pore size, boronic acid 
binding affinity, and electrostatic interactions in an effort to lower background release from 
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diffusion of insulin out of the hydrogel network as well as the slow dissolution of the hydrogel. 
 
Figure 5-2. Summary of strategies developed to decrease background insulin release by forming 
a hydrogel with poly(SET) and boronic acid-containing polymers with (A) lower pKa, (B) B-O 
dative bond stabilizing tetrahedral boronic acid conformation, or (C) positively charged amine 
comonomer. 
 
Figure 5-3. Equilibria of boronic acids. (A) The tetrahedral boronic acid geometry has a higher 
binding affinity with polyols which is stabilized through neighboring (B) amine or (C) carbonyl 
groups. 
Boronic acids exist in an equilibrium in which the anionic boronic acid form exhibits a 
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higher binding affinity for polyols, as the trigonal boronate esters formed after complexation with 
polyols are hydrolytically unstable (Figure 5-3 A and B).18 Lowering the pKa of the boronic acid, 
through subtle changes in the electronics of the attached aryl substituents, shifts the equilibrium to 
favor the anionic tetrahedral binding geometry. Thus, lowering the boronic acid pKa increases the 
propensity for the boronic acid to form the corresponding boronate ester in the presence of a polyol. 
We chose 2,4-difluoro-3-formylphenylboronic acid (FPBA) (Figure 5-2 A) to replace 4-
formylphenylboronic acid (PBA), which has a lower pKa (approximately 7.6 compared to 8.0) and 
thus stronger binding to saccharides at neutral pH.19-20 Two PEG amines with different molecular 
weight were chosen for modification with FPBA to investigate the effect of cross-linking 
density/pore size. The PEG amines, 10 kDa 8-arm PEG amine (used in our reported system12) and 
2 kDa 4-arm PEG amine (for tighter cross-linking thus smaller pore size to minimize diffusion out 
of the network), were functionalized with FPBA by reductive amination as previously performed 
with PBA. However, upon addition of the trehalose glycopolymer, no gel formed with 8-arm PEG-
FPBA. A gel formed using the 4-arm PEG-FPBA, which dissolved within 1 hour in D-PBS 
(Figure 5-4). This dissolution was deemed too fast to measure release of insulin in the gel. 
Therefore it was anticipated to be worse than the original with regard to background release and 
not explored further. 
 




The addition of neighboring atoms harboring non-bonding electrons, such as nitrogen and 
oxygen, promote the formation of the tetrahedral boronic acid form at neutral pH through donation 
of the lone-pair electrons into the empty p-orbital on boron (Figure 5-3 C and D).21-23 We 
envisioned a trehalose glycopolymer hydrogel formed with a co-polymer incorporating 
phenylboronic acids with a carbonyl that could form a B-O dative bond to increase the polyol 
binding strength would be advantageous with regard to minimizing background release. 
Additionally, we hypothesized this design could increase the cross-link density by increasing the 
spatial density of boronic acid moieties on the polymer. Free radical polymerization of 2-
acrylamido phenylboronic acid pinacol ester and 2-hydroxypropyl methacrylate followed by 
deprotection with trifluoroacetic acid (TFA) resulted in poly(2-hydroxypropyl methacrylate-co-
methacrylamidophenylboronic acid) (p(HPMA-co-PBA)) (Figure 5-2 B). This polymer formed a 
hydrogel upon addition of the trehalose glycopolymer in an initial gelation test. The weight loss 
of gel was accelerated during incubation in D-PBS buffer with increasing concentrations of 
glucose (Figure 5-5 A). Insulin release was then quantified using FITC-labeled insulin with 
different volume ratios of trehalose polymer to p(PBA-co-HPMA), but 90% or more of the FITC-
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insulin was released without glucose in solution after 2 hours for all condition (Figure 5-5 B). 
 
Figure 5-5. Examination of the effects of stabilizing the boronate ester using B-O dative bond on 
hydrogel properties. (A) Dissolution kinetics of hydrogel (n = 3) with various glucose 
concentrations at 1:1 v/v p(SET) to p(HPMA-co-PBA) and (B) FITC-insulin release from 
hydrogels (n = 1) at various volume equivalents p(SET) to p(HPMA-co-PBA) at 37 °C in DPBS 
buffer pH 7.4. 
Insulin has an isoelectric point (pI) of 5.3 and is negatively charged under biologically 
relevant conditions (pH 7.4).24 We next envisioned that synthesis of a co-polymer bearing 
monomers with amine groups or phenylboronic acid would help entrap insulin in the hydrogel 
network through the electrostatic interactions imposed by the pendant amine groups which would 
exhibit positive charge at neutral pH. Consequently, we synthesized a co-polymer with a protected 
amine and boronic acid via free radical polymerization, and deprotected with TFA to yield a 
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poly(N-(3-aminopropyl) methacrylamide-co-methacrylamidophenylboronic acid) (p(APMA-co-
PBA) (Figure 5-2 C). The polymer had 33% PBA incorporated by 1H-NMR. This co-polymer 
formed a robust hydrogel with the trehalose glycopolymer upon an initial gelation test and showed 
accelerated insulin release from the hydrogel with increased glucose concentration (Figure 5-6 
A). Moderate background release was observed that was comparable to the original 8-arm PEG-
phenylboronic acid system under the initially tested conditions (1:7 p(SET):p(APMA-co-PBA)). 
Insulin release was analyzed with hydrogels made from different ratios of trehalose glycopolymer 
and p(APMA-co-PBA) (Figure 5-6 B). The lowest background release was observed using 1:6 
p(SET):p(APMA-co-PBA), which exhibited 60% insulin release in the absence of glucose. 
However, these results were only slightly better than the 70% insulin release observed in our    
original system.12 These experiments suggest that the background insulin release is difficult to 




Figure 5-6. Investigation into the effects of altering co-polymer electrostatics on insulin release. 
(A) FITC-insulin release from hydrogels (n = 3) at various concentrations of glucose at 1:7 v/v 
p(SET) to p(APMA-co-PBA) solutions and (B) optimization of background insulin release from 
hydrogels (n = 1) at different volume ratios p(APMA-co-PBA) to p(SET) trehalose glycopolymer 
in D-PBS buffer pH 7.4 at 37 °C. 
In our previous studies, we hypothesized that the hydrogel formation was aided by the 
multivalency of the polymers, effectively strengthening the weak interaction of trehalose with the 
polymer bearing the phenylboronic acids.12 We hypothesized that changing the identity of the 
boronic acid to increase the binding affinity of phenylboronic acid to trehalose would strengthen 
the gel network and decrease background release. However, strategies to increase the binding 
affinity did not lower the background insulin release and in some cases resulted in weaker 
hydrogels. We believe this may result from changes in solubility when altering the identity of the 
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boronic acid or design of the cross-linker, which affected the strength of the gel network. The 
inclusion of charged monomers in the cross-linker to utilize electrostatic interactions resulted in 
the lowest background release of insulin without glucose in solution, though the amount of insulin 
released was only slightly lower than in our previous report. Diffusion of insulin out of the network 
in addition to the gradual dissolution of the hydrogel present challenges to all the strategies we 
have tested thus far. Because phenylboronic acid forms dynamic covalent bonds with polyols, the 
cross-linking of the hydrogel network is not permanent and undergoes dynamic rearrangement. 
Additionally, the affinity for phenylboronic acid binding to trehalose is weak (Kb = 2.57 M
-1 for 
glucose vs. 0.48 M-1 for trehalose).12 We believe these properties to be the major contributing 
factor limiting background release optimization.  
5.3 Conclusion 
This chapter details efforts to improve the unwanted background release of a glucose-
responsive hydrogel for insulin delivery and stability. Several strategies were employed to lower 
the amount of insulin released during incubation in buffer in the absence of glucose and included 
varying the phenylboronic acid binding strength, increasing the cross-link density of the gel, and 
incorporating electrostatic interactions. Altering the identity of the phenylboronic acid and 
targeting smaller pore size did not improve the background release. Incorporation of cationic 
amine comonomers in a phenylboronic acid-containing polymer decreased the background insulin 
release after optimization of gelation conditions. However, this was a small improvement to the 
original design, suggesting a fundamental limit to background optimization because of the weak 
trehalose-phenylboronic acid interaction and the dynamic nature of the hydrogel network. 
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5.4 Appendix D 
Materials 
Materials were purchased from Sigma-Aldrich and Fisher Scientific and were used without 
purification unless noted otherwise. Recombinant human insulin was purchased from Sigma-
Aldrich. Trehalose was purchased from The Healthy Essential Management Corporation 
(Houston, TX), and was azeotropically dried with ethanol and kept under vacuum until use. 
Azobisisobutyronitrile (AIBN) was recrystallized from acetone before use. 8-arm and 4-arm PEG 
amines were purchased from Jenkem Technology (Allen, TX). Human insulin ELISA kit was 
purchased from Mercodia (Uppsala, Sweden). Styrenyl ether trehalose monomer was prepared 
using the previously reported procedure.14 2-Methacrylamidophenylboronic acid pinacol ester was 
synthesized by Jeong Hoon Ko as previously reported.22 p(SET) was prepared by Juneyoung Lee 
as described previously.12 Poly(2-hydroxypropyl methacrylate-co-methacrylamidophenylboronic 
acid) was synthesized by Jeong Hoon Ko. 
 
 Analytical techniques 
Nuclear Magnetic Resonance (NMR) spectra were recorded on a Bruker AV 400 MHz 
spectrometer. Gel permeation chromatography was conducted on a Shimadzu HPLC system 
equipped with a refractive index detector RID-10A and two Polymer Laboratories PLgel 5 µm 
mixed D columns (with guard column). Lithium bromide (0.1 M) in N,N-dimethylformamide 
(DMF) at 40 °C was used as the solvent (flow rate: 0.6 mL/min). Near-monodisperse poly(methyl 
methacrylate) standards (Polymer Laboratories) were employed for calibration. Preparatory 
reverse phase high performance liquid chromatography (HPLC) was carried out on a Shimadzu 
HPLC system equipped with a UV detector using a Luna 5 µm C18 100 Å column (preparatory: 
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5 µm, 250 x 21.2 mm) with monitoring at λ = 215 nm and 254 nm. Isocratic solvent system 
(water:methanol = 50:50) was used as the mobile phase at a flow rate of 10 mL/min. Fluorescence 
measurement was made on a FlexStation II (Molecular Devices). DSC for characterization of 
nanogel VPTT was conducted on a Mettler Toledo DSC3+ with ~5 mg polymer in 40 µL 
aluminum pans with three linear gradient heat ramps (-50 to 270 °C, 270 to -50 °C, -50 to 280 °C) 
with a heating rate of 10 °C/min. 
 
Reductive amination of 8-arm PEG-amine with 4-formylphenylboronic acid 
 
8-arm PEG amine (240 mg, 10 kDa, 24 µmol) and 4-formylphenylboronic acid (70.3 mg, 
0.36 mmol) were dissolved in 1.7 mL of anhydrous MeOH in a dram vial. NaBH3CN (22.7 mg, 
0.36 mmol) was added and the reaction was stirred at 25 °C (wrapped in foil). After 5 days the 
reaction solution was purified by dialysis (MWCO 3.5 kDa) against MeOH for 3 days. MeOH was 
removed and the polymer was recovered after lyophilization from water to yield 241.6 mg (91 % 
yield). 1H NMR (400 MHz in D2O) δ: 7.75 (16 H), 7.41 (16 H), 3.69 (908 H). 
 






4-arm PEG amine (2 kDa, 100 mg, 0.05 mmol) or 8-arm PEG amine (10 kDa, 500 mg, 
0.05 mmol), 2,4-difluoro-3-formylphenylboronic acid (74 mg, 0.40 mmol), p-toluenesulfonic acid 
(1.33 mg, 0.001 mmol), and sodium cyanoborohydride (31 mg 0.49 mmol) were dissolved in 
methanol (0.7 mL) and stirred for 3 days at 23 °C. The solution was precipitated into cold diethyl 
ether, decanted, and the solvent was removed in vacuo. The product was purified by dialyzing 
against H2O (MWCO 3.5 kDa). For 8-arm PEG-FPBA: 
1H NMR (400 MHz in D2O) δ: 7.63 (8H), 
7.02 (8H), 3.72 (944 H). For 4-arm PEG-FPBA: 1H NMR (400 MHz in CD3OD) δ: 7.55 (4H), 7.36 
(4H), 6.88 (4H), 3.61 (280H). 
 
Co-polymerization of tert-butyl (3-methacrylamidopropyl)carbamate and 2-
methacrylamidophenylboronic acid pinacol  ester 
 
2-Methacrylamidophenylboronic acid pinacol ester (66 mg, 0.229 mmol), tert-butyl (3-
methacrylamidopropyl)carbamate (222 mg, 0.919 mmol), and AIBN (0.65 mg, 3.9 µmol) were 
dissolved in anhydrous DMSO (0.70 mL). The solution underwent four cycles of freeze-pump-
thaw, and polymerization was initiated by immersing the flask into an oil bath at 70 °C. The 
polymerization was monitored by 1H-NMR and was quenched at 70% conversion by exposure to 
oxygen and freezing in liquid N2. The polymer was purified by dialyzing against H2O (MWCO 
217 
 
3.5 kDa). 1H NMR (400 MHz in CD3OD) δ: 7.58-6.81, 6.72, 2.88, 1.34, 0.74. Mn= 1.8 kDa (by 
GPC), D = 1.15. 
 
Deprotection of tert-butyl (3-methacrylamidopropyl) carbamate and 2-
methacrylamidophenylboronic acid pinacol ester co-polymer 
 
To 60 mg polymer, 1.6 mL 1:1 DMSO:TFA was added and the mixture was stirred 22 h at 
100 °C. Deprotection was confirmed by 1H-NMR and the polymer was purified by dialyzing 
against H2O (MWCO 3.5 kDa). 
1H NMR (400 MHz in D6DMSO) δ: 7.70, 7.21, 6.74, 6.40, 2.88, 
1.36, 0.74. IR: ν = 3552, 2972, 2931, 1686, 1641, 1577, 1517, 1479, 1448, 1390, 1363, 1320, 1274, 
1252, 1164, 1118, 1069, 1039, 1024, 953, 860, 761. 
 
Gelation test of PBA polymers with trehalose polymer 
The poly(SET) (500 mg/mL) and PBA polymer (200 mg/mL) stock solutions were 
prepared in D-PBS, pH 7.4. The gels were prepared by adding 9:1 ratio p(SET) to PBA polymer 
stock solutions for a total of 23 µL and incubating at room temperature for 1 h. Gelation was tested 
by visual inspection and manipulation with a plastic pipette tip. 
 
FITC labeling of insulin 
Insulin labeling with fluorescein isothiocyanate isomer I (FITC) was performed by 
dissolving insulin (0.65 mg, 0.112 µmol) and FITC (3.48 mg, 8.94 µmol) in 0.33 mL of 1 M 
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sodium bicarbonate buffer, pH 8.3. The mixture was stirred for two hours, and free FITC was 
removed by repeated centrifugation through a membrane using Centriprep tubes with molecular 
weight cut-off (MWCO) of 3 kDa. Typical degree of labeling was approximately 0.7 FITC per 
insulin as determined by UV absorbance. 
 
FITC-labeled insulin release from trehalose hydrogel 
FITC-labeled insulin (13.22 mg/mL in Dulbecco’s phosphate-buffered saline D-PBS, pH 
7.4) was added to the trehalose polymer (500 mg/mL). The PBA containing polymer was dissolved 
in D-PBS at 200 mg/mL concentration. Next, various volume of each stock solution for a total of 
10 µL were added to an Eppendorf Lo-Bind centrifuge tube. The tube was agitated on a 
ThermoShaker (Allsheng Instruments, China) at 1,500 rpm at 21 °C for 1 h. The gels were 
transferred into a 24-well plate filled with 1 mL D-PBS and left to hydrate for 30 min. Next, the 
gels were transferred to a 96-well plate that had been blocked with 1% wt/vol bovine serum 
albumin (BSA) in D-PBS to prevent protein adsorption and filled with 0.3 mL of D-PBS 
containing 0, 5, or 10 mg/mL glucose. At each time point, all the solutions were aliquoted and the 
wells containing the gels were immediately refilled with 0.3 mL of the same buffer. After the last 
time point, the wells were treated with 0.3 mL of D-PBS containing 100 mg/mL glucose and 
incubated at 37 °C for 5 min to completely dissolve the gels. All the solutions were then transferred 
for measurement, and fluorescence of the time point aliquots and the residual insulin in solutions 
recovered after gel dissolution was measured. 
 
Hydrogel dissolution kinetics 
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The poly(SET) (200 mg/mL) and p(HPMA-co-PBA) (100 mg/mL) stock solutions were 
prepared in D-PBS, pH 7.4. The gels were prepared by adding 1:1 ratio p(SET) to p(HPMA-co-
PBA) stock solutions for a total of 10 µL and incubating at room temperature for 30 min. The gels 
were hydrated in D-PBS for 1 h, and then transferred to 5 mL D-PBS containing 0, 5, or 10 mg/mL 








Figure 5-8. 1H-NMR of 4-arm PEG-FPBA (CD3OD). 
 




Figure 5-10. 1H-NMR of p(APMA-co-PBA) before deprotection (CDCl3). 
 




Figure 5-12. FT-IR spectrum of p(APMA-co-PBA) 
 
Figure 5-13. DSC trace with three linear gradient heat ramps (-50 to 270 °C, 270 to -50 °C, -50 to 
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Glucagon is a therapeutic peptide used to treat emergency hypoglycemia in diabetics, 
usually in response to insulin overdose.1-2 The peptide is insoluble at neutral pH and instable in 
aqueous solutions, rapidly forming cytotoxic fibrils.3-4 For this reason, therapeutic glucagon is 
packaged as a lyophilized powder that must be reconstituted in dilute acid just prior to use.1 
Because glucagon is used in emergency response to severe hypoglycemia, administration of  this 
kit can be intimidating and requires another person to inject the drug when the patient is 
incapacitated, which can sometimes lead to inadequacy in dosing.5  A newly FDA-approved nasal 
glucagon now on the market addresses this issue and is shown to be effective and easier to 
administer but has lower bioavailability and requires a larger dose to be effective.6-7 Additionally, 
a stable ready-to-use glucagon formulated in DMSO was recently approved, though there are 
issues with discomfort stemming from the organic solvent.8 Glucagon administration that mimics 
the endogenous response to prevent dangerously low blood glucose has not yet been realized and 
yet would be very important for the regulation of glucose for persons with diabetes. 
A variety of glucose-responsive materials have been synthesized for insulin delivery, but 
only a few examples of responsive delivery of glucagon exist.9 Many glucose-responsive materials 
use phenylboronic acids as glucose sensing units. Phenylboronic acids can form dynamic covalent 
bonds with 1,2- and 1,3-diols, including those on glucose. The affinity of binding can be tuned by 
the inclusion of electron-withdrawing substituents on the phenyl ring that lower boronic acid pKa 
or through dative bonds with neighboring nitrogen or oxygen that stabilize the tetrahedral boronic 
acid geometry that favors binding.10-11 The first example of glucose-responsive glucagon delivery 
was published during the course of this study and utilized a nanogel embedded in a microneedle 
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patch. The mechanism consists of a transition from a 1:1 to a 1:2 complexation between glucose 
and boronic acids resulting in a more cross-linked material, reducing the nanogel volume and 
squeezing out glucagon at low glucose concentrations.12 Glucagon delivery in response to insulin 
concentration was also demonstrated using a glucagon-insulin aptamer conjugate that enabled 
competitive displacement from an immobilized insulin scaffold.13 
Nanogels presenting a novel mechanism of contraction upon addition of glucose were 
recently reported. These nanogels were synthesized by copolymerizing thermoresponsive N-
isopropyl acrylamide (NIPAM) with acrylic acid (AA), which was modified with 2-
aminophenylboronic acid (2-APBA) post-polymerization.14-15 Unlike similar nanogels utilizing 3-
aminophenylboronic acid that become more soluble from the increase in effective charge after 
binding with glucose due to the change from neutral trigonal to negative tetrahedral form,16 the 2-
APBA-bearing nanogels became less soluble in the presence of glucose. The selected 
phenylboronic acid does not change charge upon binding because the B-O dative bond inherently 
stabilizes the negative tetrahedral geometry.11 Instead, glucose acts as an additive, structuring 
water in its proximity, that changes the hydration of the pNIPAM chain to shift the lower critical 
solution temperature (LCST) of the polymer and volume phase transition temperature (VPTT) of 
hydrogels.17-19 Incorporation of boronic acid in the polymer chain effectively concentrates the 




Scheme 6-1. Mechanism of LCST shift for 2-APBA copolymers with glucose as additive. 
Herein, we describe the preparation of nanogels for the glucose-responsive delivery of 
glucagon (Scheme 6-2). The nanogels were synthesized using either NIPAM or poly(ethylene 
glycol) methacrylate (PEGMA) as the thermoresponsive elements. Characterization of these 
nanogels revealed glucose-dependent shifting of the VPTT below relevant physiological 
temperatures. During the loading process, native glucagon degraded and could not be released 
upon lowering glucose to swell the nanogels. Using a soluble glucagon analog, improved loading 
was achieved without degradation of the peptide.  
 
Scheme 6-2. Overview of nanogel for glucose-responsive glucagon delivery 
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6.2 Results and Discussion 
We envisioned using nanogels that would collapse upon addition of glucose to encapsulate 
glucagon in situ. Nanogels would swell when blood glucose approached the counterregulatory 
threshold (70 mg/dL), releasing glucagon by diffusion out of the nanogel network to prevent 
hypoglycemia.6 Diameters between 100 and 200 nm were targeted for extended circulation in the 
blood to control blood glucose for approximately 24 h.20 
NIPAM nanogels were synthesized as previously reported (Scheme 6-3 A), with N-
isopropylmethacrylamide (NIPMAM) as a comonomer to tune the VPTT to a physiologically 
relevant temperature.15 Precipitation polymerization with NIPAM, NIPMAM, AA, and N,N′-
methylenebis(acrylamide) (BIS) crosslinker at 70 °C with 2 mM SDS was found to give uniform 
nanogels with a diameter of 132 nm at 20 °C. Lower concentration of SDS (1 mM) resulted in 
larger nanogels with a diameter of 324 at 20 °C. Nanogels were functionalized post-polymerization 
by EDC coupling with 2-APBA as a glucose-sensing moiety. The nanogels were characterized by 
1H-NMR and FT-IR and thermo- and glucose-responsivity was characterized by DSC (Appendix 
E: Figure 6-4, Figure 6-6, and Figure 6-8). Full coupling of the AA with 2-APBA was confirmed 
by 1H-NMR. VPTT was determined to be approximately 38 °C by DSC, which is physiologically 
relevant. NIPAM nanogels with 15% 2-APBA content were found to have the best glucose 
response with a sensitivity as low as 300 mg/dL and maximum size change of 31 nm in diameter 
by DLS. The nanogels were also responsive to other polyols, as determined by DSC (Appendix E: 
Figure 6-8), including xylose and poly(vinyl alcohol), which would enable glucagon loading 




Scheme 6-3. Synthesis of (A) NIPAM and (B) PEGMA nanogels by precipitation polymerization 
and post-polymerization coupling of boronic acid. 
Because of general concern about pNIPAM toxicity in vivo,21-22 PEGMA nanogels were 
also prepared (Scheme 6-3 B). To tune the VPTT to a physiologically relevant temperature, the 
feed ratio of approximately 1 to 3 of 300 Da oligo(ethylene glycol) methyl ether methacrylate 
(OEGMA300) and diethylene glycol methyl ether methacrylate (DEGMA) was selected based on 
previous reports tuning LCST and VPTT of OEGMA copolymers and gels.23-24 Precipitation 
polymerization with OEGMA300, DEGMA, methacrylic acid (MAA), and ethylene glycol 
dimethacrylate (EGDMA) crosslinker at 70 °C with 1.5 mM SDS resulted in uniform nanogels 
with a diameter of 246 nm at 20 °C and 103 nm at 40 °C. Higher concentrations of SDS did not 
yield nanogels with controlled size. PEGMA nanogels were functionalized with 2-APBA by post-
polymerization coupling and characterized in the same manner as NIPAM nanogels (Error! 
Reference source not found., Appendix E: Figure 6-5, Figure 6-7, Figure 6-9, and Figure 6-10) 




Figure 6-1. Characterization of PEGMA nanogels by DLS 
In addition to the larger size and diameter change, PEGMA VPTT decreased by 14 °C with 
10 mg/mL glucose by DSC compared to only 4 °C for NIPAM nanogels. The behavior of NIPAM 
and PEGMA in solution may lead to these observed differences. A study of saccharide effects on 
thermoresponsive polymers found a greater effect of glucose on the LCST of PEG-based Pluronics 
than pNIPAM.17 Additionally, PEGMA lacks hydrogen bonding donors, such as the amide of 
NIPAM which is hypothesized to play a role in the hysteresis observed for pNIPAM upon cooling 
that is not observed with PEGMA.24 The mechanism of nanogel collapse is dependent upon the 
hydration of the polymer chains with glucose acting as an additive. Thus, we hypothesize that the 
increase in structured water around glucose affects the hydration of PEGMA nanogels more than 
NIPAM nanogels because of the differences in hydrogen bonding and amphiphilicity of OEGMA, 
leading to the larger change in VPTT. 
Glucagon loading into the nanogels was optimized using a three-step procedure (Scheme 
6-4). First, the nanogels were incubated with glucagon in borate buffer pH 9.5 at 4 °C 14 h to 
maintain gel swelling, maintain peptide solubility and stability, and enable equilibrium diffusion. 
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Nanogels were then collapsed by adding 5 mg/mL glucose and heating to 37 °C. Glucagon that 
was not entrapped in the nanogel was then separated by wash steps using either centrifugal 
filtration or dialysis, maintaining the glucose concentration and changing the pH by introducing 
DPBS pH 7.4 in the final step. Loading efficiency (wt. loaded glucagon/initial  wt. glucagon) and 
drug loading (wt. glucagon/total wt. of nanogel and glucagon) was determined indirectly by 
measuring the amount of glucagon in the washes by HPLC (Appendix E: Table 6-3). However, 
this method did not allow direct characterization of the amount of glucagon loaded in the nanogels. 
Additionally, very little peptide was detected when buffer was switched to DPBS pH 7.4 without 
glucose to stimulate release by enabling nanogel swelling. Similar results were also seen when 
borate buffer, stabilizing excipients, FBS, or blood were used throughout the loading and release 
steps, indicating that peptide solubility and partitioning in the buffer was not the issue but rather 
the instability (Appendix E: Table 6-3). 
 
Scheme 6-4. Protocol to load glucagon into nanogels. 
We hypothesized that a spectroscopic detection method would facilitate direct 
characterization of glucagon in the presence of the nanogels and increase assay throughput 
compared to HPLC. The fluorescamine assay is a method to quantify protein and peptide 
concentration via an increase in fluorescence upon binding of fluorescamine with primary amines. 
Additionally, it works under both basic and neutral pH, which were used during loading and 
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release. To test if this assay would be a viable detection method, it was used to quantify the amount 
of glucagon during each step in the loading protocol (Scheme 6-4), as well as the amount left with 
the nanogels in the filter at the end of the experiment (Appendix E: Figure 6-11). The amount of 
glucagon measured in the washes agreed with the HPLC method and the nanogel itself did not 
result in any background signal as expected. The amount of glucagon measured in the presence of 
the nanogels (directly measured, without the wash steps) was 47% of the expected. Fluorescamine 
is known to selectively react with solvent-accessible primary amines, resulting in lower 
fluorescence signal for amines blocked through interactions with nanoparticles.25-26 However, this 
did not account for the 81% difference in expected versus measured glucagon in the nanogels at 
the end of the experiment. Thus, we hypothesized that the low percent detection of glucagon during 




Figure 6-2. Stability of glucagon to fibrillation during loading using ThT assay to assess glucagon 
fibrillation in the presence of nanogel and during loading (n = 3, ** p < 0.01, n.s.  p > 0.1). 
Fibrillation is a major pathway of glucagon degradation in solution and may decrease the 
accessibility of glucagon’s amines for fluorescamine binding, so the formation of fibrils during the 
loading conditions was investigated as a cause of the unexpectedly low signal in the nanogel. 
Thioflavin T (ThT) assay was used to quantitatively measure the extent of fibrillation during 
loading (Figure 6-2). Upon heating, glucagon forms fibrils which bind ThT, leading to a large fold 
increase in fluorescence signal. Glucagon in the presence of nanogel and after exposure to loading 
heat conditions did not significantly increase fluorescence, indicating that glucagon does not 
fibrillate during loading. 
 
Scheme 6-5. Amino acid sequence comparing native glucagon and soluble glucagon analog with 
substitutions to eliminate deamidation site and lower isoelectric point. 
Although this data indicates that glucagon does not fibrillate during the loading procedure, 
the low total detection of native glucagon could be due to shielding of the primary amines through 
chemical degradation. Glucagon also forms trimers and other higher order oligomers at high 
concentrations.27-28 Steric blocking of amines upon formation of these aggregates from 
concentration of glucagon inside the nanogel during collapse could contribute to artificially low 
signal. To address these issues, a glucagon analog with improved solubility at neutral pH and 
greater stability was selected.29-30 This analog has two amino acid substitutions at the C-terminus 
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that shift the isoelectric point to approximately 4.8 and eliminate a site of deamidation (Scheme 
6-5). This change improves the solubility at neutral pH and could potentially disrupt glucagon self-
interaction, which is known to occur at the C-terminus. Unlike the native glucagon, all of the 
soluble glucagon could be detected in the presence of either nanogel (directly measured, without 




Figure 6-3. Amount of glucagon by fluorescamine assay during loading of soluble glucagon into 
(A) NIPAM nanogels (n = 3, * p < 0.05, ** p <0.005) or (B) PEGMA nanogels (n = 1). 
 The soluble glucagon analog was loaded and released from the nanogel using the optimized 
centrifugal filtration procedure (Scheme 6-4) with and without the heating step to collapse the gel. 
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A control of just the soluble peptide was also included to assess stability and recovery during the 
centrifugation steps. Results for loading and release of the soluble glucagon in the nanogels is 
shown in Figure 6-3 and summarized in Table 6-1. Loading efficiency and drug loading were 
again calculated indirectly from the amount of glucagon in the wash steps and the amount of 
glucagon released and in the nanogel left in the filter were determined from the fluorescamine 
assay. For the soluble glucagon control, 78% of the peptide was recovered in the wash steps, 
indicating good stability and passage through the membrane. Similar or higher recovery of the 
peptide was detected for the other conditions over the entire experiment. A difference in the 
amount of peptide in the first wash step in the presence of NIPAM nanogel was measured, with 
significantly more detected with the heating step (Figure 6-3 A). This also corresponded to the 
difference in loading efficiency and drug loading observed in Table 6-1 comparing with and 
without heating. These data suggest glucagon may be squeezed out during the collapse upon 
heating. This squeezing-out mechanism has been observed for hydrophilic drugs in NIPAM 
hydrogels,31 which agrees with our observation of this mechanism for the more hydrophilic 
glucagon analog. However, this difference could be due to degradation of native glucagon during 
the loading experiments. Very little release (< 3 µg) was observed for either nanogel condition 
when buffer was changed to DPBS pH 7.4 without glucose, same as for native glucagon. However, 
the amount of glucagon measured at the end of the experiment was significantly greater than the 
control, with 3.3 µg (17% of initial) detected in the NIPAM nanogels in the filter without heating. 
Similar results were seen with PEGMA nanogels (Figure 6-3 B) with a slight increase in the 
amount of soluble glucagon detected in the nanogel at 7.2 µg (25% of initial). This may be due to 
the larger change in diameter observed for PEGMA nanogels compared to NIPAM nanogels. 
Moreover, for all samples, a greater amount of the soluble glucagon (>77%) was accounted for 
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during the experiments than when native glucagon was studied, enabling more thorough 
characterization of loading and release.  
Table 6-1. Summary of soluble glucagon loading and release into nanogels 
 
Although loading and detection was improved using the glucagon analog, a greater amount 
of glucagon release at low glucose concentrations is still needed.  Additionally, a higher amount 
of glucagon in the final nanogels was observed without the heating step to collapse. These data 
indicate the peptide may be squeezed out during the collapse of the nanogel. This phenomenon has 
been observed for hydrophilic molecules encapsulated in NIPAM networks31 and this mechanism 
was used for release of glucagon from nanogels.12 To address these challenges, work using 
reversible covalent loading of glucagon into the nanogels is ongoing to avoid squeezing out. 
Additionally, self-assembled nanoparticles using block co-polymers containing the same glucose-
responsive polymers as the nanogels are under investigation to improve the release of glucagon at 


















‒ ‒ ‒ ‒ 78 
NIPAM 
(no heat) 
39 0.3 0.7 ± 0.1 3.3 ± 1.1 77 
NIPAM 
(heat) 
25 1.6 1.2 ± 1.7 0.6 ± 0.3 81 
PEGMA 
(no heat) 
25 2.2 2.7 7.2 78 
PEGMA 
(heat) 




We have developed glucose- and thermo-responsive NIPAM and PEGMA nanogels for 
glucagon delivery. Nanogels were synthesized by precipitation polymerization and characterized 
by DLS and DSC. PEGMA nanogels were found to be larger in size and have a larger overall 
change in diameter upon collapse than NIPAM nanogels. Initial attempts at loading native 
glucagon resulted in low release and overall detection of the peptide. ThT assay showed glucagon 
was not fibrillating during loading but the fluorescamine assay indicated accessibility of primary 
amines was decreased from either chemical degradation or peptide interactions. Loading was 
improved for both nanogels using a more stable and soluble glucagon analog, though release of 
glucagon at low glucose concentrations was not changed. Overall, these materials exhibit dual 
stimuli-responsive materials and provide a basis for glucose-responsive glucagon delivery should 
the loading, stabilization and release be optimized. Work investigating strategies to address the 
low release of glucagon and squeezing-out mechanism is ongoing in the group. 
6.4 Appendix E 
Materials 
All chemicals were purchased from Sigma-Aldrich and Fisher Scientific and were used 
without purification unless noted otherwise. Native glucagon was purchased from 
MedChemExpress or Biomatik. Soluble glucagon analog was purchased from Biomatik. Liquid 
monomers were purified by passage over basic alumina before used in polymerizations. For 





Nuclear Magnetic Resonance (NMR) spectra were recorded on a Bruker AV 400 MHz 
spectrometer. DSC for characterization of nanogel VPTT was conducted on a Mettler Toledo 
DSC3+ with 80 µL 10 mg/mL solution in 100 µL aluminum pans with gradient of 10 to 90 °C and 
a ramp rate of 5 °C/min. DLS for characterization of nanogel size and temperature response was 
conducted on a Malvern Nanozetasizer in 20 mM DPBS pH 7.4. Analytical HPLC for detection 
of glucagon was conducted on an Agilent 1260 Infinity II LC System equipped with a UV detector 
using Poroshell C18 column and a gradient solvent system (water:acetonitrile = 75:25 to 40:60 + 
0.1 % trifluoroacetic acid over 17 min at 1 mL/min). Fluorescence in fluorescamine assay and 
turbidity for nanogel temperature response characterization was measured on a Tecan M1000 plate 
reader. 
 
Synthesis of NIPAM nanogel 
 
In a 3-neck round-bottom flask under argon, NIPAM (428 mg, 3.8 mmol, 27.1 
equiv), NIPMAM (245 mg, 1.9 mmol, 13.8 equiv), AA (75 mg, 1.0 mmol, 1 equiv), N,N'-
methylenebis(acrylamide) (21.5 mg, 0.14 mmol, 1 equiv), SDS (58 mg, 0.2 mmol, 1.4 
equiv), water (9.5 mL), and a stir bar were added. The flask was placed in a 70 °C oil bath and 
stabilized under argon for 1 hour. APS (43 mg, 0.15 mmol, 1.07 equiv) dissolved in water (0.5 
mL) was added to the flask to initiate the reaction. Polymerization was ended after 7 h by exposure 
to oxygen and removal from heat source. The nanogel was purified by dialysis (6-8 kDa 
MWCO) against water 3 days. To a round bottom flask under argon, 10 mL of NIPAM nanogel 
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(0.12 mmol acrylic acid, 1 equiv) was added. To the flask, 2-APBA (305 mg, 1.8 mmol, 10 equiv), 
EDC (410 mg, 2.6 mmol, 15 equiv), and DMAP (4.3 mg, 35 µmol, 0.2 equiv) were added 
successively. The reaction proceeded at 0 °C in an ice bath for 4 hours under argon. The product 
was purified by dialysis (6-8 kDa MWCO) against water for 3 days. 1H NMR (400 MHz in D2O) 
δ: 7.44, 7.20, 6.97, 3.76, 1.83, 1.52, 1.01. IR: ν = 3302, 2971, 2930, 2675, 1634, 1524, 1449, 1387, 
1367, 1216, 1173, 1130, 1028, 962, 885, 840, 763 cm-1. 
 
Synthesis of PEGMA nanogel 
 
In a 3-neck round-bottom flask under argon, DEGMA (295 µL, 1.6 mmol, 1 equiv), 
OEGMA300 (137 µL, 0.48 mmol, 0.3 equiv), methacrylic acid (31 µL, 0.37 mmol, 0.23 
equiv), ethylene glycol dimethacrylate (8.7 µL, 0.046 µmol, 0.029 equiv), SDS (8 mg, 0.028 
mmol, 0.017 equiv), water (24.5 mL), and a stir bar were added. The flask was placed in a 70 °C 
oil bath and stabilized under argon for 1 hour. APS (8.4 mg, 0.037 mmol, 0.023 equiv) dissolved 
in water (0.5 mL) was added to the flask and the reaction was initiated. Polymerization was 
ended after 20 h by exposure to oxygen. Gels were purified by dialysis (6-8 kDa MWCO) against 
water for 5 days. PEGMA nanogel (485 mg, 0.37 mmol acrylic acid, 1 equiv) suspended in 25 mL 
water was transferred to a round bottom flask under argon in an ice bath (0 °C). To this was added 
EDC (285 mg, 1.8 mmol, 5 equiv), DMAP (22.5 mg, 0.18 mmol, 0.5 equiv) and 2-
aminophenylboronic acid (319.4 mg, 1.8 mmol, 5 equiv). The mixture was stirred at 21 °C for 16 
hours before being quenched by exposure to oxygen. The nanogels were purified by dialysis (6-8 
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kDa MWCO) against water for 3 days. 1H NMR (400 MHz in D6DMSO) δ: 8.78, 8.33, 7.76, 7.30, 
6.99, 3.98, 3.49, 3.23, 1.73, 0.91, 0.75. IR: ν = 3438, 2878, 1724, 1450, 1388, 1352, 1246, 1104, 
1028, 944, 850, 750 cm-1. 
 
Loading and release of glucagon in nanogel 
Glucagon (1 mg/mL in borate buffer pH 9.5 for native or DPBS pH 7.4 for soluble 
glucagon) and NIPAM or PEGMA nanogels (8-10 mg/mL in water) were combined in a LoBind 
tube at 1:1 volume ratio and incubated at 4 °C on the rocker for 16 h. Aliquots (200 µL) of nanogel 
or glucagon without nanogel were separated into LoBind tubes and to each was added borate buffer 
pH 9.5 (for native glucagon) or DPBS pH 7.4 (for soluble glucagon) with or without 10 mg/mL 
glucose. Samples were either heated at 37 °C for 30 min to collapse nanogels or kept at 4 °C. 
Samples were centripreped (MWCO 30 kDa) or dialyzed (MWCO 6-8 kDa) with the centrifuge at 
room temperature, refilling the reservoir with either borate buffer pH 9.5 + 10 mg/mL glucose for 
3 washes then DPBS pH 7.4 + 10 mg/mL glucose for the final wash (native  glucagon) or all 
washes with DPBS pH 7.4 + 10 mg/mL glucose. Filters were filled with DPBS pH 7.4 for release 
cycles and centripreped (MWCO 30 kDa) or dialyzed (MWCO 6-8 kDa). Filtrates and samples 




A 3 mg/mL stock solution of fluorescamine was prepared in DMSO. 80 µL of samples, 
calibrators, and buffer blanks were plated on a black 96-well plate. To each well was added 30 µL 
of the fluorescamine solution and the plate was incubated at 37 ˚ C for 30 minutes. The fluorescence 
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(λex = 380 nm, λem = 460 nm) was measured and the amount of glucagon in each sample was 
calculated using the calibrators. 
 
ThT assay 
ThT solution was prepared at 50 µM (0.0159 mg/mL) in 20 mM DPBS pH 7.4. Into a 96-
well plate, 50 µL each sample was pipetted. To these was added 250 µL ThT solution and the plate 
was incubated at room temperature (21 °C) for 20 min. Fluorescence intensity was measured on 




For assessment of the statistical significance of differences, one-way ANOVA followed by 
two-tailed Student’s t-test assuming unequal sample variance was employed. Results were 






Figure 6-4. 1H-NMR spectrum of NIPAM nanogel (D2O) 
 




Figure 6-6. FT-IR spectrum of NIPAM nanogel 
 




Figure 6-8. DSC of NIPAM nanogel with various polyols 
Table 6-2. Characterization of NIPAM nanogel VPTT by DSC with various polyols 
Condition Onset (°C)a VPTT (°C)b 
No additive 34.8 41.9 
10 mg/mL PVA 29.2 38.4 
5 mg/mL xylose 33.5 38.1 
5 mg/mL glucose 33.9 39.0 
a Onset temperature was calculated from the initial change from baseline of the DSC peak, b VPTT 




Figure 6-9. DSC of PEGMA nanogels with and without glucose 
 
Figure 6-10. Turbidity of PEGMA nanogel VPTT by UV-vis 
Table 6-3. Native glucagon loading and release with NIPAM nanogels 
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Condition Loading efficiency (%) Glucagon release (%) c 
PBS a 83 2 
Borate buffer a 79 7.7 
Borate buffer with 0.1% 
SDS a 
80 0.27 
FBS b 98 0.2d 
Dialysis in PBS b 97 0.7d 
Whole blood b 81 0.8d – 4e 
a HPLC, b ELISA, c Maximum glucagon released over 24 h, d 37 °C, e 4 °C 
 
Figure 6-11. Amount of glucagon (blue) and cumulative glucagon detected over all steps (red) by 
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